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Abstract 
Introduction: 
Percutaneous coronary intervention (PCI) for unprotected left main coronary artery 
(ULMCA) disease has emerged as a viable alternative to coronary artery bypass graft 
(CABG) surgery in specific patterns of coronary involvement. Recent evidence suggests it 
is best utilised in patients with limited overall coronary disease burden and complexity, 
yet in current practice it is often employed for those with high surgical risk. While there 
are published data on outcomes following ULMCA PCI is selected groups of patients, 
there are limited data describing current real-world practice. Current revascularisation 
guidelines apply data from randomised studies using traditional outcome measures to 
stratify the appropriate use of treatment modalities. Although measures of health-related 
quality of life (HRQOL) are recognised to be important to patients, they are rarely taken 
into consideration in contemporary guidelines or clinical decision making. While there is 
limited knowledge surrounding the HRQOL outcomes from randomised studies of LMCA 
revascularisation, no published studies have assessed HRQOL outcomes in the ‘real world’ 
population treated for LMCA disease, including those who are medically managed.  
Methods: 
First, we undertook a retrospective analysis of patients undergoing PCI for ULMCA at a 
single cardiac centre in the UK. We identified a retrospective cohort of patients who 
received LMCA PCI between March 2005 and March 2013. We applied Cox proportional 
hazards model to identify the major predictors of poor survival and clinical outcomes. The 
primary composite outcome was major adverse cardiac and cerebrovascular events 
(MACCE), comprising all-cause mortality, myocardial infarction, stroke and repeat 
revascularisation. In separate analyses, we excluded patients with cardiogenic shock, 
while other subgroups analysed included LMCA bifurcation cohorts and octogenarians.   
Second, we recruited a prospective cohort of patients with LMCA disease managed 
conservatively or by PCI or CABG and applied an HRQOL questionnaire at 4 times points 
over the course of 1 year follow-up. Multilevel modelling using linear mixed models was 
used to conduct longitudinal analyses of HRQOL outcomes. 
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Results: 
The Kaplan-Meier estimate of MACCE at 1 year was 26.2% and at the median (IQR) 
follow-up of 584 (1036) days it was 41.8%. Significant factors associated with MACCE 
include SYNTAX score(SS) [ Hazard ratio (HR) 1.01; 95% Confidence Interval (CI): 1.00 - 
1.02; p<0.05], presentation in cardiogenic shock [adjusted Hazard Ratio (aHR) 5.88, 95% 
CI 3.81-9.06, p<0.05], previous MI [aHR 1.94, 95% CI 1.37-2.75, p<0.05] and a history of 
diabetes [aHR 1.61, 95% CI 1.12-2.31, p<0.05] after long term follow-up. With a separate 
analysis excluding patients with cardiogenic shock we found SS [aHR 1.02, 95% CI 1.00-
1.04, p<0.05], previous MI [aHR 1.89, 95% CI 1.28-2.80, p<0.05], peripheral vascular 
disease [aHR 1.68, 95% CI 1.09-2.61, p<0.05] and renal impairment [aHR 1.89, 95% CI 
1.05-3.43, p<0.05] were significantly associated with MACCE; for every 10 unit increase in 
SS there was a 2% increase in the risk of MACCE. In a separate analysis of patients with 
‘True’ LMCA bifurcation disease, there was no difference in survival from a single or two 
stent strategy. Residual coronary disease amongst octogenarians was assessed using the 
residual SS, each 10 unit increase in rSS was associated with a 3% increase in all-cause 
mortality (aHR 1.03; 95% CI, 1.00-1.06; p=0.04].  HRQOL was found to deteriorate 
significantly over 1 year for patients managed conservatively, while despite earlier 
improvement in HRQOL following PCI, the HRQOL for patients treated with CABG 
overtook these and showed greater and more sustained improvement over 1 year. 
Conclusion:  
This database describes a real world cohort of patients with LMCA, with significantly 
greater coronary disease burden and comorbidity than most published studies. While 
cardiogenic shock was a strong predictor of poor outcomes, the SS was also associated 
with poor outcomes. Other measures of coronary disease burden, such as ‘True’ 
bifurcation disease are significant predictors of poor outcomes. Diabetes is a predictor of 
outcome, yet after excluding cardiogenic shock, the association is no longer evident. After 
adjusting for the sequelae of the diabetes, such as renal impairment and burden of 
atheromatous disease (SS and PVD), these variables become significant predictors of  
poor outcomes.. Residual SS following PCI was associated with poor outcomes in this 
long-lived population, suggesting that untreated coronary disease is undesirable, 
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although it is not clear that more aggressive revascularisation is indicated. HRQOL 
measures suggest that, despite selection bias, patients currently selected for conservative 
management for LMCA may benefit from some form of targeted revascularisation despite 
limited prognostic benefit.   
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multifactorial pencil-and-paper questionnaire which assesses the five cognitive illness 
representations. It uses a single-item scale, across nine items, approach to assess 
perceptions on a continuous linear scale. It was developed by forming one question that 
best summarised the items contained in each subscale of the IPQ-R (Illness Perception 
Questionnaire-Revised). 
IQR: Interquartile range 
LAD: Left anterior descending 
LCx: Left circumflex artery 
LMCA: Left Main Coronary Artery 
LSOA: Lower super output area 
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LST: Late stent thrombosis 
LTHT: Leeds Teaching Hospitals Trust 
MACE: Major Adverse cardiac events 
MACCE: Major adverse cardiac and cerebrovascular events 
MB: Main branch 
MDT: Multi-disciplinary Team 
Medina classification: The Medina classification was proposed to classify coronary 
bifurcation disease in 2006, it is a binary system indicating the angiographic presence of 
disease in the main vessel (MV), main branch (MB) and side branch (SB) around the 
bifurcation (i.e. disease present in all three vessels MV,MB,SB = 1,1,1). 
MI: Myocardial Infarction 
MV: Main vessel 
NHS: National Health Service 
NIGB: National Information Governance Board (for Health and social care) 
NIHR: National Institute for Health Research  
NOBLE trial: Nordic-Baltic-British Left Main Revascularization Study  
NS: Not significant 
NSTEMI: Non-ST segment Elevation Myocardial Infarction 
N3 Network: This is a Wide Area IP Network (WAN) which is the national broadband 
network of the NHS. It runs over a high-speed IP-based Virtual Private Network which 
connects all locations within NHS England & Scotland. Acute hospitals and GP surgeries in 
England are linked through 58 points of presence (POPs), with a further 5 POPs in 
Scotland. Other networks, such as the Internet, are connected via Gateways, eg. Internet 
Gateway. British Telecom was awarded the contract to deliver and manage N3 on behalf 
of the NHS in 2004 
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NOBLE: Nordic–Baltic–British left main revascularisation study 
Non-WB: Non-whole bifurcation 
ONS: Office for National Statistics 
OR: Odds ratio 
PAS: Patient Administration System 
PatID: patient identifier 
PCI: Percutaneous Coronary Intervention 
PIS: Patient Information Sheet 
PRECOMBAT: PREmier of Randomized COMparison of Bypass Surgery Versus AngioplasTy 
Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease 
QOL: Quality of life 
RCT: Randomised controlled trial 
Residual SYNTAX score (rSS): the sum of all residual coronary disease after coronary 
intervention as calculated using the SS. The baseline score for a treated lesion is 
subtracted from the overall baseline score. In most published studies of rSS, the lesion 
characteristics of calcification, tortuosity, angulation and thrombus are deducted. 
However in this study these measures of jeopardy of treated lesion were retained for 
calculation of the rSS. 
SB: Side branch 
SD: Standard deviation 
SQL: Structured Query Language 
SS: SYNTAX score. The SS is a comprehensive anatomical assessment derived from 
various pre-existing classifications. It is calculated by analysing diagnostic angiograms. 
Each lesion producing ≥50% luminal obstruction in vessels ≥1.5 mm is defined based on 
the modified AHA coronary tree segment classification and separately scored regarding 
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bifurcations or trifurcations or aortic ostial localisation, chronic occlusion, vessel 
tortuosity, length, calcification and thrombus formation. Finally, the score of each lesion 
is added to obtain the patient’s raw SS. Thus, the SS reflects a comprehensive anatomical 
assessment, with higher scores indicating more complex coronary disease; a low score 
was defined as ≤22, an intermediate score as 23 to 32, and a high score as ≥33. 
SSL: Secure Sockets Layer, communication between a user web browser and a secure 
website requires this layering of security. SSL certificates assure users that the website is 
legitimate and not a copycat website. Communications between the web browser and 
study website is encrypted. This level of security is commonly employed on websites 
transferring sensitive information such as credit card details -the URL protocol https// 
instead of http:// is used to designate an SSL secure website. The encryption is 
automatically employed by the website. Certificates are validated by the Certificate 
Authority for a fee after registering company details. The certificate is installed on the 
server where the website is hosted. 
ST: Stent thrombosis 
STEMI: ST segment Elevation Myocardial Infarction, indicating transmural infarction of 
myocardium usually due to a complete occlusion of the coronary artery. 
SYNTAX trial: Synergy between PCI with Taxus and Cardiac Surgery trial 
TLR: target lesion revascularisation 
TVR: Target vessel revascularisation 
ULMCA: Unprotected Left Main Coronary Artery is considered ‘unprotected’ if there is no 
functioning graft to any of the left coronary arteries. 
WB: Whole bifucation 
VLST: Very late stent thrombosis
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1. Introduction  
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1.1 LMCA disease background 
 
Significant left main coronary artery (LMCA) disease, defined as >50% diameter stenosis, 
may be found in 5-7% of patients undergoing coronary angiography [1, 2]. A more recent 
meta-analysis of published studies suggests a prevalence of greater than 12% amongst 
patients who are treated for coronary disease [3]. Intuitively, those with the largest 
amount of myocardium at risk, such as unprotected LMCA (ULMCA) disease or 
multivessel coronary disease, would suffer worse outcomes if left untreated. The LMCA 
supplies 100% of the blood to the left ventricle in a left dominant circulation and about 
75% in a right dominant circulation [4]. Studies have confirmed that coronary artery 
bypass grafting (CABG) in patients with LMCA disease improves long term survival when 
compared with conservative treatment (Table 1) [5-8]. While amongst those who are 
revascularised for multivessel coronary disease, ULMCA disease is an independent 
predictor of poor long term outcomes [9].  
 
The evidence in support of CABG for ULMCA disease dates back to the Coronary Artery 
Surgery Study (CASS) registry in the 1970s, soon after the introduction of CABG in the 
1960s. Over a 15-year follow-up, CABG conferred a median survival advantage which was 
double that of medical management. Median survival in the surgical group was 13.3 years 
(12.8-13.8 years, 95% Confidence interval [CI]) compared with 6.6 years (5.4-7.9 years) in 
the medically managed group (difference, 6.7 years; p < .0001) [4]. Randomised trials of 
CABG compared to medical management consistently identify ULMCA disease as an 
independent predictor of poor survival over long term follow-up [10], these studies 
include patients with single or multivessel coronary disease [11, 12]. It is further shown in 
these studies that ULMCA disease confers higher operative risk than all other subsets of 
multivessel coronary disease. 
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Table 1: Studies comparing CABG to medical management for LCMA disease 
 
 
 
 
Author Year Study 
design 
CABG  Medically 
managed 
Survival for CABG vs medically managed 
1 year 3 year 5 year 
Talano[5] 1975 registry 89 32 89% vs. 61% (p<0.05)   
ECS study group[10] 1980 RCT 395 373   93% vs 84% (p=NS) 
Chaitman[6, 7] 1981 registry 1183 309  91% vs. 69% (p<0.05) 88% vs 57% (p=0.02) 
Takaro[8] 1982 RCT LMCA 
subgroup 
48 43  88% vs. 65% (p=0.05)  
CABG – coronary artery bypass grafting; LMCA – left main coronary artery; RCT – randomised controlled trial; ECS  –  European Coronary 
Surgery; NS – not significant 
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1.2 PCI of LMCA disease 
 
Percutaneous coronary intervention (PCI) as treatment of the ULMCA was performed 
sporadically at first and was limited to balloon angioplasty in patients ineligible for CABG. 
The proximal, readily accessible, muscular and large calibre LMCA would seem the ideal 
target for this form of revascularisation. The initial observational data on LMCA PCI from 
registry analysis revealed high rates of ‘bail out’ surgery and the subsequent need for 
surgical revascularisation during medium-term follow-up [13]. These adverse outcomes 
were related to acute vessel closure, vessel recoil and subsequent restenosis; the solution 
seemed to be the introduction of bare metal stents (BMS) which reduced the peri-
procedural risk of acute vessel failure [14]. However, the early benefits of BMS were 
offset by the high restenosis rates, of up to 23%, resulting in subsequent target vessel 
revascularisation (TVR) or target lesion revascularisation (TLR) [15]. Drug-eluting stents 
(DES) have reduced the restenosis rates compared to BMS in coronary arteries [16, 17], 
these results were subsequently replicated in the LMCA [18, 19] (Table 2). 
Data exploring outcomes from DES and BMS are derived mainly from registries and 
reflect the transition of practice in interventional cardiology from BMS to DES during the 
early noughties. The first studies comparing DES to BMS in the LMCA included matched 
retrospective cohorts of patients, confirming the benefit of reducing the risk of 
myocardial infarction (MI) and TVR [18]. There remains only one randomised trial 
comparing DES to BMS in the LMCA using a paclitaxel-eluting stent; this study showed a 
significantly reduced binary angiographic restenosis rate with DES [20]. First generation 
DES including sirolimus- [21] and paclitaxel-eluting [20, 22] platforms were studied 
independently and in mixed cohorts [23, 24].  Despite high-risk cohorts including worse 
coronary anatomy, such as more distal LMCA disease and smaller calibre vessels, both 
DES platforms reduced the risk of major adverse cardiac and cerebrovascular events 
(MACCE), concerning TVR and TLR, when compared with BMS for the treatment of the 
LMCA [21, 22]. While these studies confirmed the reduced restenosis rates, a meta-
analysis of studies comparing DES to BMS in ULMCA disease suggests there is a better 
survival from DES treatment in addition to the reduced TVR/TLR [25].
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Table 2: Bare metal stents vs. drug eluting stents for LMCA disease 
Author Year Study design Adjustment DES BMS Duration 
(months) 
Outcomes 
MACCE TLR/TVR 
Chieffo [21] 2005 Historical 
cohort 
Propensity score 
matching 
85 64 6 OR-0.27 (0.09-0.73) p<0.05 OR- 0.28(CI0.09-0.73) p<0.05 
Erglis [20] 2007 Randomised Randomisation 53 50 6 OR- 0.36 (0.13-0.96) p<0.05 OR-0.10 (0.01-.84) p<0.05 
Gao [23] 2008 Cohort study Propensity score 
matching 
220 224 15 OR- 0.53 (0.30-0.94) p<0.05 OR- 0.48 (0.24-0.96) p<0.05 
Palmerini [24] 2008 Multicentre 
registry 
Propensity 
adjusted 
1111 342 24 aHR 0.49 (0.32 -0.77) p<0.05   
Han [22] 2009 Cohort study Propensity score 
matching 
178 109 35 OR- 0.23 (0.09-0.58) p<0.05 OR- 0.26 (0.08-0.83) p<0.05 
Kim [26] 2009 Prospective 
cohort 
Probability 
weighting 
864 353 36 aHR- 0.81 (0.54–1.21) p<0.05 aHR - 0.32 (0.17–0.61) p<0.05 
Tamburino 
[18] 
2009 Multicentre 
registry 
Propensity score 
matching 
187 187 18   aHR - 0.68 (0.21-0.69) p<0.05 
Tamburino 
[27] 
2009 Multicentre 
registry 
Propensity score 
matching 
334 145 15 aHR- 0.73 (0.44-1.21) NS aHR - 0.79 (0.33-1.90) NS 
BMS – bare metal stent; DES – drug eluting stent; LMCA – left main coronary artery; MACCE – major adverse cardiac and cerebrovascular disease; TLR – target lesion revascularisation; TVR – 
target vessel revascularisation; OD – odds ratio; aHR – adjusted hazard ratio; NS – not significant 
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1.2.1 DES vs CABG, data from published registries  
 
Early published registries with follow-up of up to 5 years have demonstrated favourable 
survival from LMCA PCI using DES when compared to CABG. A meta-analysis of 16 
observational studies, including 1278 patients, demonstrated the safety of DES for treating 
ULMCA disease with a 2.3% in-hospital mortality rate and 5.5% mortality rate at a median 
follow-up of 10 months [28]. While virtually all these studies showed no significant 
difference in MACCE at one year, there were significantly higher rates of TVR and TLR for 
DES PCI (Table 3). 
 
Despite the growing evidence supporting the safety endpoints of DES PCI for treating 
patients with ULMCA disease, given the heterogeneous study cohorts, it remained uncertain 
whether PCI would be appropriate for treating all presentations, especially those with a 
greater burden of coronary artery disease. In keeping with the nature of observational 
studies, there were huge disparities between treatment groups for the burden of coronary 
disease; patients considered for PCI had less extensive coronary involvement when 
compared with those treated with surgery [29-33]. While other studies with well-matched 
cohorts, despite no significant difference in death or MACCE, continued to show higher 
rates of TVR/TLR with DES PCI [34]. A randomised trial comparing CABG to PCI in patients 
suitable for both procedures would identify the threshold of coronary disease burden at 
which the short term benefits of PCI are outweighed by the poor long term outcomes  [35].  
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Table 3: PCI vs CABG for LMCA disease 
Author Year Study design PCI (%DES) CABG Duration 
(months) 
Outcomes 
Death MACCE TLR/TVR 
Lee [36] 2006  50(100%) 123 12   17.0% vs. 25.0% p= NS   
Palmerini [37] 2006 Prospective 157(60%) 154 14 13.4% vs. 12.3 p= NS   25.5% vs. 2.6% p<0.05 
Sanmartin [38] 2007 Retrospective 96(100%) 245 12 5.2% vs. 8.4% p= NS 10.4%  vs. 11.4% p= NS 0.8% vs. 5.2% p<0.05 
Rodes-Cabau [39] 2008 Retrospective 104(46%) 145 23   43.3% vs. 35.3% p= NS   
White [40] 2008 Retrospective 67(100%) 67 24   aHR-1.8 (1.0-3.3) p= NS   
Brener [41] 2008 Retrospective 97 190 36 20.0% vs. 15.0% p= NS     
Shimizu [32] 2010 Prospective 64(100%) 89 18 8.1% vs. 6.6% p= NS 37.3% vs. 17.8% p= NS   
Kang [31] 2010 Retrospective 205(100%) 257 36 14.1% vs. 12.1% p= NS 35.1% vs. 21.8% p<0.05 22.4% vs. 5.1% p<0.05 
Wu [30] 2010 Prospective 131(100%) 245 48 4.6% vs. 9.4% p= NS 27.0% vs. 22.0% p= NS 18.0% vs. 9.4% p<0.05 
Park [29] 2010 Prospective 1102(71%) 1138 60 aHR-1.1(0.9-1.4) p= NS   aHR-5.1 (3.5-7.4) p<0.05 
Chieffo[34] 2010 Prospective 107(100%) 142 60 15.9% vs 18.3% p= NS 32.4% vs. 38.3% p= NS 18.7% vs. 8.4% p<0.05 
Park [42] 2011 Prospective 645(100%) 501 55 10.4% vs 16.2% p= NS   14.4% vs 3.4% p<0.05 
Chieffo [43] 2012 Retrospective 1874 (100%) 901 43 14.1% vs 11.4% P=NS 30.3% vs 20.1% P<0.05 25.7% vs 8.9% P<0.05 
PCI – percutaneous coronary intervention; CABG – coronary artery bypass grafting; DES – drug eluting stent; LMCA – left main coronary artery; MACCE – major adverse cardiac and cerebrovascular 
disease; TLR – target lesion revascularisation; TVR – target vessel revascularisation; aHR – adjusted hazard ratio; OD – odds ratio; NS – not significant 
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1.2.2 Overall results from randomised trials DES vs CABG for LMCA disease 
 
In the first published randomised trial comparing outcomes from LMCA PCI to CABG, 
DES was only used when the LMCA measured ≤3.8mm [44] (see Table 4). The results 
indicated equivalent outcomes from PCI and CABG. However, the trial was 
underpowered. Notably, almost two-thirds of patients screened were excluded from 
the study.  Similarly, more than half the patients screened were excluded from a trial 
reported by Boudriot et al [45]. This study was the first designed to show non-
inferiority of LMCA PCI to CABG when using DES. While the study failed to demonstrate 
non-inferiority using the composite end-point of MACCE, non-inferiority was 
demonstrated using the composite of safety endpoints death, MI and stroke. As with 
the previous non-randomised studies, there was significantly more TVR and TLR with 
PCI treatment. 
The randomised PREmier of Randomized COMparison of Bypass Surgery Versus 
AngioplasTy Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery 
Disease (PRECOMBAT) study reported 5 year results, which are consistent with earlier 
registry findings, with no significant difference in MACCE between PCI and CABG (17.5% 
vs 14.3%, p=NS). However, significantly more TVR was reported with PCI (11.4% vs. 
5.5%)[46]. The data did not quantify the specific burden of coronary disease for which 
DES PCI would achieve similar outcomes compared with CABG. A standardised, 
repeatable and reliable method for quantifying the burden of coronary disease would 
be required to allow the accurate matching of patients. The objective would be to 
establish cut-off values that would describe a distinct watershed of outcomes between 
scores; this would require an extensive trial incorporating all multi-vessel disease. 
The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial was a 
randomised multicenter trial designed to show non-inferiority of PCI, using Taxus DES, 
versus CABG in patients with multivessel coronary disease including LMCA disease [47]. 
The SYNTAX score (SS ) was formulated to quantify the amount and complexity of 
coronary disease [35]. The SS is a comprehensive anatomical assessment calculated 
when analysing the diagnostic angiogram, which was derived from various pre-existing 
classifications. The coronary tree was divided into segments according to the modified 
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American College of Cardiology/American Heart Association (ACC/AHA) coronary tree 
segment classification [48, 49]. Application of a weighting factor per significant 
coronary lesion is based on the Leaman score and the expected obstruction to the 
blood flow of the left ventricle [50]. Lesions with a luminal narrowing of ≥50% in 
vessels ≥1.5 mm in size were considered significant. A weighting factor of 2 was 
added for a complete total occlusion and 1 for lesions with 50-99% stenosis. Tandem 
lesions were counted as a single lesion if within three reference vessel diameters of 
each other. Characteristics which define lesion complexity according to the ACC/AHA 
lesion classification system were considered additive [51], such as bifurcations or 
trifurcations or aortic ostial localisation, chronic total occlusion, vessel tortuosity, 
length, calcification and thrombus formation. Additional scores were given for the 
specific characteristics of a chronic total occlusion [52] and for bifurcation or 
trifurcation lesions according to the Duke and ICPS bifurcation lesion classification 
systems [53][54]. Finally, the scores for each coronary obstruction were added 
together to obtain the patient’s overall SS. Thus, the SS reflects a comprehensive 
anatomical assessment, with higher scores indicating more complex and extensive 
coronary disease. The study cohort was ordered by SS and then divided into tertiles, a 
low score was defined as ≤22, an intermediate score as 23 to 32, and a high score as 
≥33 [55].  
The primary non-inferiority end-point was not met for the overall study population in 
the SYNTAX trial. The subgroup analysis of the LMCA group, therefore, should be 
considered observational and hypothesis generating as it was underpowered. In the 
LMCA subgroup, 348 patients were randomised to CABG and 357 to PCI. The MACCE 
rate at 12 months and three years were comparable for the two groups. However, the 
rate of repeat revascularisation was significantly higher in patients randomised to PCI 
(Table 5). In this study, patients with an intermediate SS (23-32) or high SS (≥33) had 
worse outcomes from PCI than CABG, which was driven mainly by higher rates of TVR 
[12]. At 12 months there was no significant difference in survival or MACCE between 
the two groups. However, the rate of repeat revascularization among patients treated 
with PCI was significantly higher. Pooled results from a meta-analysis of all randomised 
trials of ULMCA PCI vs. CABG have confirmed these results [56-58]. At three years 
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follow-up the MACCE rate was comparable (26.8% vs. 22.3%; p = NS), however rates of 
repeat revascularisation remained higher in the PCI group (20.0% vs. 11.7%; p<0.05). 
When considering the composite safety endpoint (death, CVA or MI), there was a 
statistical trend towards better outcomes from PCI. Pooled results from over fourteen 
thousand patients with five years of follow-up confirmed the comparable survival from 
PCI and CABG, with the ongoing trend towards increased need for repeat 
revascularisation from PCI [58]. 
The recently published Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for 
Effectiveness of Left Main Revascularization (EXCEL) and the Nordic-Baltic-British Left 
Main Revascularization Study (NOBLE) randomised trials reported conflicting results 
for revascularisation of intermediate complexity coronary disease [59, 60]. While both 
studies aimed to recruit patients with a low to intermediate burden of coronary 
disease, the EXCEL investigators defined this according to a SS ≤32 while the NOBLE 
investigators did not use the SS. Instead they included patients with a significant lesion 
(>50.0% stenosis or FFR<0.80) of the LMCA (ostium, mid-shaft and/or bifurcation) AND 
with no more than three additional non-complex PCI lesions. Complex lesions were 
defined as calcified/tortuous coronary artery lesions, >25 mm in length, Chronic Total 
Occlusion (CTO) or a bifurcation lesion requiring treatment with a 2-stent strategy. 
After three years follow-up, the EXCEL investigators reported non-inferior outcomes 
from PCI compared to CABG for MACCE. However, they reported an increased risk of 
repeat revascularisation from PCI. The NOBLE investigators reported significantly 
worse outcomes from PCI for the composite outcomes of MACCE and the secondary 
outcomes of non-procedural myocardial infarction, any revascularisation and stroke.   
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Table 4: Randomised studies of PCI vs. CABG 
Author Year Study design PCI (%DES) CABG Duration 
(months) 
Outcomes 
Death MACCE TLR/TVR 
Buszman [44] 2008 Randomised 52(35%) 53 12 1.9% vs. 7.5%% p=NS 28.8% vs. 25.5% p=NS 9.6% vs. 9.4% p=NS 
Morice [61] 2010 Randomised, multicentre  357(100%) 348 12 4.2% vs. 4.4% p=NS 15.8%% vs. 13.6% p=NS 11.8% vs. 6.5% p<0.05 
Boudriot [45] 2011 Randomised 100(100%) 101 12   19.0% vs. 13.9% p=NS 13.0% vs. 4% p<0.05 
Park [62] 2011 Randomised 300(100%) 300 24   12.2% vs. 8.1% p=NS 9.0% vs. 4.2% p<0.05 
Mäkikallio [60] 2016 Randomised, multicentre 598 603 60 12.0% vs 9.0% p=NS 29.0% vs 19.0% p<0.05 16.0% vs 10.0% p<0.05 
Stone [59] 2016 Randomised, multicentre 948 957 36 8.2% vs 5.9% p=NS 23.1% vs 19.1% p=NS 12.9% vs 7.6% p<0.05 
PCI – percutaneous coronary intervention; CABG – coronary artery bypass grafting; DES – drug eluting stent; LMCA – left main coronary artery; MACCE – major adverse cardiac and 
cerebrovascular disease; TLR – target lesion revascularisation; TVR – target vessel revascularisation; aHR – adjusted hazard ratio; OD – odds ratio; NS – not significant 
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1.2.3 Implications for clinical practice from the randomised data 
 
The SS is a useful measure which allows the valid comparison of the burden of 
coronary disease among patients [35], even when applied across different studies. The 
SS has been validated when applied retrospectively to assess observational registries 
with results consistent with the randomised trials. One such study confirmed 
equivalent outcomes from PCI and CABG amongst the low SS group (score ≤22), but 
inferior outcomes from PCI in the high SS (score ≥33) group [42]. Another registry 
confirmed the discriminative ability of the SS to predict worse outcomes for patients 
with high SS [63]. The very low event rates reported in the PRECOMBAT trial, when 
compared to all other randomised trials and registries, may be explained by the less 
extensive coronary disease burden (median SYNTAX score only 25)  [64].  
While the SS is predictive of outcomes amongst patients with ULMCA disease treated 
with PCI [63, 65, 66], there is disagreement when it comes to predicting outcomes 
from CABG. Some studies have shown that it is a predictor of MACCE amongst patients 
treated with CABG [67], while others suggest it is not as useful as other clinical scores 
[65, 68]. There is significant interobserver variability with calculating the SS, which may 
explain some of the conflicting data, yet it creates doubt when comparing SS across 
various studies [68]. 
Randomised trials inform clinical revascularisation guidelines, yet one could argue they 
do not represent the ‘real world’ patient population to which these guidelines are 
applied. The SYNTAX trial was an all-comers study design, yet failed to recruit more 
than 58% of all patients screened while almost 30% of all patients were enrolled into a 
separate registry as they were ineligible for one or other of the treatment modalities 
[55]. A screening log was maintained at only five centres which recruited 506 of the 
1201 patients in the NOBLE trial; these five centres rejected close to half of all patients 
screened [60]. Similarly, the EXCEL trial kept a screening log for the first 1747 patients 
only, of whom they were able to recruit 747 (42.7%) patients, thereafter they closed 
the registry and recorded only patients recruited to the study.  
   34 
 
1.2.4 Current guidelines:  
 
The evidence from observational studies and randomised trials indicate that CABG is 
superior to PCI due to increased need for repeat revascularisation with PCI. The 
randomised studies have not shown a different signal compared to the observational 
data, but the SYNTAX trial and more recently the EXCEL trial have allowed us to 
identify a cohort of patients which may have similar outcomes from PCI, those with a 
SS≤32. Given the NOBLE trial data, we should weigh up the risks and benefits for each 
patient individually. So while we may conclude that particular coronary disease 
patterns and patient risk profiles could indicate favourable outcomes from PCI if used 
as an alternative to CABG [69], management decisions should continue to be made by 
a multi-disciplinary team (MDT). Thus CABG remains a Class I recommendation to 
improve survival for significant (angiographic stenosis ≥ 50% diameter) LMCA stenosis. 
PCI is a Class IIa recommendation to improve survival as a reasonable alternative to 
CABG in selected stable patients with significant (≥ 50% diameter stenosis) 
unprotected LMCA disease (ULMCA). These patients include: 
1. Anatomical characteristics indicating a low PCI procedural risk and a likely good 
long-term outcome [e.g., a low SYNTAX score (≤ 22), ostial or trunk LMCA 
disease]; and 
2. Patient characteristics associated with increased risk of adverse outcomes from 
surgery (high surgical operative risk scores) [70]. 
It is considered a Class IIb recommendation for PCI to be used as a reasonable 
alternative to CABG in patients with: 
1. Anatomic characteristics indicating a low to intermediate PCI procedural risk 
with an intermediate to high probability of good long-term outcome (e.g., a low 
to intermediate SS of ≤33, LMCA bifurcation disease); and 
2. Patient characteristics predicting increased risk from surgery (e.g. history of 
chronic obstructive pulmonary disease (COPD), previous stroke and previous 
cardiac surgery) [70]. 
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The SYNTAX score is a useful tool to describe various study populations. 
Notwithstanding these benefits, the vast majority of patients excluded from these 
trials represent the real population requiring careful decision making. While the 
published literature has identified a cohort of patients for whom PCI is a viable 
alternative for revascularisation of the LMCA, the findings may not apply to the 
patients for whom PCI is the only option. It is for these patients that observational 
studies present an ideal means to identify the particular challenges of PCI for which 
further studies could be designed. 
 
1.3 LMCA bifurcation disease 
 
LMCA bifurcation stenoses have been identified as an independent predictor of long 
term MACCE [26, 28, 71-77]. The left main coronary artery is divided into three 
anatomical sections, the ostium, the body and the bifurcation. The ostium and body 
can be treated with great success using PCI; however the treatment of the bifurcation 
is fraught with procedural complications and long term poor outcomes [78], yet 
debate still remains as to the best approach to treat the LMCA with PCI.  
 
1.3.1 Approach to coronary bifurcations 
 
Coronary bifurcation disease represents one of the more challenging lesion types to 
treat with PCI; procedural success depends on operator experience. Compared with 
non-bifurcation coronary PCI there is a greater chance of procedural complications 
when attempting PCI of the coronary bifurcation, such as acute vessel closure of the 
side branch (SB) [79, 80], while poor long-term outcomes include high rates of TLR [81]. 
The choice of stent strategy, either a provisional single stent or elective two stent 
strategies, are influenced by the distribution of disease in the branches, the size of the 
side branch and the branch angle. One should first consider whether a stent should be 
inserted into the SB electively, as this dictates further treatment strategies.  A 
provisional single stent, where the first stent is placed from the main vessel (MV) into 
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the main branch (MB) across the SB, is recommended. If the SB becomes compromised, 
further ‘bail out’ strategies could be considered where the SB may be treated with an 
additional stent. Data supporting this approach comes from large randomised clinical 
trials, such as the BBC ONE and Nordic trials [82, 83]. These trials’ populations, 
however, included less than 4% of cases with LMCA bifurcation disease. One should 
note that these studies analysed on an ‘intention to treat’ basis and employed rigorous 
treatment protocols for decision making. 
The European Bifurcation Club (EBC) consensus favours a provisional single stent 
approach for all coronary bifurcations with certain caveats [84]. The operator may 
decide to use a two stent approach depending upon: (1) the size of the side branch 
(SB), and therefore the myocardium at risk; and (2) the distribution of disease around 
the side branch. A two stent approach, securing the SB with a stent from the outset, 
may be considered in patients with a large SB with significant ostial disease extending 
further into the side branch vessel.  
 
1.3.2 Specific features of LMCA bifurcation disease 
 
While significant (>50% stenosis) LMCA disease may be found in up to an eighth of 
patients undergoing coronary angiography for chest pain [85], up to 80% of these 
stenosed LMCA’s involve the bifurcation, and up to 80% of patients with left main 
disease will have associated multi-vessel coronary artery disease [45, 61, 86-88]. There 
are specific features which present a challenge when considering PCI of the LMCA 
bifurcation including: (1) usually a large calibre (>2.5mm) SB, the circumflex (LCx) 
vessel; (2) atheromatous disease of the bifurcation is often more extensive involving 
the ostia of both branches; and (3) there is a large amount of myocardium at risk. Due 
to the acute angulation of the bifurcation, the distribution of atheroma is not always 
apparent on conventional angiography; one may have to consider unusual and steeper 
views or the use of intravascular imaging to delineate the anatomy and the 
involvement of branch ostia [89]. The LMCA bifurcation presents the operator with 
different challenges when compared with other coronary bifurcations; outcomes from 
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elective two stent strategies for the LMCA bifurcation are worse than those for left 
anterior descending (LAD) bifurcations with higher TLR rates in LMCA bifurcations [90, 
91]. 
 
1.3.3 Classification of atheromatous burden at the bifurcation 
 
Six different classification systems were used to report outcomes amongst studies of 
LMCA bifurcation PCI. Consequently, this creates difficulty with comparing the results 
due to the heterogeneous populations [92][93][94][95][53]. Extensive plaque 
involvement at the bifurcation is strongly associated with high TLR rates regardless of 
the stent strategy used [96]. These classification systems rely on the accurate 
identification of significant plaque burden, which can be difficult, with angiography 
alone. Significant LMCA atheroma may be detected with intra-vascular ultrasound 
(IVUS) assessment when angiography is equivocal [97-100]. IVUS findings may help 
determine the distribution of disease around the LMCA bifurcation [89, 101, 102] and 
influence the choice of treatment strategy due to predicted change in LMCA geometry 
and side branch stenosis [103]. 
 
A recent study suggested the use of ‘whole bifurcation’ (WB) and ‘non-whole 
bifurcation’ (non-WB) to describe the atheroma burden at the LMCA bifurcation. WB’s 
were associated with worse outcomes. However, this classification system was 
considered impractical for everyday use [96]. Rather the Medina classification has 
been proposed, it is a simplified way to describe the distribution of significant 
atheroma burden around the bifurcation [104]. This classification system allowed the 
standardised reporting of results across studies (Figure 1) [92, 105]. To indicate the 
absence or presence of disease within 5mm of the bifurcation in either the main vessel 
(MV), main branch (MB) or side branch (SB), one uses binary coding, e.g. disease in all 
three (MV, MB, SB) vessels is designated as 1,1,1. More recently lesions have been 
classified as ‘True’ and ‘Non-true’ bifurcation disease, this simply relies on the Medina 
classification and has been adopted by the European Bifurcation Club (EBC) [106, 107]. 
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‘True’ bifurcation disease includes Medina classes 1,1,1. 1,0,1 and 0,1,1, where the SB 
is diseased in all categories, these lesions are typically associated with worse outcomes 
[108-110]. 
 
 
Figure 1 Medina Classification of bifurcation disease, adapted to the 
LMCA 
 
 
The LMCA bifurcation contributes up to 2 points to the SYNTAX score if it involves the 
side branch ostium otherwise only 1 point. So this would include all ‘True’ bifurcation 
lesions by Medina classification, except the 1,0,1 lesion [35]. The stenosed distal LMCA 
represents a small addition to the SYNTAX score, yet it is a significant independent 
factor contributing to poor long-term outcomes.  
 
1.3.4 LMCA bifurcation PCI outcome measures 
 
The use of DES in the distal LMCA has reduced the risk of TLR when compared with 
BMS use [26]; however poor outcomes from PCI of the LMCA bifurcation are mainly 
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driven by repeat revascularisation [71, 111]. Repeat revascularisations are reported to 
include various combinations of target vessel revascularisation (TVR) and TLR [26, 28, 
71-73].  Distal LMCA disease is typically associated with a greater burden of multi-
vessel disease; this could, therefore, confound outcomes when reporting ‘repeat 
revascularisations’ as TVR may be secondary to distal vessel coronary disease rather 
than restenosis of the LMCA bifurcation. Repeat revascularisation reported in these 
studies may also include the subsequent treatment of non-ischaemic lesions; routine 
angiographic follow-up after LMCA PCI was considered standard clinical practice 
previously, which may result in additional TLR [96, 112]. 
 
1.3.5 Stent strategy for the LMCA bifurcation 
 
Evidence from LMCA bifurcation PCI registries 
There are limited data to guide the choice of stent strategy for the treatment of LMCA 
bifurcation disease. Registries of LMCA bifurcation PCI have reported conflicting results 
(Table 5). Some studies indicate there is no difference in outcome between single and 
two stent strategies [113, 114] while others report fewer MACCE from a provisional 
single stent approach [77]. Inherent selection bias may account for this conflict due to 
the differences between treatment groups. One large registry reported a higher risk of 
TLR and MACCE when using two stents compared with one stent [115]. However, the 
two treatment groups differed with regards to comorbidity, and another criticism of 
this study was the lack of reporting the atheroma burden for the left main bifurcation 
and the rest of the coronary tree. The choice of PCI strategy is guided by the atheroma 
burden, while the distribution of atheroma around the bifurcation predicts the 
outcome; extensive atheroma at the LMCA bifurcation is associated with worse 
outcomes [96, 113]. Patients with less extensive atheroma of the LMCA bifurcation 
tend to receive a single stent treatment and have less TLR in the long term, while those 
with complex lesions tend to have a two stent strategy [116]. This bias may lead to 
excess repeat revascularisations when MACCE includes TVR rather than TLR.  Therefore, 
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to assess the outcome of the LMCA bifurcation stent strategy, it would be more 
accurate to assess TLR rather than TVR [73].  
 
Evidence from LMCA bifurcation PCI RCT’s 
The only published randomised trial compared two complex stent strategies for the 
treatment of LMCA bifurcation disease, the culotte versus the double kiss crush 
techniques. They included Medina 1,1,1 and 0,1,1 lesions only, where treatment of the 
side branch may be considered necessary [117]. In this trial, where the side branch was 
treated in all cases, they showed significantly better outcomes from the double kiss 
crush technique compared to the culotte technique for PCI of the LMCA bifurcation. 
However this did not answer the question of whether a provisional single stent 
technique would offer equal or superior results to a 2 stent strategy. 
 
The EBC recommends the provisional single stent strategy for treatment of the LMCA 
bifurcation  but notes that the circumflex is ‘almost always’ considered a major SB 
which would favour a two stent technique. They recommend assessing the MB and SB 
with fractional flow reserve (FFR) [118], if FFR is not possible, due to downstream 
disease, they recommend the use of IVUS [119]. Intravascular imaging should be used 
to size the bifurcation stents [120]. Questions remain regarding the choice of stent 
strategy in ‘True’ LMCA bifurcation disease and how the distribution of disease around 
the LMCA bifurcation impacts on the outcome. 
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Table 5: Single stent vs Two stent strategy for LMCA bifurcation 
Author Year Study design Stent Strategy Duration 
(months) 
Outcomes 
Single Two Death MACCE TLR/TVR 
Kim[112] 2006 Prospective cohort 67 49 18 0%    0% vs 12.2% P<0.05 
Valgimigli [113] 2006 Prospective cohort 48 46 19   28% vs 31% p = NS 10.0% vs 13.0% p = NS 
Toyofuku [90] 2011 Retrospective cohort 741 204 12 5.8% vs 8.8% p = NS   5.6% vs 24.2% p<0.05 
Palmerini [115] 2008 Retrospective cohort 456 317 24   24.7% vs. 32.4% p<0.05 13.0% vs 26.9% p<0.05 
Song [116] 2014 Retrospective cohort 509 344 36 1.6% vs 4.1% P<0.05   15.5% vs. 38.1% P<0.05 
LMCA – left main coronary artery;  PCI – percutaneous coronary intervention; MACCE – major adverse cardiac and cerebrovascular disease; TLR – target lesion revascularisation; TVR – 
target vessel revascularisation; aHR – adjusted hazard ratio; OD – odds ratio; NS – not significant 
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1.4 LMCA disease in Octogenarians 
 
1.4.1 Epidemiology 
 
World and UK populations are expected to experience acceleration in the proportion 
of older people in the next 20-30 years [121-123]. The elderly are more likely to suffer 
with extensive and complex coronary disease, including a greater incidence of ULMCA 
disease [3, 124-126]. Patients undergoing revascularisation for ULMCA disease are 
older than those with no ULMCA disease [127]. Octogenarians have been identified as 
a group of patients with a significantly greater risk from revascularisation and have 
been studied extensively within national registries [1, 126, 128-132]. This is not 
surprising given that amongst the elderly, cardiac death remains a significant cause of 
death [133]. The proportion of the population over the age of 80, is predicted to rise 
from less than 5%  currently to 20% by 2050 [134]. Coupled to this is the increasing life 
expectancy for octogenarians, a recent report suggesting a life expectancy of 7 years in 
North America and Western Europe for this age group [135]. According to the 
published Office of National Statistics (ONS) life tables the life expectancy of an 80 year 
old has increased from two years in 1981 up to ten years in 2015 [136].   
 
1.4.2 Revascularisation in the elderly 
 
Age is a major predictor of death from cardiac surgery [137]. PCI and CABG are both 
viable options for revascularisation in the elderly; however advanced age is often given 
as a reason to defer CABG in patients undergoing non-emergent ULMCA PCI [138, 139]. 
Indeed the higher incidences of perioperative morbidity and mortality, coupled with 
longer in-hospital stay, after CABG in elderly patients make PCI an attractive 
alternative to surgery [132, 140]. Notwithstanding the higher peri-procedural risk, age 
alone should not be given as a reason to defer coronary revascularisation amongst the 
elderly [141, 142].  
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For LMCA stenosis treated by CABG, advancing age is strongly correlated with poor 
survival [78]. However, when carefully selecting appropriate patients, ULMCA PCI in 
octogenarians may achieve similar [39, 143] or better outcomes [144] than CABG 
without incurring the penalty of longer post-operative stays and greater cost to the 
healthcare system [128].  Less extensive coronary disease burden and higher surgical 
risk favour PCI.  
 
Evidence supporting revascularisation strategies amongst octogenarians is sparse and 
is mainly described by non-randomised data [39, 141-144].  Revascularisation in the 
elderly carries a higher risk of complications than in younger patients [1, 126, 129, 132, 
133, 142, 145, 146] with nearly four times the procedural mortality rate compared to 
younger patients [1, 128], where the largest difference is amongst the unstable 
patients [126].  Notably, coronary revascularisation offers greater absolute gains in 
survival in the elderly in comparison to the young [130, 142], where octogenarians 
receiving revascularisation can achieve similar survival to the general octogenarian 
population [128]. Indeed the survival benefit is highest amongst octogenarians treated 
with ULMCA PCI compared to the young across all clinical syndromes [147],    
Revascularisation with PCI or CABG achieves a better risk-adjusted survival in 
octogenarians compared with patients under 70 years old [130]. The number needed 
to treat for those under 70 years old was four times greater than for octogenarians. It 
is not surprising that coronary revascularisation could be so effective in improving 
outcomes given that Ischaemic heart disease is the leading cause of death amongst 
men and women over the age of 80  [148][149, 150] . 
 
1.4.3 Complete revascularisation and residual coronary disease 
 
Up to three quarters of patients with  significant left main coronary artery disease have 
associated multi-vessel coronary artery disease [151]. Octogenarians are more likely to 
have multivessel disease, left main disease and more complex lesions compared to 
younger patients [1, 126, 130, 141, 146, 152]. The prevalence of left main coronary 
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artery disease in patients investigated for angina increases with age from 10-15% in 
the 5th and 6th decades to 25% in the 8th decade of life [151]. Among octogenarians, 
the prevalence of LMCA disease requiring revascularisation may be as high as 40% 
[153].  Octogenarians represent up to 24% of all patients treated with PCI to the 
ULMCA in a recent national linked cohort study [154]. In each clinical category, 
STEMI/NSTEMI/Stable angina, octogenarians were found to have higher 1 year 
mortality.   
 
Notably, with greater complexity of coronary disease one finds incremental levels of 
incomplete revascularisation [47, 155] while residual coronary disease is significantly 
associated with increased mortality [156-158]. The mortality benefit of complete 
revascularisation was found in the context of CABG [159, 160]. CABG is considered 
superior to PCI in achieving complete revascularisation [161, 162], even more so in the 
treatment of ULMCA disease [39, 47, 143, 144]. In addition to the prognostic benefit, 
quality of life improves to a greater extent with complete revascularisation [163]. 
 
Complete revascularisation is defined either as either anatomical [164] or functional 
[165]. Within the anatomical definitions there are variations [166], such as 1) a graft to 
each disease main vessel artery; 2) a graft to all diseased main or primary segmental 
vessels; 3) all disease coronary segments subtended by a distal anastomosis; and 4) all 
main coronary artery systems subtended by at least one anastomoses. Functional 
complete revascularisation can be defined where all ischaemic, and viable territories, 
have been reperfused.  
 
Residual coronary disease, post revascularisation, is an independent predictor of 
increased mortality in multi-vessel coronary disease [9, 156-158]. The SYNTAX score 
(SS) [47], was developed as a quantification of multi-vessel disease by adding lesion 
scores based on angiographic analysis. The residual SS (rSS)[167], is a novel measure of 
residual coronary disease calculated after revascularisation. It allows us to describe a 
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continuum of values from incomplete to complete anatomical revascularisation by 
subtracting scores for all treated lesions. The residual SYNTAX score (rSS) is a 
quantitative and reproducible measure of the severity and complexity of residual 
coronary disease after PCI, which is predictive of long term clinical outcomes in 
younger populations [47, 167]. Patients with rSS >8 have higher all-cause mortality at 
long term follow-up [155] and are at increased risk of recurrent ischaemic events [167]. 
In patients who receive PCI for ULMCA disease, rSS is a prognostic discriminator and 
has been identified as an independent predictor of cardiac mortality at two years [168]. 
However, the patients included in this study were relatively young (mean age 71 years) 
and the results may not be applicable to older individuals.  Both, the SS and rSS, have 
been shown to be predictive of long term outcomes amongst a younger population 
[155, 167, 168]. In these studies complete revascularisation was achieved in at least 60% 
of patients treated.  
 
Greater coronary artery lesion severity and complexity as well as the presence of 
multi-morbidity may introduce challenges in achieving complete revascularisation in 
elderly patients with ULMCA disease. Indeed while it is known that incomplete 
revascularisation following CABG in elderly is associated with worse survival compared 
with complete revascularisation [169]; it is uncertain whether the residual coronary 
disease burden, as measured by the rSS, is associated with poor long term outcomes 
among octogenarians treated with ULMCA PCI. A recent study of fewer than 100 
patients suggested that residual coronary disease was associated with poor outcomes 
in octogenarians presenting with ACS [170]. However, a much larger retrospective 
study, including the largest ever analysis of angiograms calculating the SS and rSS, 
found no association between rSS and poor outcomes in octogenarians [171]. Neither 
of these studies assessed patients with LMCA disease exclusively, with fewer than 10.0% 
of patients in the larger study and fewer than a third of patients in the smaller study 
having LMCA disease. Furthermore, the larger study included a fairly low risk 
population: the median SS was only 18.3 with a median rSS of 10.1 [171], compared 
with those patients included in the study which initially validated rSS for predicting 
mortality [155]. Given the sparsity of data for outcomes in Octogenarians with LMCA 
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disease, we sought to determine whether the residual coronary artery disease burden, 
as measured by the rSS, was associated with mortality in the elderly treated with 
ULMCA PCI. 
 
1.5 Indices of multiple deprivation 
 
1.5.1 Definition of deprivation 
 
Deprivation indices are commonly used to describe spatial health heterogeneity. 
Deprivation is a relative term, comparing different populations across local 
communities, regions within countries and the world. Deprivation has been quantified 
using a score obtained by summing standardised variables, each measuring different 
ecological dimensions derived from census data. The indices of deprivation cover 
seven distinct domains: health deprivation and disability, crime and the living 
environment, barriers to housing services, income, employment, education skills and 
training. 
 
1.5.2 The English indices of multiple deprivation  
 
Local measures of deprivation for England have been calculated since the 1970s by the 
Department for Communities and Local Government (DCLG). The DCLG commissioned 
the Social Disadvantage Research Centre at Oxford University to develop the English 
Indices of deprivation; the aim was to develop a broader definition of multiple 
deprivation which would include several dimensions of deprivation. The local 
measures of deprivation are derived from the census data, and the indices of 
deprivation which are produced by DCLG are measures of deprivation for every Lower 
Layer Super Output Area (LSOA) and local authority area in England. Separate Indices 
at LSOA level are provided for each of the seven domains of deprivation. This 
information is then combined into one overall Index of Multiple Deprivation. Thus all 
32,844 LSOAs can then be ranked according to how deprived they are relative to each 
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other. Using this information one can identify and explore the causes of unmet needs 
in the local communities.  
 
The scores for each domain are derived from subjective self-assessment by the 
individual. For example, assessment of the 'health deprivation and disability' domain 
included asking respondents whether they felt limited in daily activities due to a health 
problem or disability lasting or expected to last 12 months or more   (see Box 2).  
 
The individual scores for each deprivation domain are then summated to give an 
overall score which allows ranking of the LSOAs. The seven domains, including their 
relative of weighting in the combined score, are as follows: 
-    Employment Deprivation (22.5%) 
-    Income Deprivation (22.5%) 
-    Health Deprivation and Disability (13.5%) 
-    Education, Skills and Training Deprivation (13.5%) 
-    Living Environment Deprivation (9.3%) 
-    Crime (9.3%) 
-    Barriers to Housing and Services (9.3%) 
 
The Index of Multiple Deprivation (IMD) is the official measure of relative deprivation 
for LSOAs in England. The indices of deprivation are calculated every few years for 
many local areas across England; previous publications include 2004, 2007, 2010 and 
more recently 2015. The indices are comparable over time; however, the 2015 score is 
not directly comparable due to significant changes in the way the indices were 
measured. The LSOAs can include several postcode territories; they have on average 
about 1,600 residents or 650 households and may include adjacent output areas.  
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LSOAs are the smallest geographical unit within a Clinical Commissioning Group (CCG) 
for which most indicators are available and are non-overlapping. Comparisons 
between CCGs, enable sensitive identification of pockets of deprivation. The IMD 
scores are divided into quintiles which allow comparisons to be made between similar 
areas of deprivation and between different quintiles. Quintile group IMD score range: 
1    ≤ 8.49 (Least deprived) 
2    8.5 - 13.79 
3    13.8 - 21.35 
4    21.36 - 34.17 
5    ≥ 34.18 (Most deprived) 
The IMD 2010 has been adjusted to reflect the LSOA boundary changes of 2011. 
   
 
 
1.5.3 Relationship between coronary disease outcomes and deprivation 
 
Deprivation has been linked to the greater incidence of cardiac death [172], coronary 
artery disease [173], peripheral vascular disease and cerebrovascular disease [174]. It 
is known if there is an earlier onset of coronary artery disease amongst the more 
deprived [173, 175-177]. Patients from more deprived backgrounds have worse 
outcomes following PCI [178]. It is not known if the burden of disease within the 
coronary arteries, in particular subsets of left main coronary artery disease, are related 
to deprivation nor if the survival post PCI is related to deprivation indices. 
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1.6 Revascularisation outcome measures 
 
1.6.1 MACCE 
 
Composite endpoints include measures of safety and effectiveness of treatments 
employed. However, questions surround the specificity and sensitivity of these 
composite end-points. The choice of outcomes in the composite end-point, through 
their weighted contribution, may change the interpretation of results significantly 
[179]. Furthermore, the nature of the study population and length of follow-up may 
alter the specificity of the outcome measures. There remain some controversy and 
inconsistency in the choice of composite endpoints for various studies reporting on 
coronary revascularisation. 
 
All cause death may be a reasonable measure of treatment safety and effectiveness at 
thirty days or one year following revascularisation procedures; however, with longer-
term follow-up in an older population, it may be less specific due to the greater 
proportion of non-cardiac deaths in this cohort. The Academic Research Consortium 
(ARC) recommendations indicate that all-cause death is the most unbiased method to 
report outcomes but does recognise that over longer term follow-up cardiac cause of 
death would be a more specific outcome measure [180].  After all, death is inevitable.  
It has been suggested for several reasons that all-cause death, rather than cause-
specific death, should be reported in clinical studies. The data recorded on the death 
certificate may be incorrect [181]. There is an incremental incidence of wrongly 
identifying coronary disease as a cause of death with increasing age of the patient 
[182]. Up to a third of published data includes disagreement between autopsy findings 
and death certificates [182-184]. Based on clinical records, one cannot exclude 
significant pre-existing cardiac disease as a major contributor to the cause of death 
despite other present mechanisms [185]. However, the ARC gives clear guidance, 
albeit a conservative approach, to attributing a cardiac cause of death after 
independent review [180]. In randomised controlled trials the cause of death will not 
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affect the interpretation of the outcome; however the further away one moves from 
the intervention the less precise death becomes as a measure of treatment effect. For 
example in the long term follow-up of the left main subgroup of the CASS registry, 
after 15 years, the survival curves of medically managed and surgically managed 
patients converged [186]. Finally, it is asserted that ‘dead is dead’ when assessing 
outcomes, based on the critical evaluation of amiodarone in the CAMIAT and EMIAT 
trials; in this trial, there was no benefit from amiodarone when evaluating all-cause 
death but significant benefit with using ‘arrhythmic death’ [187-189]. However, in this 
situation where the drug therapy itself may be toxic, it may be more appropriate to 
use all-cause death. This approach may not apply to procedural interventions, where 
the presumed ‘harm’ from the treatment would be limited by early events and would 
be restricted to cardiac-specific events. 
 
Repeat revascularisation is defined in various ways resulting in differing levels of 
sensitivity for outcomes. Some studies report target lesion revascularisation (TLR) 
and/or target vessel revascularisation (TVR) in the composite endpoint of MACCE. TVR 
and TLR may contribute over half of all MACCE, so it is important to define the 
diagnostic criteria, the circumstances in which these events arise and the approach to 
management. In studies which employ routine angiographic follow-up, one could end 
up with over-reported TLR; asymptomatic restenosis may only require ‘ischaemia 
driven’ revascularisation in less than half of these cases [190]. More recently in trials 
reporting upon the effect of completeness of revascularisation, non-TVR repeat 
revascularisations have also been reported [59]. 
 
Due to the binary nature of MACCE end-points, an uncomplicated PCI for TVR is 
measured as severely as a disabling stroke. Furthermore, the first event results in 
censorship of patients who may suffer two or more consecutive events; and due to the 
time-to-event analysis, significant or more informative second events are excluded 
from analysis. For example in the EXCEL trial, despite significantly greater ischaemia 
driven repeat revascularisations amongst the PCI group, the composite secondary 
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endpoint did not differ between the two groups, presumably as patients were 
censored for an earlier event [59].  
 
 MACCE as a composite end-point may not present an appropriate measure of long-
term outcomes; there is a debate about which endpoints should be included in the 
composite [179, 191]. Depending on the context or patient group studied different 
composite end-points may inform specific questions about treatment effectiveness. 
The application of trial data to real world populations may not always be appropriate. 
So death as an end-point in the long-lived, with limited life expectancy, may be an 
inappropriate outcome measure, as the benefit of the intervention would be negated 
by other factors. In these populations, the benefit may lie in freedom from 
hospitalisation or improvement in the quality of life rather than longevity. 
 
Health-related quality of life (HRQOL) is a multifaceted idea of well being including 
physical, emotional, social and mental spheres. It is not known whether quality of life 
may help better define which of these end-points are significant life events. Could we 
establish a method of weighting outcomes based on their influence on quality of life? 
In this way, the change in quality of life would act as an indicator of whether the end-
point had a significant impact on quality of life or whether it is a minor inconvenience. 
 
1.7 Study hypothesis 
 
Hypotheses 
1. PCI represents a safe and effective strategy for treatment of ULMCA 
disease, for which predictors of clinical outcomes can be identified 
by studying a real-world all-comers population.  
2. Revascularisation leads to improved quality of life in patients with 
LMCA disease in comparison to conservative management. 
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Aims and Objectives 
Aims: To identify the main factors associated with adverse outcomes following PCI and 
to assess changes in quality of life measures following revascularisation in a real-world 
population with LMCA disease. 
Study objectives 
i. to determine the factors associated with adverse long-term 
outcomes, such as death, myocardial infarction, repeat 
revascularisation and stroke, in patients treated with LMCA PCI. 
ii. To investigate the influence of (i) the Medina class of bifurcation 
disease or (ii) the PCI treatment strategy on clinical outcomes in 
patients with bifurcation disease requiring ULMCA PCI. 
iii. To investigate whether residual coronary artery disease after 
ULMCA PCI is associated with survival in octogenarians.  
Iv.  To study patient recorded outcome measures of HRQOL before 
and after treatment for LMCA disease according to mode of 
revascularisation. 
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2. Methods chapter 
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2.1 Study Design 
 
The Leeds left main revascularisation registry was developed for the purpose of 
measuring outcomes for LMCA revascularisation amongst patients treated at the Leeds 
Teaching Hospitals NHS Trust (LTHT) for left main coronary artery disease.  
Chief investigator: Prof U.M. Sivananthan  
Co-Investigators: Dr S.B. Wheatcroft, Dr C.P. Gale, Dr F. Astin, Dr I.R. Pearson and Dr D. 
Barmby 
Medical co-ordinator: Dr C. A. Maart 
Nurse co-ordinators: Mrs R. Maindonald, Mrs R. Dickinson and Mrs E. Ikon.  
Database manager: Mr R. Gillott 
This was an observational study of all patients undergoing LMCA revascularisation at 
the Yorkshire Heart Centre, comprising:  
1) a retrospective cohort of patients who had LMCA PCI between June 2005 and March 
2013 and;  
2) a prospective cohort of patients undergoing revascularisation with PCI/CABG or 
medical management for LMCA disease between March 2013 and August 2015. 
 
2.2 Ethics 
 
We were granted approval for the retrospective study under Section 251 of the NHS 
Act 2006 (Control of Patient Information Regulations 2002, 
http://www.hra.nhs.uk/about-the-hra/our-committees/section-251/what-is-section-
251/#sthash.h8Rt8nlc.dpuf). For the purposes of data collection the common law duty 
of confidentiality had to be overridden in order for the LTHT trust and general 
practices (GP’s) to disclose confidential patient information for purposes of this 
research. It was not possible to use anonymised information and seeking retrospective 
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consent was not practical. Formerly this approval was granted by the National 
Information Governance Board for Health and Social Care (NIGB) in 2010, this body has 
now been replaced by the Health Research Authority's Confidentiality Advisory Group 
(CAG) in April 2013. 
 
2.3 Funding 
 
Initial funding for the project through the Jimmy Savile Trust was withdrawn in August 
2012. Ongoing funding for research fellow salaries was provided by a local Imaging 
fund for 12 months and further funding continued for 6 months through support from 
LTHT. Additional funds for the licensing and printing of quality of life questionnaires 
were provided by the School of Healthcare, University of Leeds, under the supervision 
of Professor Felicity Astin.  In January 2014 ongoing salary support was withdrawn, the 
post of research fellow associated with the study was terminated. The study was 
adopted onto the National Institute for Health Research (NIHR) Clinical Research 
Network (CRN) portfolio and a research nurse, employed by the NIHR, provided 
support for the consenting of patients. Furthermore, a data clerk and the database 
manager were provided similarly through the NIHR CRN portfolio. 
 
2.4 Review of literature strategy 
 
Relevant literature related to Left main coronary artery revascularisation was 
identified from Pubmed between January 1966 to May 2017 and was restricted to 
English articles using search terms: left main stem/left main stem revascularisation/left 
main coronary artery/left main coronary artery revascularisation/incomplete coronary 
revascularisation. The results were transferred to Endnote and duplicates were 
removed. I then re-applied additional search terms: CABG/percutaneous coronary 
intervention/PCI/bifurcation/bifurcation PCI/ bifurcation stenting/SYNTAX 
score/residual coronary disease/residual SYNTAX score/octogenarians/quality of life. 
Abstracts of articles were scanned and relevant articles were reviewed including a 
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further search of their bibliographies and citation trees were followed in order to 
identify other pertinent articles.  
 
2.5 Leeds left main registry 
 
2.5.1 Retrospective study 
 
Data collection 
We studied patients who received PCI for ULMCA disease at LTHT, a large UK 
cardiothoracic centre, between 10th May 2005 and 30th May 2013. All patients who 
received ULMCA PCI during the study period were identified from a bespoke 
procedural electronic health records database (Cardiobase®). We included clinical 
syndromes of chronic stable angina, non-ST-elevation myocardial infarction (NSTEMI) 
and ST-elevation myocardial infarction (STEMI), defined according to the joint 
European Society of Cardiology (ESC) and American College of Cardiology (ACC) 
consensus on definition of myocardial infarction [192]. Baseline clinical and 
demographic data were extracted from medical case notes and procedural details 
collected from the electronic health record database. Where additional patient data 
were required, the hospital notes and correspondence were reviewed. In addition the 
following referring hospitals were contacted to provide additional data: York Teaching 
Hospital National Health Service (NHS) Foundation Trust, Mid-Yorkshire NHS Hospital 
trusts, Bradford Teaching Hospitals NHS Foundation Trust, Calderdale and Huddersfield 
NHS Foundation Trust, Harrogate and District NHS Foundation Trust and the Airedale 
General Hospital. GP summaries were collected for all patients where available, for 
deceased patients these were not available. All cause mortality was tracked through 
linkage to the Office of National Statistics (ONS) using the NHS number.  An enquiry 
was raised through the Patient Administration Systems (PAS) at the LTHT and local 
hospitals to verify subsequent admissions to hospital after the date of the ULMCA PCI. 
We were then able to identify potential MACCE events using International Statistical 
Classification of Diseases and Related Health Problems 10th revision (ICD-10) codes. 
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As a research group we decided to accept the diagnosis of comorbidities as recorded 
on the bespoke procedural electronic health records database (Cardiobase®). We did 
not define specific criteria for the diagnosis of relevant comorbidities, so accepted the 
adjudication of the treating physician. 
Derived Data 
Indices of multiple deprivation 
Using post-code identifiers for patients, indices of deprivation were derived from the 
Office of National statistics. Pseudonymised patient identifier’s (PatID’s) were used to 
order post-codes and these were entered into an online indices of multiple deprivation 
(IMD) Postcode search tool (https://tools.npeu.ox.ac.uk/imd/) to find the associated 
IMD quintile group and score. Indices for the periods covering the date of treatment 
were used, thus the 2011 Indices were used for all patients as the 2015 indices were 
derived from data for the period 2012-2013. 
 
Data storage and database design 
A bespoke database was designed on the Google™ Structured Query Language (SQL) 
platform. The database is hosted on the NHS secure N3 network. The design allows 
multicentre recruitment and data input using the N3 network. Security includes 
password protected accounts; data encryption and pseudonymised patient data using 
sequentially allocated PatID’s.  
Research committee meetings, headed by the Chief Investigator Prof Sivananthan, 
were held to discuss the design of the database. Our aim was to integrate automated 
EuroSCORE, SYNTAX score, eGFR/BMI calculators into the design. The platform could 
be used in the cathlab for the imputation of data directly by cathlab staff. 
The database set out to include a robust drug history including antiplatelet initiation, 
use of anti-anginals at the time of the procedure through the entire follow-up. 
   58 
 
Database management is through a central management structure including the Chief 
investigator, Prof Sivananthan and database manager Richard Gillott. Applications for 
research on the data held can be made to the research committee. Account access for 
data entry and data downloads is made through a similar process.   
 
 
Missing Data 
Missing values were checked against the existing in-house database and clinical notes. 
Local GP practices and district general hospitals were contacted in order to collect the 
missing data. Any contradictory data points were discussed with the CI, generally the 
data held on Cardiobase was taken in preference as they were entered by the clinician 
prospectively at the time of the procedure. 
 The analysis and handling of missing data will be explored in the statistical analysis 
section below. 
 
Patient follow-up 
All retrospective patients received a telephone follow-up or outpatients follow-up 
which recorded any clinical events after the PCI. This follow-up date was taken as the 
censorship time point. All patient-reported clinical events were investigated by 
collecting GP summaries or discharge summaries from local general hospitals 
    
2.5.2 Prospective study design 
 
Recruitment: referral process 
Correspondences from referring district cardiologists were to a named surgeon 
involved in the LTHT LMCA revascularisation clinic or to the cardiac interventionist. 
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Patients referred to the LTHT multidisciplinary team meeting (MDT) were approached 
for consent at the time of admission for revascularisation to the LTHT. 
 
Patients who were diagnosed after angiography at the LGI were at the time of their 
revascularisation procedure, either as an in-patient or upon elective admission. In the 
case of emergency revascularisation, such as STEMI, we sought consent from these 
patients after their revascularisation procedure. 
The heart team is a concept approved by the ESC and AHA for patients considered for 
LMCA revascularisation. All patients were considered for a multidisciplinary discussion 
in the following ways: 
Elective patients were either discussed at their local district general hospitals (DGH’s) 
and then referred to a named surgeon at the LTHT, or referred to the LTHT MDT. 
Urgent admissions to the LTHT were discussed at the LTHT MDT. Patients admitted as 
an emergency, often had treatment in their best interest, but where possible 
discussions between the interventional cardiologist and on-call surgeon were 
documented. 
 
Issues with recruitment 
We recognised potential issues relating to recruitment, and instituted strategies to 
address these as follows:  
1) Direct referrals to a named surgeon would bypass the discussion at an MDT and lead 
to missed recruitment – The project outline was presented to the Yorkshire Consultant 
Cardiology Regional Working Group in November 2012. All DGH centres were invited 
to participate as research centres or to refer patients to the LTHT MDT. Furthermore, 
the study design and ethics application made possible the recruitment from multiple 
centres.  
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2) Emergency admissions at night may be repatriated to regional hospitals following 
treatment, representing a missed opportunity for recruitment– We placed posters in 
the cathlab area with contact details of the research team. Our research team would 
go to coronary care unit (CCU) on a daily basis to recruit overnight emergency 
admissions.  
Follow-up of prospectively-recruited patients 
Prospectively-recruited patients had a planned telephone or clinic follow-up conducted 
at 6 months post-procedure and then yearly. The HRQOL measures we used and 
questionnaire design was planned with the advice of Dr F. Astin, formerly of the School 
of Healthcare, University of Leeds. HRQOL questionnaires were completed by patients 
at the following time points to allow for longitudinal analysis: 
• 2 weeks prior to procedure (either PCI or CABG): MacNew [66], Brief 
illness perception [70] 
• 1-Month post-procedure: MacNew, Brief illness perception and PPE-
15(Picker Questionnaire) posted 
• 6 month post-procedure/recruitment: MacNew, Brief Illness 
perception 
• 1 year post-procedure/recruitment: MacNew and Brief Illness 
perception 
 
Documents approved for the recruitment and collection of data include the Patient 
information leaflet (PIS) (Appendix 1), consent form (Appendix 2) and letter to the GP. 
The HRQOL measures include the combined questionnaires for use at 2 weeks prior, 1, 
6 and 12 months post-procedure (sample questionnaire, Appendix 3). These 
questionnaires are validated for use in measuring outcomes from cardiovascular 
disease.  
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Inclusion and exclusion criteria 
All consenting patients with significant left main coronary artery disease were included. 
These include patients treated with PCI or CABG revascularisation as well as those on 
medical treatment. Patients with a predicated lifespan of less than 90 days, with some 
other terminal diagnosis, were excluded from the study. 
 2.6 Angiographic data 
 
All angiograms were reviewed by an experienced interventional cardiologist who was 
blinded to all outcomes. Baseline coronary angiograms were reviewed to confirm the 
presence of de novo left main coronary artery disease (defined as a stenosis >50%) and 
to exclude patients with patent bypass grafts to the left coronary artery tree (denoting 
a protected circulation). 
 
2.6.1 SYNTAX score (SS) 
 
The SS is a comprehensive anatomical assessment derived from various pre-existing 
classifications. It is calculated by analysing diagnostic angiograms. Each lesion 
producing ≥50% luminal obstruction in vessels ≥1.5 mm is defined based on the 
modified AHA coronary tree segment classification and separately scored regarding 
bifurcations or trifurcations or aortic ostial localisation, chronic occlusion, vessel 
tortuosity, length, calcification and thrombus formation. Finally, the score of each 
lesion is added to obtain the patient’s raw SS. Thus, the SS reflects a comprehensive 
anatomical assessment, with higher scores indicating more complex coronary disease; 
a low score was defined as ≤22, an intermediate score as 23 to 32, and a high score as 
≥33. The SYNTAX score was calculated the syntax score (SS) using an online calculator 
(www.syntaxscore.com).  
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2.6.1 Residual SYNTAX score (rSS) and Delta SYNTAX score (deltaSS) 
 
The residual SS (rSS) was derived by subtracting all treated lesion scores from the SS, 
thus, representing the complexity of the remaining coronary artery disease. The 
amount of coronary artery revascularisation undertaken was estimated using the Delta 
SS (defined as the difference between baseline SS and rSS). 
2.6.2 Medina classification 
 
Left main bifurcation disease was classified according to the Medina classification 
[104]. The Medina classification uses the binary notation to describe the presence (1) 
or absence (0) of significant coronary atheroma at the bifurcation within the Main 
vessel, main branch and side branch. The annotation for disease at all segments is as 
follows: 
Main Vessel,Main Branch,Side Branch = 1,1,1 
Through this annotation, bifurcation disease can be classified as ‘True’ bifurcation 
disease (1,1,1 and 0,1,1 and 1,0,1) and ‘non-true’ bifurcation disease. 
 
2.6.3 Procedural Complications 
 
Complications reported at the time of the procedure were recorded on Cardiobase® 
and then verified by angiographic review. At the time of angiographic review if further 
complications were recorded or if those on the database were recorded in error, the 
complications logged at the time of the angiographic review were taken as final. 
 
2.7 Outcome measures 
 
Traditional measures of outcome from revascularisation studies include hard 
endpoints of MACCE such as all cause death, myocardial infarction, repeat 
revascularisation events (target lesion and vessel revascularisation) and stroke. 
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Definitions of these outcomes are provided in original research articles but may differ 
between studies.  
 
 
2.7.1 Major adverse cardiovascular and cerebrovascular events 
 
Definitions 
For the purpose of this study outcomes were defined using the ARC guidelines [180], 
here the ARC recommends using all-cause mortality in preference to cardiac death.  
Further, it recommends the diagnosis of MI according to biomarker rise in accordance 
with the current guidelines [193, 194].  
For the purposes of this study we adopted the classification of repeat revascularisation. 
After MACCE review with an independent interventional cardiologist, we included all 
ischaemia driven non-TVR and TVR. 
Stroke was defined as a new and persistent neurologic deficit developing over a short 
period of time, which is caused by an obstruction to cerebral blood flow and/or 
cerebral hemorrhage in the absence of a non-vascular cause (e.g. infection/trauma/ 
tumour) 
 
Data collection 
All retrospective patients received a telephone follow-up or outpatients follow-up 
which recorded any clinical events after the PCI. The research nurse or doctor would 
use a prescribed questionnaire to direct the interview. All patient-reported clinical 
events were investigated by collecting transcripts of treatment summaries from 
primary care or discharge summaries from local general hospitals. Hospital electronic 
database systems, such as Patient Administration Service (PAS), were searched using 
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the patient NHS number for unreported MACCE events. Details of the date and cause 
of death was tracked through linkage of the registry to the Office for National Statistics.  
 
Independent MACE review 
All clinical events were independently reviewed by a consultant interventional 
cardiologist, Dr C.J. Malkin. Events were classified according to the academic research 
consortiums (ARC) definitions for myocardial infarction, repeat revascularisations and 
stent thrombosis (ST) [180]. Events were classified as either definite/probable/possible 
ST.  
Patient deaths were also investigated to establish the likelihood of ST. ONS data on 
cause of deaths were used to identify cardiac deaths and then further investigation 
included Cardiobase®, discharge summaries, clinical notes and investigations to 
diagnose ST. In a small number of cases post-mortem reports were used for review. 
 
2.7.2 Quality of life measures 
 
Quality of life measures were used in the prospective study including the MacNew and 
the Brief illness perception. 
The MacNew questionnaire has 27 items with a Likert-type, single response 
questionnaire to assess the three domains of quality of life; emotional, social and 
physical. The global and subscale scores are used to assess quality of life over time. To 
calculate, divide the sum of the scores by the number of questions aggregated, to 
assess a particular domain [195, 196]. 
The Brief illness perception score uses a 0-to-10 Likert scale to assess responses to 8 
questions. Each question assesses a separate item of the cognitive and emotional 
illness representations [197]. An increase in the score represents an increase in the 
domains measured. The means of the score are calculated and allow us to observe 
change over time. 
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2.1.1.1 Public consultation  
 
We conducted a public consultation with the West Yorkshire Cardiovascular Network 
Patient and Public group on the 6th September 2013. This consultation process 
informed the study design, implementation and the recoding of outcome measures. Of 
note, their consensus opinion (refer to Appendix 4: West Yorkshire Cardiac patient and 
public group consultation) was that the components of MACCE should not be 
considered as equal.  
In summary: 
- ‘’The group felt that ‘quality of life is the single most important indicator’ for patients 
who survive the initial procedure. 
- They also felt that stroke should be weighted more heavily than the risk of MI or 
repeat revascularisation, however 
-The severity of each MACCE event should be measured individually, that is, for an MI 
which results in the need for CABG should carry more weight than a simple TIA/Stroke 
from which a patient makes a full recovery.  
Indeed, the impact that these events would have on a patient’s quality of life was 
considered the main factor when weighing the decision between two treatments.’’ 
While the consultation process emphasised that weighting MACCE may better inform 
the impact of outcomes, no validated weighting exists. We felt that using quality of life 
as a separate outcome measure would adequately demonstrate the impact a MACCE 
event has on the patient. 
  
 2.8 Statistical methods 
 
Statistical analysis was performed with IBM SPSS statistics version 20 (IBM Corporation, 
NY, USA). 
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2.8.1 Data descriptors 
 
Baseline characteristics were described using numbers and percentages for categorical 
data. Means and standard deviations (SD) or medians and interquartile ranges (IQR) 
were used for normally and non-normally distributed continuous variables respectively. 
Categorical data were compared using a Pearson Chi-squared test. Continuous 
variables were compared using one way ANOVA for normally distributed variables and 
the Kruskal-Wallis test for non-normally distributed data. 
 
 
 
2.8.2 Survival analysis 
 
Kaplan-Meier Survival analysis 
We used Kaplan-Meier estimates for cumulative event rates and constructed survival 
curves. Survival curves were compared using the log-rank test. 
 
Cox Regression analysis 
Test variables, with a plausible association to adverse outcomes were entered into an 
unadjusted regression analysis. Resultant significant variables, p<0.10, were used to 
study adjusted survival using Cox proportional hazards model, with the stepwise 
removal of non-significant factors. The final model adjusted for mode of presentation, 
comorbidity (renal impairment, diabetes, previous cardiac surgery, previous 
myocardial infarction, peripheral vascular disease) and PCI strategy. Final estimates 
were represented as adjusted hazard ratios (aHR) with associated 95% confidence 
intervals (CI). The proportional assumptions were tested and not violated. We adjusted 
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for varying levels of baseline disease severity using the baseline SS in the Cox model. 
All tests were two-sided, and statistical significance was considered as p<0.05.  
 
2.8.3 Methods to deal with confounders and bias 
 
We addressed potential confounders by exploring causal relationships using a directed 
acyclic graph. In the case of collinearity of variables, we included those variables with a 
perceived greater discrimination, such as Syntax Score (SS) used in preference to 
specific lesion-level data, such as coronary lesion calcification or length of the coronary 
atheromatous lesion.   
 
 
2.9 Missing data 
 
Missing data are a common finding in retrospective studies. A significant amount of LV 
function assessments were missing in spite of investigating clinical notes as well as 
contacting local hospitals. I received assistance from Mr Sami Saeed S Almudarra, 
Biostatistics University of Leeds, with the analysis and statistical methods used to 
assess missing data including building multiple imputation models.  
 
2.9.1 Defining missing data and tests of missing data 
 
A sensitivity analysis was conducted to test associations and potential confounders. 
We were then able to explore the mechanisms which lead to the missingness of data 
allowing us to classify missing data into several types. By understanding the nature of 
our missing data, we were able to consider appropriate ways to mitigate the effects of 
missing data on the analysis. We therefore applied the following missing data 
classification: 
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-Missing Completely at Random (MCAR), where the missing value (y) neither depends 
on x nor y. No observed data or values can explain the missing data, and there is no 
systematic or recurrent issue which makes some data more likely to be missing than 
others. 
-Missing at Random (MAR), where the missing value (y) depends on x, but not y. In this 
case, the missing values show an association with observed data but not with the 
missing data; there IS a systematic relationship. For example, in a survey of incomes 
within a community, the income data are missing for high earners as they are unwilling 
to submit the information. 
-Missing not at Random (MNAR), where the probability of a missing value is dependent 
on the variable that is missing. For example, poor LV function is missing because the LV 
function is indeed poor. 
2.9.2 Methods of dealing with missing data 
 
Once the missing data were classified, we considered appropriate methods to deal 
with them. Statistical methods which deal with missing data assume MCAR or MAR, 
yet most often we find data MNAR [198]. Due to the limited number of patients and 
the potential for increased bias with MNAR we did not consider either list-wise or 
pairwise deletion techniques. Similarly, we decided against single imputation 
techniques, such as mean/mode substitution or conditional mean substitution, due to 
the potential for reduced variability and bias [199]. While a maximum likelihood 
estimation would use all the available cases, it produces significant bias with data 
which is MNAR; we opted for multiple imputation as there is evidence it may offer 
unbiased estimates of the missing data even when the data are MNAR [200]. We used 
the regression method of multiple imputation [201] . Using this method, a regression 
model is fitted for each variable with missing values, with the previous variables as 
covariates. This regression model is used to impute the missing values for each 
variable. Multiple imputation replaces missing data with imputed values. An appraisal 
of the distribution of the observed data, allows us to use predictor variables to impute 
missing values. In this way multiple imputation incorporates a robust bayesian 
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approach and thereby reduces bias. An acyclic directed graph was used to identify the 
predictor variables related to the missing values. Five datasets were imputed in this 
analysis, in this way we can create the necessary variability to accommodate for the 
unpredictability of the missing data. By applying the model to all of the datasets we 
can then draw valid conclusions.  
 
2.10 Logistical problems 
 
Regular research team meetings between co-investigators UMS, IRP, DB, CAM, RGG 
and RM were held to discuss the database design and to troubleshoot. The database 
evolved over time with additional fields added at different stages of the recruitment 
process. The intention was to develop a database which could collect the clinical data 
fields recommended in the British Cardiac Interventional Society’s (BCIS) guidance on 
database design. The goal was a database with the dual purpose of live research data 
collection as well as serving as an in-house working database for interventional 
procedures.  
The resultant ongoing changes in the database design resulted in the unfortunate 
delay in data entry while ongoing recruitment continued. Furthermore, this created 
significant amounts of missing data and led to a recurring data re-entry on the same 
group of patients. Where our intention was to collect data prospectively, these issues 
naturally created problems aligning data, and therefore some of the data was ‘re-
entered’ several times over.  
 
Data were regularly re-validated which again created a time-consuming treadmill of 
data collection. We considered this a learning experience; the lesson learnt was that 
the database design was probably the most important initial step in this research 
process. 
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3. Overall retrospective cohort of left main 
coronary PCI 
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3.1 Study cohort 
 
 
We studied all patients who received percutaneous coronary intervention (PCI) of the 
unprotected left main coronary artery (ULMCA) at the Leeds General Infirmary from 
March 2005 up to March 2013. A search of the bespoke in-house procedural database 
identified 491 patients. We reviewed angiograms and procedural notes to determine if 
any patients had a patent graft to the left coronary artery, a protected left coronary 
circulation. We excluded 125 patients with a protected LMCA from further analysis. 
We were left with 366 patients for further analysis. The number of patients treated 
increased year upon year from 2005-2008 and then continued above 50 patients per 
year apart from the year 2009, during which only 40 patients were treated (see Table 
6).  
 
The median (IQR) age of the cohort was 76.0(18.0) years (Table 7), with 42.1% (154) of 
patients in the octogenarian/nonagenarian age group (see Figure 2).  Patient profiles 
varied depending upon the mode of presentation, and there was a significant 
difference in age with younger patients presenting with STEMI. A third of the patients 
were female. Almost three-quarters of patients presented with an acute coronary 
syndrome (ACS), close to a third (29.0%) presented with STEMI. Patients presenting 
with STEMI were more likely to be haemodynamically compromised with over a third 
presenting in cardiogenic shock, and greater chances of developing cardiac arrest 
during the procedure.  
 
Comorbidity showed considerable variation across the modes of presentation, with 
generally more comorbidity in patients presenting with stable coronary disease or 
NSTEMI. Diabetes was present in 22.1% of patients. However, patients presenting with 
STEMI were least likely to have diabetes. Peripheral vascular disease was present in 
15.6% of patients and was more prevalent in patients with stable coronary disease and 
NSTEMI on presentation. While up to 38.8% of patients had a history of previous MI, 
   72 
 
this was the first presentation with an MI for 86% of patients suffering an STEMI. 
STEMI patients were also less likely to give a history of previous coronary 
revascularisation with either PCI or CABG. Despite 5.8% of patients having had 
previous cardiac surgery, none of these patients had protected left coronary arteries. 
The EuroSCORE II (IQR), was 8.4% (13.7), with only 34 (9.3%) of patients with a 
EuroSCORE of less than 2%. Of these 34 patients, 26 (7.1%) had a SS of under <32  and 
22(6.0%) had distal LMCA disease. Given this background, about 32.2% of patients had 
missing LV function assessments.   
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Table 6: Unprotected LMCA PCI in calendar year 
Year Number of LMCA PCI %DES 
2005 17 52.9 
2006 31 61.3 
2007 31 54.8 
2008 57 49.1 
2009 40 82.5 
2010 58 93.1 
2011 57 89.5 
2012 59 96.6 
2013 (up to March) 16 75.0 
 
LMCA – left main coronary artery; PCI: percutaneous coronary intervention; DES: drug eluting stent 
 
 
   74 
 
Table 7: Patient characteristics (n=366) 
 Overall      
n=366 
Stable 
angina (1) 
99 (27.0%) 
NSTEMI (2) 
163 (44.5%) 
STEMI (3) 
104 (28.4%) 
p 
(1v3) 
p   
(1v2) 
p  
(2v3) 
Missing data % 
Median age (IQR), years 76.0 (18.0) 78.0 (17.0) 75.6 (12.0) 66.9 (24.0) p<0.05 p=NS p<0.05 0 
Female Sex 122 (33.3%) 27 (27.3%) 65 (39.9%) 30 (28.8%) p=NS p<0.05 p=NS 0 
Cardiac arrest 8 (2.4%) 0 3 (1.9%) 5(4.95%) p<0.05 p=NS p=NS 0 
Cardiogenic shock 46 (12.6%) 0 9 (5.5%) 37 (35.6%) p<0.05 p<0.05 p<0.05 0 
Hyperlipidaemia 172 (47.0%) 57 (60.0%) 86 (54.8%) 29 (30.9%) p<0.05 p=NS p<0.05 0 
Diabetes 81 (22.1%) 20 (20.2%) 50 (30.7%) 11 (10.6%) p=NS p=NS p<0.05 0 
Hypertension 174 (47.5%) 56 (32.2%) 90 (55.2%) 28 (26.9%) p=NS p<0.05 p<0.05 0 
Current or ex-smoker 172 (47.0%) 49 (53.8%) 75 (54.3%) 48 (58.5%) p=NS p=NS p=NS 0 
Previous Stroke 37 (10.1%) 13 (13.1%) 16 (9.8%) 8 (7.7%) p=NS p=NS p=NS 0 
Peripheral vascular disease 57 (15.6%) 20 (20.2%) 29 (17.8%) 8 (7.7%) p<0.05 p=NS p<0.05 0 
Previous MI 142 (38.8%) 40 (40.4%) 87 (53.4%) 15 (14.4%) p<0.05 p<0.05 p<0.05 0 
Previous PCI 60 (16.4%) 24 (24.2%) 31 (19.0%) 5 (4.8%) p<0.05 p=NS p<0.05 0 
Previous Cardiac surgery 21 (5.8%) 8 (8.1%) 11 (6.7%) 2 (1.9%) p<0.05 p=NS p=NS 0 
Renal Impairment 38 (10.4%) 8 (8.1%) 24 (14.7%) 6 (5.8%) p=NS p<0.05 p<0.05 0 
Moderate to severe LV impairment 128 (35.0%) 26 (26.2%) 66 (40.4%) 36 (34.6%) p<0.05 p<0.05 p=NS 32.2% 
Logistic EuroSCORE (IQR) 8.4(13.7) 5.7(8.7) 8.4(13.)3) 15.0(27.2 p<0.05 p<0.05 p<0.05  
 
IQR: interquartile range; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; MI: myocardial infarction; 
PCI: percutaneous coronary intervention; LV: left ventricular; NS: not significant 
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Figure 2: Number of ULMCA PCI according to 5 year age groups 
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3.1.1 Missing LV function 
 
For those with a valid LV assessment, moderate to severe LV impairment was present 
in 128 (35.0%), which included 27 patients with cardiogenic shock on presentation. 
While amongst those with no LV assessment, 19 patients presented in cardiogenic 
shock. Therefore, with no further way to assess LV function at the time, we were 
unable to include LV function in modelling predictors of outcome. 
 
Significant differences in clinical characteristics were apparent between patients with 
missing LV function assessments and those with assessments present (see Table 8).  
Those with missing LV function assessments were more likely to present with an ACS 
and in particular an STEMI. Those with LV assessments present were more likely to 
have hypertension, renal impairment, a history of previous MI, previous PCI and were 
older at presentation.  Furthermore, those with missing LV assessments were 
significantly younger. 
 
The burden of coronary disease did not differ between the two groups; neither was 
there a difference in the history of diabetes or peripheral vascular disease. 
Interestingly, concerning the presentation with cardiogenic shock, there was no 
significant difference between the groups. 
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Table 8: Comparison of patients with missing LV assessment to those with LV assessments present 
 Missing LV, n=118 (%) LV assessment present, n=246 (%) p-value 
Female gender 36 (30.5%) 86 (35.0%) p=NS 
Median age(IQR), years 72.0(28.0) 77.0(14.0) p<0.05 
Acute coronary syndrome 97 (82.2%) 168 (68.3%) p<0.05 
STEMI at presentation 55 (46.6%) 47 (19.1%) p<0.05 
Cardiogenic shock 19 (16.1%) 27 (11.0%) p=NS 
Renal impairment 6 (5.1%) 32 13.0%) p<0.05 
History of diabetes 26 (22.0%) 55 (22.4%) p=NS 
Peripheral vascular disease 15 (12.7%) 42 (17.1%) p=NS 
Hypertension 44 (37.3%) 130 (52.8%) p<0.05 
Previous PCI  12 (10.2%) 48 (19.5%) p<0.05 
Previous MI  30 (25.4%) 112 45.5%) p<0.05 
Median(IQR) SYNTAX score 30.0 (20.8) 31.0 (18.3) p=NS 
DES used 83 (70.3%) 197 (80.1%) p=NS 
 
LV: left ventricular; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; IQR: interquartile range; PCI: percutaneous coronary 
intervention; MI: myocardial infarction; SYNTAX: synergy between PCI with taxus and cardiac surgery; STEMI: ST-elevation myocardial infarction; DES: drug eluting stent;  
NS: not significant 
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3.1.2 Angiographic data 
 
The majority of patients presented with extensive coronary artery disease with a 
median (IQR) SS of 31.00 (18.5), with no significant difference between the three 
clinical syndromes (Table 9). In the overall cohort, 163 (44.5%) of patients were 
grouped in the high (≥32) SYNTAX tertile [55] ( see Table 9 and Figure 3). The majority 
of patients in each clinical syndrome group fell in the high SYNTAX tertile. There was 
no significant difference in the distribution of the SYNTAX scores across tertiles for the 
mode of presentation.  
 
We found significant stenoses of the LMCA bifurcation in close to three-quarters of 
patients. Only 124 (33.8%) patients presented with associated multi-vessel disease, 
including LM +2VD and LMCA +3VD.  Over half of patients had a significant coronary 
stenosis in the RCA. Chronic total occlusions (CTO’s) were present in 17.5% of patients 
and were within the proximal to mid segments of vessels in 16.7% of patients. 
 
3.1.3 PCI procedural data 
 
Table 10 includes the procedural data for the coronary interventions. The majority of 
procedures were carried out via femoral artery access with only 106 (29.0%) 
procedures via radial artery access. Change of access from the radial to the femoral 
route occurred in 15 (4.1%) patients; numerically this occurred more frequently in 
patients presenting with STEMI. Larger sheath sizes, 7Fr and 8Fr, were favoured in the 
stable and NSTEMI patient groups, those presenting with STEMI were more likely to be 
treated using a 6Fr sheath.   7/8Fr catheters were used more frequently in patients 
with LMCA bifurcation stenosis compared to those with no stenosis at the bifurcation 
(82.6% vs.  65.8%, p<0.05).   
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The intra-aortic balloon pump (IABP) was used pre-PCI in a 15.8% of patients, with 
STEMI patients more likely to have an IABP before PCI. Patients with STEMI were more 
likely to receive Bivalirudin than stable patients or those with NSTEMI, where heparin 
was preferred. 
 
The proportion of drug eluting stents (DES) used increased from about half in the years 
2005-2008, to close to 90% in the years 2009-2013 (see Table 6). DES use differed 
significantly across modes of presentation, those with stable angina and NSTEMI were 
more likely to receive a DES than those presenting with STEMI. Still, in all these groups 
the majority of patients were treated with a DES. The proportion of second generation 
DES to 1st generation DES was more than fourfold. The median total stent length (IQR) 
was 35mm (25mm) per patient. The single stent strategy was favoured in patients with 
LMCA bifurcation disease; while only 115 patients, or 43.9% of patients with LMCA 
bifurcation disease, received a two-stent strategy.  
 
Intravascular imaging, including intravascular ultrasound (IVUS) and optical coherence 
tomography (OCT), was used in 81 (22.1%) of cases, including 18.3% of STEMI patients. 
There was no relationship to the presence of LMCA bifurcation disease and the use of 
IVUS/OCT. Rotational atherectomy was successfully applied to segment 5 in over 10.0% 
of patients, with only one STEMI patient treated with this modality. PCI was considered 
successful after angiographic review in 340 (92.9%) of cases. 
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Table 9: Angiographic data for overall study population (n=366)   
Characteristic Overall  
366 
Stable angina (1) 
99 (27.0%) 
NSTEMI (2) 
163 (44.5%) 
STEMI (3) 
104 (28.4%) 
p       
(1v2) 
p  
(1v3) 
p  
(2v3) 
LMCA Bifurcation lesion 264 (72.1%) 77 (77.8%) 118 (72.4%) 69 (66.3%) p=NS p=NS p=NS 
‘True’ LMCA bifurcations 193 (52.7%) 57 (57.6%) 95 (58.2%) 42 (40.4%) p = NS p<0.05 p<0.05 
LM+1VD 147 (40.2%) 46 (46.5%) 58 (35.6%) 43 (41.3%) p<0.05 p=NS p=NS 
LM+2VD 88 (24.0%) 20 (20.2%) 47 (28.8%) 21 (20.2%) p=NS p=NS p=NS 
LM+3VD 36 (9.8%) 9 (9.1%) 16 (9.8%) 11 (10.6%) p=NS p=NS p=NS 
Median SYNTAX score (IQR) 31.0(18.5) 31.0 (14.0) 30.0 (18.0) 34.8 (23.9) p=NS p<0.05 p<0.05 
Lower SS tertile  ≤23 90 (24.6%) 19 (19.6%) 45 (27.8%) 26 (25.5%) p=NS p=NS p=NS 
Intermediate SS tertile  23-32 108 (29.5%) 38 (39.2%) 48 (29.6%) 22 (21.6%) p=NS p<0.05 p=NS 
High SS tertile  ≥32 163 (44.5%) 40 (41.2%) 69 (42.6%) 54 (52.9%) p=NS p<0.05 p=NS 
Dominant RCA 336(95.5%) 93 (96.9%) 148 (94.3%) 95 (96.0%) p=NS p=NS p=NS 
Significant RCA disease 177 (50.6%) 47 (49.5%) 83 (53.2%) 47 (47.5%) p=NS p=NS p=NS 
CTO present 64 (17.5%) 14 (14.1%) 26 (16.0%) 24 (23.1%) p=NS p=NS p=NS 
CTO of proximal/mid vessel segments  61 (16.7%) 13 (13.1%) 26 (16.0%) 22 (21.2%) p=NS p=NS p=NS 
NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; LMCA: left main coronary artery; LM: left main; 
VD: vessel disease; SYNTAX: synergy between PCI with taxus and cardiac surgery; IQR: interquartile range; SS: SYNTAX score RCA: right 
coronary artery; CTO: chronic total occlusion;  NS: not significant 
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Figure 3: Distribution of SYNTAX Score (SS) tertiles for the overall study population (n=366) 
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Table 10: PCI data for overall study population (n=366)  
 Overall Stable angina 
99 (27.0%) 
NSTEMI 
163 (44.5%) 
STEMI 
104 (28.4%) 
p  
(1v2) 
p  
(1v3) 
p  
(2v3) 
Femoral access 245 (66.9%) 74 (74.7%) 114 (69.9%) 57 (54.8%) p=NS p<0.05 p<0.05 
Radial Access 106 (29.0%) 24 (24.2%) 44 (27.0%) 38 (36.5%) p=NS p<0.05 p<0.05 
Radial and Femoral access 15 (4.1%) 1 (1.0%) 5 (3.1%) 9 (8.7%) p=NS p<0.05 p<0.05 
6 Fr Sheath 91 (24.9%) 12 (12.4%) 33 (20.2%) 47 (45.2%) p<0.05 p<0.05 p<0.05 
7 Fr Sheath 218 (59.6%) 65 (67.0%) 104 (63.8%) 49 (47.1%) p=NS p<0.05 p<0.05 
8 Fr Sheath 36 (9.8%) 15 (15.5%) 19 (11.7%) 2 (1.9%) p=NS p<0.05 p<0.05 
IABP use pre – PCI 58 (15.8%) 4 (4.1%) 17 (10.4%) 37 (35.6%) p<0.05 p<0.05 p<0.05 
IABP use during PCI 15 (4.1%) 2 (2.0%) 5 (3.1%) 8 (7.7%) p=NS p<0.05 p<0.05 
Heparin 229 (62.5%) 78 (78.8%) 117 (71.8%) 43 (41.3%) p=NS p=NS p=NS 
Bivalirudin 115 (31.4%) 21 (21.2%) 45 (27.6%) 58 (55.8%) p=NS p<0.05 p<0.05 
Abciximab 114 (31.1%) 27 (27.3%) 48 (29.4%) 39 (37.5%) p=NS p<0.05 p<0.05 
Tirofiban 12 (3.3%) 1 (1.0%) 10 (6.1%) 1 (1.0%) p<0.05 p=NS p<0.05 
2 stent strategies for LMCA bifurcation 115 (32.8%) 33 (33.3%) 57 (35.0%) 25 (24.0%) p=NS p<0.05 p<0.05 
DES use (patient level data) 284 (77.6%) 89 (89.9%) 129 (79.1%) 66 (63.5%) p<0.05 p<0.05 p<0.05 
1st generation DES 48 (13.1%) 15 (15.2%) 25 (15.3%) 8 (7.7%) p=NS p<0.05 p<0.05 
2nd Generation DES 236 (64.5%) 74 (74.7%) 104 (63.8%) 58 (55.8%) p<0.05 p<0.05 p<0.05 
Median (IQR) total stent length 35.0 (25.0) 36.0 (26.0) 32.0 (25.3) 36.0 (27.0) p<0.05 p=NS p=NS 
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Rotational atherectomy 39 (10.7%) 20 (20.8%) 18 (11.0%) 1 (2.6%) p=NS p<0.05 p<0.05 
IVUS 79 (21.6%) 27 (27.3%) 33 (20.2%) 19 (18.3%) p<0.05 p<0.05 p=NS 
OCT 2 (0.5%) 1 (1.0%) 1 (1.0%) 0 p=NS p=NS p=NS 
Operator reported successful PCI 340 (92.9%) 97 (98.0%) 153 (93.9%) 91 (87.5%) p=NS p<0.05 p<0.05 
 
PCI: percutaneous coronary intervention; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; Fr: 
french size; IABP: intra-aortic balloon pump; LMCA: left main coronary artery; IVUS: intravascular ultrasound; OCT: optical coherence 
tomography; NS: not significant 
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3.1.4 PCI complications 
 
Over a quarter of patients, 92 (25.1%), were reported to have suffered a procedural or 
access site complication (Table 11). The vast majority of complications were 
procedural, coronary dissections were identified in 48 (13.1%) of patients and occurred 
with equal frequency amongst STEMI, NSTEMI and stable patients. Arterial access 
complications were reported on Cardiobase® in 21 (5.7%) of cases (see Table 12). In all 
but two cases of access site complications a 7 or 8 Fr sheath was used from the 
femoral artery. Only one case out of seven femoral arterial haemorrhages required 
surgical intervention. The two reported arterial occlusions were not further defined. 
Patients presenting with STEMI were more likely to develop cardiogenic shock during 
the procedure, and were more likely to suffer a cardiac arrest. 
 
 
   85 
 
Table 11: PCI procedural complications for overall study population (n=366) 
Complication Overall Stable angina 
99 (27.0%) 
NSTEMI 
163 (44.5%) 
STEMI 
104 (28.4%) 
P  
(1v2) 
P 
(1v3) 
P 
(2v3) 
Coronary dissection 48(13.1%) 14 (24.1%) 22 (13.5%) 12 (11.5%) p<0.05 p<0.05 p=NS 
Coronary perforation 6(1.6%) 2 (2.1%) 2 (1.2%) 2 (2.0%) p=NS p=NS p=NS 
Cardiac tamponade 3(0.8%) 2 (2.0%) 0 1 (1.0%) p=NS p=NS p=NS 
Cardiogenic shock developing during procedure 8(2.2%) 2 (2.0%) 6 (3.7%) 13 (12.5%) p<0.05 p<0.05 p<0.05 
Pulmonary oedema 2(0.5%) 0 2 (1.2%) 0 p=NS p=NS p=NS 
Cardiac arrest 9(2.5%) 1 (1.0%) 1 (0.6%) 7 (6.8%) p=NS p<0.05 p<0.05 
Propagation of thrombus 6(1.6%) 0 4 (2.5%) 2 (1.9%) p=NS p<0.05 p<0.05 
Side branch occlusion 8(2.2%) 2 (2.0%) 3 (1.8%) 3 (2.9%) p=NS p=NS p=NS 
Stroke 1(0.3%) 0 1 (0.6%) 0 p=NS p=NS p=NS 
Underdeployed stent 6(1.6%) 0 5 (3.1%) 1 (1.0%) p<0.05 p=NS p<0.05 
 
PCI: percutaneous coronary intervention; BARC: Bleeding Academic research consortium defined bleeding complications; NSTEMI: non-ST 
elevation myocardial infarction; STEMI: ST elevation myocardial infarction; NS: not significant 
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Table 12: Access site complications for the overall study population (n=366) 
Arterial complication Overall Stable angina 
99 (27.0%) 
NSTEMI 
163 (44.5%) 
STEMI 
104 (28.4%) 
 
Retroperitoneal bleed 1(0.3%) 0 1 (0.6%) 0  
Surgical intervention 1(0.3%) 0 1 (0.6%) 0  
Arterial dissection 6(1.6%) 0 6 (3.7%) 0  
Arterial occlusion 2(0.5%) 0 0 2 (1.9%)  
Arterial haemorrhage 7 (1.9%) 3 (3.0%) 3 (1.8%) 1 (1.0%)  
False aneurysm requiring thrombin injection 1(0.3%) 0 1 (0.6%) 0  
False aneurysm requiring compression 1(0.3%) 1 (1.0%) 0 0  
False aneurysm conservative management 1(0.3%) 1 (1.0%) 0 0  
 
NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; NS: not significant 
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3.1.5 Indices of multiple deprivation (IMD)  
 
Based on the postcodes on record for patients, we allocated English indices of multiple 
deprivation (IMD) for lower super output areas (LSOA’s). The office for national 
statistics supplied the LSOA's and IMD's; we used the recognised national quintiles for 
further analysis (Table 13). The quintiles represent five groups of increasing levels of 
deprivation from the 1st to the 5th. There was a significant difference in age between 
the quintiles with older patients in the 1st and 2nd quintiles, representing the least 
deprived areas. Patients in the most deprived quintiles had significantly more diabetes 
and renal impairment compared to the least deprived quintiles. There was no 
significant difference in the mode of clinical presentation, between the quintiles. 
Previous cardiac disease was prevalent amongst all quintiles equally with no difference 
in previous PCI or MI. The burden of coronary disease did not differ between the 
groups either; the high burden of left main coronary bifurcation disease was similar 
between groups. The SS did not differ between groups, and neither did the distribution 
of SS across the three tertiles. 
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Table 13:Overall study population characteristics by quintile of indices of multiple deprivation 
Characteristic 1st Quintile (n=53) 2nd Quintile (n=93) 3rd Quintile (n=51) 4th Quintile (n=76) 5th Quintile (n=91) p-value 
Female gender 15 (28.3%) 30 (32.3%) 13 (25.5%) 30 (39.5%) 34 (37.4%) p=NS 
Median (IQR) age, years 78.0 (19.0) 80.0 (16.0) 76.0 (20.0) 76.0 (17.0) 74.0 (20.0) p<0.05 
NSTEMI 22 (41.5%) 39 (41.9%) 24 (47.1%) 35 (46.1%) 42 (46.2%) p=NS 
Stable Angina 15 (28.3%) 29 (31.2%) 13 (25.5%) 18 (23.7%) 24 (26.4%) p=NS 
STEMI at presentation 16 (30.2%) 25 (26.9%) 14 (27.5%) 23 (30.3%) 25 (27.5%) p=NS 
Cardiogenic shock 7 (13.2%) 10 (10.8%) 7 (3.7%) 12 (15.8%) 9 (9.9%) p=NS 
Renal impairment 1 (1.9%) 5 (5.4%) 4 (7.8%) 11 (14.5%) 16 (17.6%) p<0.05 
History of diabetes 10 (18.9%) 13 (14.0%) 6 (11.8%) 22 (28.9%) 29 (31.9%) p<0.05 
Previous stroke 7 (13.2%) 7 (7.5%) 8 (15.7%) 3 (3.9%) 12 (13.2%) p=NS 
Peripheral vascular disease 9 (17.0%) 9 (9.7%) 12 (23.5%) 13 (17.1%) 14 (15.4%) p=NS 
Hypertension 22 (41.5%) 47 (50.5%) 29 (56.9%) 32 (42.1%) 43 (47.3%) p=NS 
Previous PCI  9 (17.0%) 18 (19.4%) 6 (11.8%) 9 (11.8%) 18 (19.8%) p=NS 
Previous MI  21 (39.6%) 38 (40.9%) 16 (31.4%) 30 (31.4%) 37 (40.7%) p=NS 
Median(IQR) SYNTAX score 34.0 (17.0) 31.0 (17.0) 28.5 (20.0) 32.0 (20.0) 29.0 (19.9) p=NS 
LMCA Bifurcation lesion 39 (73.6%) 68 (73.1%) 34 (66.7%) 53 (69.7%) 68 (74.7%) p=NS 
LM+1VD 20 (37.7%) 41 (44.1%) 21 (41.2%) 26 (34.2%) 37 (40.7%) p=NS 
LM+2VD 10 (18.9%) 21 (22.6%) 13 (25.5%) 20 (26.3%) 24 (26.4%) p=NS 
LM+3VD 7 (13.2%) 9 (9.7%) 5 (9.8%) 12 (15.8%) 3 (3.3%) p=NS 
   89 
 
Dominant RCA 46 (92.0%) 84 (95.5%) 48 (94.1%) 70 (95.9%) 86 (97.7%) p=NS 
Significant RCA disease 26 (51.0%) 41 (47.1%) 26 (52.0%) 40 (55.6%) 42 (47.7%) p=NS 
CTO present 15 (28.3%) 9 (9.7%) 10 (19.6%) 14 (18.4%) 15 (16.5%) p=NS 
CTO of proximal/mid vessel segments  13 (24.5%) 8 (8.6%) 10 (19.6%) 14 (18.4%) 15 (16.5%) p=NS 
 
IQR: interquartile range; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; PCI: percutaneous coronary intervention; 
PCI: percutaneous coronary intervention; MI: myocardial infarction ; LMCA: left main coronary artery; SYNTAX: synergy between PCI with taxus and cardiac 
surgery; LM: Left main; CTO: chronic total occlusion; NS: not significant 
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3.2 Outcomes 
 
Median (IQR) follow-up was 584 (1036) days. The crude 30-day mortality rate was 
12.0%, one-year mortality was 20.2% and the overall mortality rate for the follow-up 
period was 35.2%. Table 14 shows a breakdown of all the MACCE during the study 
follow-up. The MACCE rate for the overall follow-up was 41.8%, where death makes up 
81.7% of all MACCE. The MACCE rate at 30 days was 13.1% consisting of a high 
proportion of cardiac deaths. Cardiac deaths made up 85% of all MACCE at one month, 
62.5% at one year and 52.2% for the entire follow-up period. 
 
The proportion of non-cardiac cause of death rose steadily from 6.8% in one month to 
18.9% at one year and 36.0% for the entire follow-up. At one year we report a repeat 
revascularisation rate of 2.5% and 5.2% over the whole follow-up period.  
 
Myocardial infarction occurred in 10.1% of patients for the entire follow-up. We report 
definite and probable ST rates in this analysis. The early and late ST rates are 1.6% (6 
cases) and 0.3% (1 case) respectively, with a VLST rate of 0.6 % (2 cases).  
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Table 14: MACCE at 30 days, 1year and median follow-up period for overall 
study population (n=366) 
 0-30 days 1 year Overall follow-up 
All-cause death 44 (12.0%) 74 (20.2%) 125 (34.2%) 
Cardiac Death 41 (11.2%) 60 (16.4%) 80 (21.9%) 
MI 6 (1.6%) 32 (8.7%) 37 (10.1%) 
Repeat 
revascularisation 
2 (0.8%) 9 (2.5%) 19 (5.2%) 
Stroke 1 (0.3%) 1 (0.3%) 4(1.1%) 
Definite/Probable ST 6 (1.6%) 7 (1.9%) 9 (2.5%) 
MACCE 48 (13.1%) 96 (26.2%) 153 (41.8%) 
 
MACCE: major adverse cardiac and cerebrovascular events; MI: 
myocardial infarction; ST: stent thrombosis 
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3.2.1 Survival Analysis  
 
Unadjusted Kaplan-Meier survival estimates 
Unadjusted Kaplan-Meier survival curves show a significant difference in outcomes for 
the 3 SYNTAX score tertiles, see figure 4.  There is a definite visual separation of the 
curves for the low and intermediate SS groups from the curve for the high SS group. 
  
Survival curves for the three modes of presentation (Figures 5-7) show a significant 
difference in survival for the stable patients compared to those presenting with STEMI 
(Figure 5). The survival curve for STEMI patients show a large number of early events, 
and then a plateau, the survival curve of NSTEMI patients seem to converge with the 
survival curve of STEMI patients at about two years (Figure 6). A further analysis 
comparing patient presenting with NSTEMI to stable patients also showed no 
significant difference, although there seem to be more early events within the NSTEMI 
patients the two curves run in parallel after that with a similar attrition rate (Figure 7).  
Patients presenting with cardiogenic shock suffered significantly worse outcomes, with 
a thirty-day mortality of 65.9% compared with 9.6% for those who did not suffer 
cardiogenic shock (Figure 8). 
Unadjusted survival curves for quintiles of indices of deprivation showed no significant 
differences between the quintiles for survival free from MACCE (Figure 9). A separate 
analysis comparing the upper and lower quintiles did not reveal any significant 
differences (Figure 10).  
Unadjusted survival of all patients older than 80 years old was similar to those under 
80 years old, (Figure 11). 
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Figure 4: Kaplan-Meier (KM) survival curve of all LMCA PCI by SYNTAX score 
 
 
Figure 5: Kaplan-Meier survival curve of stable vs. STEMI patients in the overall cohort 
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Figure 6: Kaplan-Meier survival curve of patients with NSTEMI vs STEMI in the overall cohort. 
 
 
Figure 7: Kaplan-Meier survival curve of stable vs NSTEMI patients in the overall cohort 
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Figure 8: Kaplan-Meier survival curves for the overall study population presenting with and without cardiogenic 
 shock on presentation 
 
 
Figure 9: Kaplan-Meier survival curves for quintiles of indices of deprivation in the overall population 
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Figure 10: Kaplan-Meier survival curves of 1st and 5th Quintiles of indices of multiple deprivation 
 
 
Figure 11: Kaplan-Meier survival curves comparing patients over 80years old to those less than 80 years old
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Cox proportional hazards regression 
Up to 14 explanatory covariates could be included in developing the regression model 
[12]: 
 
N=10k/p 
 
Where, N=number of cases in the study, k =the number covariates in the study, and     
p = the proportion of cases with events to those with no events. The model did not 
include LV function due to the high rate of missing values; however, we have reported 
the results of the analysis of multiple imputation datasets separately. The regression 
model used included: Age, gender, clinical syndrome on presentation, presentation 
with cardiogenic shock, renal impairment, diabetes, previous stroke, previous MI, 
previous PCI, peripheral vascular disease, median SYNTAX score and left main 
bifurcation disease. 
After adjustment for baseline clinical and procedural characteristics, we found that the 
SS [aHR 1.01, 95% CI 1.00-1.02, p<0.05], presentation in cardiogenic shock [aHR 5.88, 
95% CI 3.81-9.06, p<0.05], previous MI [aHR 1.94, 95% CI 1.37-2.75, p<0.05] and a 
history of diabetes [aHR 1.61, 95% CI 1.12-2.31, p<0.05] were significantly associated 
with MACCE (see Table 15). When the regression analysis was repeated using a 
composite adverse endpoint of cardiac death, myocardial infarction, stroke and 
unplanned repeat revascularisation, SS was no longer found to have a significant 
association with poor outcomes (Table 16). 
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Table 15: Independent predictors of MACCE over long term follow-up in patients treated with LMCA PCI 
Covariate aHR (95%CI) p-value 
SYNTAX score (mean – 31.70) 1.01 (1.00-1.02) <0.05 
Cardiogenic shock 5.88 (3.81-9.06) <0.05 
Previous MI 1.94 (1.37-2.75) <0.05 
Any history of diabetes 1.61 (1.12-2.31) <0.05 
 
MACCE: major adverse cardiac and cerebrovascular events; LMCA: left main coronary artery; PCI: percutaneous coronary 
intervention;  aHR: Adjusted Hazard ratio; CI: confidence interval; SYNTAX: synergy between PCI with taxus and cardiac 
surgery 
 
Table 16: Independent predictors of  the composite end-point of cardiac death, myocardial infarction, stroke and unplanned repeat 
revascularisation  over long term follow-up in patients treated with LMCA PCI 
Covariate aHR (95% CI) p-value 
Cardiogenic shock 8.89 (5.75-13.75) <0.05 
Previous MI 1.91 (1.28-2.83) <0.05 
Any history of diabetes 1.93 (1.28-2.90) <0.05 
 
LMCA: left main coronary artery; PCI: percutaneous coronary intervention; aHR: Adjusted Hazard ratio; CI: confidence interval; MI: myocardial infarction 
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Patients with cardiogenic shock 
Patients with cardiogenic shock on admission were more likely to present with STEMI, 
while only a fifth presented with NSTEMI (Table 17). They were less likely to have any 
cardiac history prior to this presentation, such as a previous MI or PCI, but were 
otherwise equally matched with regards to comorbidity. Coronary disease burden was 
similar between the two groups with no significant difference in SS; however acute 
occlusion of the LMCA was more likely in patients with cardiogenic shock. Patients with 
cardiogenic shock on presentation were more likely to have a CTO of the main 
epicardial vessels. 
 
Those presenting in cardiogenic shock were more likely to receive treatment with an 
intra-aortic balloon pump (IABP) prior to PCI, and significantly more procedures were 
performed using femoral access. Bare metal stents were twice as likely to be used in 
shocked patients as non-shocked patients. Total radiation dose was significantly higher 
in the shocked group.  There was no significant difference in the rate of procedural 
complications; however, the only retroperitoneal bleed was found in the non-shocked 
group.  
 
The thirty day and one-year mortality for shocked patients was 67.4% and 69.6% 
respectively (figure 8). Cardiac death accounts for over 93.8% of all deaths at 30 days 
and 96.9% of all deaths at one-year in this group. 
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Table 17: Characteristics of 46 patients with cardiogenic shock on presentation compared with 320 patients with no cardiogenic 
shock 
Characteristic Cardiogenic shock No Cardiogenic shock p-value 
Female gender 12 (26.1%) 110 (34.4%) p=NS 
Median (IQR) age, years 72.0 (15.0) 76.0 (20.0) p=NS 
NSTEMI 9 (19.6%) 154 (48.1%) p<0.05 
Stable Angina 0 (0.0%) 99 (30.9%) p<0.05 
STEMI at presentation 37 (80.4%) 67 (20.9%) p<0.05 
Cardiogenic Arrest on presentation 4 (8.7%) 4(1.4%) p<0.05 
Renal impairment 7 (15.2%) 31 (9.7%) p=NS 
History of diabetes 8 (17.4%) 73 (22.8%) p=NS 
Previous stroke 4 (8.7%) 33 (10.3%) p=NS 
Peripheral vascular disease 4 (8.7%) 53 (16.6%) p=NS 
Previous PCI  2 (4.3%) 58 (18.1%) p<0.05 
Previous cardiac surgery 1 (2.2%) 20 (6.3%) p=NS 
Previous MI  8 (17.4%) 134 (41.9%) p<0.05 
Median(IQR) SYNTAX score 43.0(20.0) 27.5(19.0) p=NS 
LMCA Bifurcation lesion 37 (80.4%) 227 (70.9%) p=NS 
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LMCA acute occlusion 17 (42.5%) 26 (10.8%) p<0.05 
LM+1VD 15 (32.6% 132 (41.3%) p=NS 
LM+2VD 15 (32.6%) 73 (22.8%) p=NS 
LM+3VD 3 (6.5%) 33 (10.3%) p=NS 
Significant RCA disease 27 (61.4%) 150 (49.0%) p=NS 
CTO present 14 (30.4%) 50 (15.6%) p<0.05 
CTO of proximal/mid vessel segments 13 (28.3%) 48 (15.0%) p<0.05 
Femoral access 38 (82.6%) 20 (64.7%) p<0.05 
Total radiation dose Units(IQR) 8345.0 (7307) 7461 (5569) p<0.05 
Inotropes 6 (13.0%) 2 (0.6%) p<0.05 
IABP prior o PCI 35 (76.1%) 23 (7.2%) p<0.05 
BMS used 22 (47.8%) 58 (18.2%) p<0.05 
Total stent length, mm (IQR) 36.0 (35.0) 33.0 (30.0) p=NS 
Cardiac arrest during PCI 6 (13.0%) 3 (0.9%) p<0.05 
IQR: interquartile range; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; PCI: percutaneous 
coronary intervention; PCI: percutaneous coronary intervention; MI: myocardial infarction ; LMCA: left main coronary artery; SYNTAX: synergy 
between PCI with taxus and cardiac surgery; LM: Left main; CTO: chronic total occlusion; IABP – intra-aortic balloon pump 
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Patients with cardiogenic shock excluded 
The median survival of patients with cardiogenic shock was three days. The SHOCK trial 
and registry show that cardiogenic shock on presentation with a myocardial infarction 
is strongly associated with early in-hospital death independent of the burden of 
coronary disease [202]; for these patients, better outcomes are dependent on the 
speed with which cardiac reperfusion is restored and multi-organ dysfunction is 
corrected. To better assess the long-term outcomes from LMCA PCI, we excluded 
patients with cardiogenic shock. Thus we performed a separate survival analysis. After 
excluding patients presenting with cardiogenic shock, we show the breakdown in 
MACCE in Table 18. The one-month mortality was now only 4.1%, compared with 12.0% 
for the overall cohort (Table 14).   
 
The baseline characteristics of 320 patients with no cardiogenic shock on presentation 
reveal a smaller proportion of STEMI patients with only a marginal reduction in the 
percentage of patients presenting with NSTEMI (see Tables 19 and 20). The burden of 
coronary disease, as measured by the median SYNTAX score, has not changed 
significantly. A similarly sized majority of patients were within the high SYNTAX score 
tertile. 
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Table 18: MACCE at 30 days and overall follow-up in 320 patients with no cardiogenic shock on presentation 
 0-30 days 1 year Overall follow-up 
All-cause death 13 (4.1%) 42 (13.1%) 90 (28.1%) 
Cardiac Death 11 (3.4%) 29 (9.1%) 48 (15.0%) 
MI 5 (1.6%) 22 (6.9%) 33 (10.3%) 
Repeat revascularisation 2 (0.6%) 9 (2.8%) 16 (5.0%) 
Stroke 1 (0.3%) 1 (0.3%) 4 (1.3%) 
Definite/Probable ST 5 (1.6%) 6 (1.9%) 7 (2.2%) 
MACCE 17 (5.3%) 64 (20.0%) 116 (36.3%) 
 
MACCE: major adverse cardiac and cerebrovascular events; MI: myocardial infarction; ST: stent thrombosis 
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Table 19: Patient characteristics for 320 patients with no cardiogenic shock (n=320) 
 Number (Percentages) Missing data % 
Median (IQR)Age 77.0 (19.0) 0 
Female Sex 110 (31.4%) 0 
Stable Angina 99 (30.9%)  
NSTEMI 154 (48.1%) 0 
STEMI 67 (20.9%) 0 
Unstable angina 1 (0.3%) 0 
Cardiac arrest 2 (0.6%) 0 
Hyperlipidaemia 164 (51.2%) 0 
Diabetes 73 (22.8%) 0 
Hypertension 158 (49.4%) 0 
Current or ex-smoker 159 (49.7%) 0 
Previous Stroke 33 (10.3%) 0 
Peripheral vascular disease 53 (16.6%) 0 
Previous MI 134 (322%) 0 
Previous PCI 58 (18.1%) 0 
Previous Cardiac surgery 19 (5.9%) 0 
Renal Impairment 31 (9.7%) 0 
Moderate to severe LV impairment 103 (32.2%) 30.9% 
IQR: interquartile range; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; MI: myocardial 
infarction; PCI: percutaneous coronary intervention; LV: left ventricle 
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Table 20: Angiographic data in patients with no cardiogenic shock (n=320) 
Characteristic Number (%) 
LMCA Bifurcation lesion 227 (70.9%) 
LM+1VD 132 (41.3%) 
LM+2VD 73 (22.8%) 
LM+3VD 33 (10.3%) 
Median SYNTAX score (IQR) 30.0(18.0) 
Lower SS tertile  ≤23 85 (24.6%) 
Intermediate SS tertile  23-32 98 (29.5%) 
High SS tertile  ≥32 134 (44.5%) 
Dominant RCA 150 (46.9%) 
Significant RCA disease 50 (15.6%) 
CTO present 48 (15.0%) 
CTO of proximal/mid vessel segments  45 (14.1%) 
 
LMCA: left main coronary artery; LM: left main; VD: vessel disease; SYNTAX: synergy between PCI with taxus and 
cardiac surgery; IQR: interquartile range; SS: SYNTAX score; RCA: right coronary artery; CTO: chronic total occlusion 
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The median follow-up was 710 (1118) days. The 30 day, 1 year and overall mortality 
rates are 4.1%, 13.1% and 28.1% respectively. After adjustment for baseline clinical, 
angiographic and procedural characteristics, SS [aHR 1.02, 95% CI 1.00-1.04, p<0.05], 
previous MI [aHR 1.89, 95% CI 1.28-2.80, p<0.05] , peripheral vascular disease [aHR 
1.68, 95% CI 1.09-2.61, p<0.05] and renal impairment [aHR 1.89, 95% CI 1.05-3.43, 
p<0.05] were significantly associated with MACCE (see Table 21). Thus, for every 10 
point change in SS there is a 2% increase in risk of MACCE. 
 
Cox regression analysis of covariates was used to detect predictors of the composite 
adverse end-point of cardiac death, MI, stroke and repeat revascularisation. After 
adjustment for covariates, we found: that for every 10 point increase in SS there was a 
2% increase in risk of the composite adverse endpoint [aHR 1.02, 95% CI 1.02-1.04, 
p<0.05]. In addition previous MI [aHR 1.82, 95% CI 1.15-2.88, p<0.05] and diabetes 
[aHR 1.81, 95% CI 1.13-2.91, p<0.05] were associated with poor outcomes (see Table 
21).  
 
Diabetes was not significantly associated with MACCE when adjusting for other 
variables (see Table 21). However, it was significantly associated with the composite of 
cardiac death, MI, stroke and repeat revascularisation (see Table 22). Diabetic patients 
had more commonly experienced previous MI or undergone cardiac surgery. They 
were more likely to have suffered a stroke in the past and were more likely to have a 
history of hyperlipidaemia. Despite a similar SYNTAX score, diabetic patients were 
more likely to have LMCA bifurcation disease. DES use did not differ between the 
groups, and the mean total stent length was similar between the two groups (see 
Table 23). 
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Table 21: Independent predictors of MACCE  over long term follow-up in 320 patients treated with LMCA PCI, all 
cardiogenic shock patients excluded 
Covariate aHR (95% CI) p-value 
SYNTAX score 1.02 (1.00-1.04) <0.05 
Previous MI 1.89 (1.28-2.80) <0.05 
Peripheral vascular disease 1.68 (1.09-2.61) <0.05 
Renal impairment 1.89 (1.05-3.43) <0.05 
 
LMCA: left main coronary artery; PCI: percutaneous coronary intervention; aHR: Adjusted Hazard ratio; CI: confidence 
interval; MI: myocardial infarction 
 
Table 22: Independent predictors of the composite end-point (cardiac death, MI, stroke and repeat 
revascularisation) over long term follow-up in 320 patients treated with LMCA PCI, all cardiogenic shock 
patients excluded 
Covariate aHR (95% CI) p-value 
SYNTAX score 1.02 (1.00-1.04) <0.05 
Previous MI 1.82(1.15-2.88) <0.05 
Diabetes 1.81(1.13-2.91) <0.05 
 
LMCA: left main coronary artery; PCI: percutaneous coronary intervention; aHR: Adjusted Hazard ratio; CI: confidence 
interval; MI: myocardial infarction 
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Table 23: Diabetic patients compared to non-diabetic patients, cardiogenic shock patients excluded (n=320) 
 Diabetic patients, n=73 (%) No diabetes, n=247 (%) p-value 
Median (IQR)Age 74.7(9.4) 72.5(13.9) p=NS 
Female Sex 24 (32.9%) 86 (34.8%) p=NS 
Hyperlipidaemia 48 (65.8%) 116 (47.0%) p<0.05 
Hypertension 47(64.4%) 111 (44.9%) p<0.05 
Previous Stroke 12(16.4%) 21 (8.5%) p<0.05 
Peripheral vascular disease 16 (21.9%) 37 (15.0%) p=NS 
Previous MI 41 (56.2%) 93 (37.7%) p<0.05 
Previous PCI 15 (20.5%) 43 (17.4%) p=NS 
Previous Cardiac surgery 10 (13.7%) 9 (3.6%) p<0.05 
Renal Impairment 11 (15.1%) 20 (8.1%) p=NS 
ACS 53 (72.6%) 166 (67.2%) p=NS 
Median (IQR) SS 32.0 (11.8) 30.0(13.6) p=NS 
LMCA bifurcation disease 59 (80.8%) 168 (68.0%) p<0.05 
All CTO’s 16 (21.9%) 34 (13.8%) p=NS 
DES used 60 (82.2%) 196 (79.4%) p=NS 
Median (IQR)Total stent length 38.5(21.6) 37.5(22.3) p=NS 
 
IQR: interquartile range; MI: myocardial infarction; PCI: percutaneous coronary intervention; ACS: acute coronary syndrome; SS: 
SYNTAX score; LMCA: left main coronary artery; CTO: chronic total occlusion;  DES: drug eluting stent; NS: not significant 
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Imputed data 
5 datasets were imputed with co-morbidity, clinical presentation and severity of 
coronary disease used as predictors of LV function. All 5 datasets were used in the Cox 
proportional hazards regression analysis, which included the imputed LV function 
assessment as a covariate. Adjusted hazard ratios and 95% confidence intervals are 
displayed in Table 24. 
 
The imputed data confirm that patients with cardiogenic shock had a greater than five 
times hazard of MACCE; other independently associated covariates include a previous 
MI, diabetes and the SS. Additionally, we can conclude that moderate to severe LV 
impairment was an independent predictor of MACCE. The analysis has also identified 
renal impairment, age and DES use as independent predictors of poor outcomes. 
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Table 24: Independent predictors of MACCE  over long term follow-up for imputed data of 
patients treated with LMCA PCI 
Covariate aHR (95% CI) p-value 
SYNTAX score (mean – 31.6) 1.013(1.008-1.018) p<0.05 
Cardiogenic shock 5.081(4.165-6.197) p<0.05 
Previous MI 1.774(1.527-2.061) p<0.05 
Any history of diabetes 1.551(1.331-1.807) p<0.05 
Age 1.01(1.004-1.016) p<0.05 
Renal impairment 1.250(1.002-1.558) p<0.05 
Moderate to severe LV impairment 1.407(1.206-1.641) p<0.05 
DES used 1.245(1.061-1.460) p<0.05 
 
LMCA: left main coronary artery; PCI: percutaneous coronary intervention; aHR: Adjusted Hazard ratio; CI: 
confidence interval; SS: SYNTAX score; MI: myocardial infarction; LV: left ventricular; DES: drug eluting stent 
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3.3 Summary 
3.3.1 Key results 
 
In this retrospective analysis of unselected patients with ULMCA disease treated with 
PCI, cardiogenic shock before intervention contributed more than fivefold hazard to 
the risk of MACCE when compared to other significant covariates. Other independent 
covariates associated with MACCE include the burden of coronary disease, as 
measured with the SS, previous MI and a history of diabetes.  
 
Left Ventricular function was missing in over 30.0% of patients; to assess the 
association between LV function and outcomes, we conducted multiple imputation. 
After imputation of 5 datasets, using predictor variables identified with a directed 
acyclic graph, we analysed the data using Cox proportional hazards modelling. The 
results were consistent with the first analysis and confirm the independent association 
between SS, cardiogenic shock, previous MI and diabetes with poor outcomes. In 
addition to this, moderate to severe LV dysfunction was confirmed to be 
independently associated with MACCE. Furthermore, we identified age, renal 
impairment and DES used as predictors of poor outcomes; however, these findings 
should be viewed with caution. 
 
Cardiac death represents more than half of all the MACCE events throughout the 
follow-up period. Cardiac death in patients with cardiogenic shock contributed more 
than 60% of all MACCE in the first month; this represents 27% of all MACCE for the 
entire follow-up period. The one-year survival for our patients presenting with 
cardiogenic shock, 30.1%,  was less than that reported for patients treated with 
revascularisation in both the SHOCK trial and the SHOCK trial registry [202, 203]. Less 
than a quarter of patients in both of these study cohorts had significant LMCA stenosis 
though; while patients with LMCA disease in the SHOCK trial registry had a much worse 
survival compared to those in our study [204]. We can conclude from these studies 
that with increasing severity of coronary disease, patients presenting with cardiogenic 
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shock have worse outcomes and those with LMCA stenosis or three vessel disease 
have the worst survival rates overall. MACCE in this context becomes a sensitive 
indicator of covariates associated with early cardiac death. Thus we identified 
cardiogenic shock, with the consequent multi-organ dysfunction, as a predictor of poor 
short-term outcomes [180]. Indeed, with a change in the composite outcome measure 
from MACCE (Table 15) to one which replaced all cause death with cardiac death 
(Table 16), we see that the SS was no longer predictive of worse outcomes. Where 
cardiogenic shock is so closely related to early cardiac death, it blunts the sensitivity of 
covariates on the sample, and the regression analysis becomes less discriminatory of 
long term outcomes.   
 
We conducted a separate analysis, excluding patients presenting with cardiogenic 
shock, to assess more specifically the predictors of long-term outcomes. The MACCE 
rate for this cohort was 20.0% at one year and 36.3% over the median follow-up period 
of almost two years. We found that the SS, previous MI, peripheral vascular disease 
and renal impairment were associated with MACCE. Furthermore, when one assesses 
the components of MACCE, we report a repeat revascularisation rate of only 2.8% in 1 
year; while in other retrospective studies the repeat revascularisation rates are 
between 5-10% [18, 73, 205]. The incidence of myocardial infarction though was 
comparable to these studies. Death therefore makes up the largest component of our 
MACCE. There may be two reasons for the differences in composite event rates 
between our study and other published studies. Firstly, there may be a tendency to 
manage subsequent ischaemic events in this older cohort conservatively compared 
with other studies [18, 73, 170, 206, 207]. Secondly, death may be the earlier event in 
this older population, so it may be appropriate to measure cardiac death.  
 
It is known that the choice of outcome indicators included in a composite end-point, 
through their weighted contribution, may change the interpretation of results of 
studies significantly [179, 191]. Death is recommended by the ARC as a safety indicator 
within the composite end-point of MACCE [180]. All-cause death contributed over 80.0% 
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of all of the MACCE in our study. Considering the individual components of MACCE, 
with a proportionately large weighting of all-cause death on the composite end-point 
in the context of our relatively aged study population, cardiac death would seem a 
more specific measure of treatment safety and effectiveness. The ARC considers 
cardiac death a useful alternative to all-cause death in long term studies [180], the 
further one moves away from the treatment the less specific all-cause death becomes 
as a measure of treatment outcomes. In older populations we would argue the same 
principle applies. Cardiac death can be considered a specific measure of target lesion 
failure following LMCA PCI [111, 208]. Thus, we assessed the separate composite end-
point of: cardiac death, MI, stroke and repeat revascularisation. For this composite 
end-point we found that SS, previous MI and diabetes were associated with worse 
outcomes. 
 
3.3.2 Discussion 
 
This retrospective registry represents a unique study population with respect to 
demographics, comorbidity and coronary disease burden. Compared with other 
published observational studies and randomised trials, this study has an older 
population with a median age almost 10 years greater than other published LMCA 
revascularisation studies in the drug-eluting stent era[25, 30, 31, 33, 59-61, 209, 210]. 
The proportion of patients 80 years and older in our study is near twice that reported 
in a recently published British Cardiovascular Interventional Society (BCIS) national 
dataset [147, 154]. Our study population had more comorbidity than previously 
published studies; including higher rates of previous MI, CKD and more than three 
times the level of peripheral vascular disease [25, 33, 210]; but similar levels of 
diabetes were observed. So this represents a higher surgical risk population compared 
with other published studies [211]. 
 
The SS was independently associated with MACCE within the overall cohort such that 
for every 10 point increase in the SS there was a 2.0% increase in risk of MACCE.  It was 
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independently associated with the composite end-point when substituting all-cause 
death with cardiac death.  The SS is predictive of death and MACCE following PCI and 
has been consistently demonstrated in multivessel revascularisation [47, 212] as well 
as LM revascularisation [61-63, 213].  However the interaction between SS and 
outcomes are not consistent depending on the distribution of coronary atheroma [46, 
62, 64], as well as in it’s application in individual studies depending on different 
median SS between studies thus affecting the tertile cut points [64, 212]. The 
revascularisation guidelines recognise that the SS may not reflect all the individual 
factors in a case which may predict hazard from PCI [64, 214]. While the SS describes 
the ‘total’ burden of significant coronary stenoses as well as the complexity, the 
specific distribution of atheroma within the LM may impact on outcomes [73]. Despite 
a similar median SS, we found a greater proportion of patients with a high SS (SS ≥32) 
when compared with the SYNTAX trial [61]. Compared with the left main subgroup of 
the SYNTAX trial our study population had more distal left main coronary disease (72% 
vs. 54% respectively), but less multi-vessel disease (LM + 2VD and LM +3VD in 33.9% vs. 
65.6%) and fewer chronic total occlusions [61]. The SYNTAX trial included all-comers 
and was designed to study PCI vs. CABG in multivessel disease, the posthoc analysis of 
the LMCA subgroup, therefore, reflects this selection bias for multivessel disease. In 
the SYNTAX trial the SS therefore was a measure of the burden of multi-vessel disease, 
while in our study the SS weighting seemed to reflect the complexity of distal LMCA 
disease [61]. So while our patients may have a similar median SS, they have different 
distribution of coronary atheroma. In agreement with other studies, we found that the 
SS was significantly associated with MACCE [47, 63] and furthermore, patients in the 
high SS tertile had the worst survival compared to the other two groups [215]. 
 
In comparison to our study, the EXCEL and NOBLE trials reported a similar burden of 
distal LMCA disease and multi-vessel disease, yet the median SS was significantly lower 
[59, 60]. Both EXCEL and NOBLE included over 80.0% pf patients with significant left 
main bifurcation disease; however they did not disclose the number of patients with 
‘True’ bifurcation disease. While these two studies did not show an association 
between left main bifurcation disease and poor outcomes, it is known that long term 
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outcomes from PCI of the left main bifurcation are worse when compared with ostial 
or mid-shaft disease [73], particularly when complex two stent strategies are required 
[114]. While we did not identify the left main bifurcation as a specific predictor of 
outcomes, there is significant collinearity with the SS. A further analysis of this specific 
coronary lesion for which a separate results chapter is included, vide infra. 
  
We report similar levels of diabetes amongst the study cohort compared with other 
reported registries [36, 113-115] and randomised trials of left main coronary artery 
disease [61, 62, 216]. In our study diabetes was independently associated with MACCE 
in the overall cohort, but it was not found to be associated with MACCE when we 
excluded patients with cardiogenic shock. DM was associated with a nearly twofold 
increase in the combined adverse event rate (cardiac death, stroke, repeat 
revascularisation and MI) in patients with no cardiogenic shock on admission. Diabetic 
patients have an increased risk of cardiac death [217-219], which may explain the 
difference in sensitivity between the composite endpoints. Cardiac death may provide 
a more specific examination of the cardiovascular system effects of diabetes in this 
aged population.  
 
Diabetic patients have an earlier onset of more extensive coronary disease [220, 221], 
including LMCA disease [125]. It is known that diabetic patients do worse from 
multivessel revascularisation than non-diabetics, where CABG offers better survival 
than PCI for individuals with diabetes [212, 222]. However, there is some conflict in the 
published data on revascularisation of diabetic patients with significant LMCA disease. 
A registry of multivessel and LMCA revascularisation showed no interaction between 
diabetes and outcomes [223]. Some registries reporting outcomes from PCI for LMCA 
disease have not identified DM as a predictor of poor outcomes [18, 24, 224]; yet 
other registries reporting on LMCA revascularisation have shown diabetes was a 
predictor of poor outcomes [36, 225, 226]. However, these studies were not designed 
to examine outcomes from LMCA revascularisation in diabetic patients. Despite early 
results from the SYNTAX trial and left main subgroup which identified diabetes as a 
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predictor of worse outcomes [61, 227]; in a later analysis at 4 years the association was 
no longer evident [228]. Indeed diabetes was not included in the SYNTAX II model of 
predictors of long term outcomes [229]; the SYNTAX II was later externally validated in 
the Drug Eluting stent for LefT main coronary Artery disease (DELTA) registry [43]. 
Other randomised studies of left main revascularisation, comparing CABG and PCI, 
found no excess hazard with diabetes [62, 216]. These studies can be criticised for 
significant differences in the burden of coronary disease between diabetic and non-
diabetic groups. 
  
It is suggested that the end-organ consequences, rather than the presence of diabetes 
are strongly predictive of poor outcomes [229-231]. The burden of coronary disease 
can be viewed as an end-organ effect of diabetes. This is evident in the BARI registry, 
where patients received physician-led choice of treatment strategy; they found no 
difference in outcome between CABG and PCI for diabetic patients [232]. As the 
majority of patients screened ended up in the registry, the choice of revascularisation 
strategies were based on the merits of treating the specific pattern of coronary disease 
burden. Similarly in the LMCA, where the choice of revascularisation strategy was 
based on the burden of disease, we find no interaction between diabetes and poor 
outcomes [216].  However, randomised studies of ULMCA revascularisation comparing 
groups with similar burdens of coronary disease have found significantly worse 
outcomes in diabetic patients [233].  While there is a lack of data for outcomes 
amongst diabetic patients with ULMCA disease, after correction for SS and other 
comorbidities, we found a significant association between diabetes and adverse 
outcomes. Our study indicates diabetes may be an important factor with respect to 
outcome in ULMCA revascularisation independent of SS.  
 
A meta-analysis of patients with multivessel disease has shown a survival advantage of 
CABG over PCI over long term follow-up in diabetic patients [234]. Our findings 
therefore could indicate that diabetic patients may benefit from consideration for high 
risk CABG. However, while we report a significantly greater burden of coronary disease 
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than the studies included in this meta-analysis, our patients have more comorbidity 
and therefore higher surgical risk. Further studies evaluating the effect of diabetes on 
outcomes in patients with ULMCA disease is warranted. 
We identified previous MI as a significant predictor of MACCE. However, as LV 
dysfunction was not included in the multivariate analysis it is not clear to what extent 
previous MI was merely a surrogate of LV dysfunction. LV dysfunction is known to be 
an independent predictor of adverse outcomes of MACCE following revascularisation 
across all patient age groups and presentations [235, 236]. A similar proportion of 
missing LV function has been observed in the BCIS national database of left main 
disease [147], and for almost half of all patients who undergo PCI in the UK [235]. 
Those with LV assessments present had significantly greater comorbidity with higher 
rates of previous MI, previous PCI and renal impairment. The patients with missing LV 
function were more likely to present with a STEMI and were younger than those with 
LV function assessments available. This indicates the data were MNAR. The PPCI 
service in West Yorkshire operates on a ‘spoke and wheel’ design, patients presenting 
with STEMI are treated at the tertiary centre and then discharged to the districts 
hospitals where LV assessments may not have been completed. While we could not 
confirm the reason for missing LV function assessments, this is a recognised 
mechanism for missing LV function assessments [237]. Five multiple imputation 
datasets were analysed for predictors of the adverse end-point, thereby allowing us to 
assess the independence of these two factors, MI and moderate to severe LV 
dysfunction. The adjusted model revealed both of these covariates were 
independently associated with worse outcomes. Possible mechanisms for this 
association should include not only pump failure but also scar related arrythmogenesis. 
 
Older patients are more likely to suffer with LMCA disease [3, 124, 125] and 
considering the median age of this study population, it was surprising that age was not 
a predictor of poor outcomes in the overall cohort. Other studies have shown a 
significant correlation with increasing age and poor outcomes from LMCA PCI [78, 228]. 
Cox regression analysis of the multiple imputation datasets suggests that age has a 
weak association with poor outcomes, for every 10 year increase in age there was a 1% 
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increase in the risk of MACCE. Renal failure too was identified as a predictor of MACCE 
in the analysis of the multiple imputation datasets, while this finding is similar to other 
studies [78], we had three times the proportion of renal failure within our study 
population. It was reassuring that the findings from the analysis of the multiple 
imputation datasets correlated with the initial findings from our overall cohort and 
with other published data despite the data MNAR.  
  
Patients from more deprived LSOAs, as indicated by high IMD quintiles, were 
significantly younger than with those in the least deprived quintiles. There were 
significant differences in co-morbidity between the quintiles of deprivation. We found 
a significantly greater prevalence of diabetes and renal impairment amongst the 4th 
and 5th quintiles of deprivation, this is congruous with other studies of PCI populations 
[178], as well as large national and international studies of unselected patients [238]. 
While peripheral vascular disease is a marker of severity of coronary artery disease and 
is predictive of poor outcomes from revascularisation [228], we did not show a 
significant difference in the prevalence of peripheral vascular disease between the 
quintiles of deprivation. This differs to studies of deprivation in unselected populations 
where the prevalence of peripheral vascular disease was highest amongst the most 
deprived [174], but this finding is not always consistent [178].  
 
While it is known the there is an earlier onset of subclinical coronary disease amongst 
the more deprived [239], we found no difference in the burden of coronary disease 
amongst the quintiles of deprivation when measured with the SS. Nor did we find an 
excess of multivessel disease in the more deprived.  However, no study has identified a 
specific pattern of coronary disease associated with deprivation. This may reflect the 
earlier development of worse categories of coronary artery disease, such as left main 
coronary artery disease amongst the more deprived. Coronary artery disease has a 
prolonged incubation period from the onset of subclinical disease [175, 239] to the 
presentation of severe disease. So, while we were unable to demonstrate a significant 
difference in survival after PCI between the quintiles of deprivation, the period of 
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deprivation which antecedes the manifestation of coronary disease may lead to an 
earlier onset of severe coronary artery disease in the more deprived. Hence the 
younger more deprived with severe disease.  Other studies though have found worse 
outcomes following PCI amongst the more deprived [178, 240, 241]. However, it is not 
known if these studies were comparing patients with similar burdens of coronary 
disease while in our study we found a similar burden of coronary disease across the 
quintiles of deprivation.  
 
We report a large number of complications, over 25.1%. While one may accept this 
high complication rate is due to the significantly older cohort of patients it is five times 
that reported for elderly patients in other studies [133]. These complications represent 
a combination of operator-reported complications, recorded on Cardiobase® at the 
time of the procedure, and those identified at the time of angiographic review for this 
analysis. The interventionalist who reviewed the angiograms was blinded to the 
procedural notes; complications were imported directly into the database and were 
not allocated separately to the reviewer or operator. Due to this method of data 
collection and coding, we were unable to discriminate those reported by the operator 
from those reported at the time of angiographic review. Complications are divided into 
procedural or access site related complications.  
 
Over half of our reported complications include coronary dissections. Untreated 
coronary dissections post-angioplasty may result in poor long term outcomes whether 
in the context of balloon angioplasty or post-stenting [242-244]. As a consequence 
additional stenting to cover the dissection flap may be indicated. In the pre-stent era it 
was recognised that the risk of acute complications, such as side branch occlusion and 
MI, were associated with angiographically higher grades of dissections post-
angioplasty [244, 245]. There is debate as to whether dissections detected on 
intravascular imaging are of significant clinical consequence with some studies 
advocating additional stenting [246, 247] , while other data suggests a conservative 
approach would be appropriate [248, 249]. Due to the way in which our data were 
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collected we were unable to elucidate whether these reported dissections were edge 
dissections post-stenting and whether these resulted in unplanned additional stenting. 
In addition there was lack of information concerning the angiographic grades of 
dissection being reported. Nevertheless, we did not demonstrate an association 
between poor long term outcomes and angiographic LMCA dissection during 
angioplasty. 
 
Access site complications were reported in 5.7% of all patients, 90.4% of these were 
reported in cases of femoral access with a large (7/8Fr) sheath and over three quarters 
of these patients had LMCA bifurcation disease. Arterial sheaths greater than 7 Fr in 
size were used in almost 70.0% of our patients which is ten times the proportion 
reported in other studies [250, 251]. As a consequence of these larger sheaths and the 
much higher levels of PVD in our study, we report access site complications in nearly 
twice the number of patients compared with these studies. However, the pattern of 
coronary disease and PCI strategy is not known for these published studies. The large 
burden of distal LMCA disease in our study may account for the need to use larger 
sheaths and catheters. There could be a number of reasons for this, one consideration 
is potentially one operator with a preference for the femoral approach, yet we do not 
have the data to speculate. Another reason could be the consideration that distal 
LMCA disease may require a two stent strategy, further analysis is required to 
determine the mechanisms and decision making leading to the use of large catheters 
in a population with higher than reported rates of peripheral vascular disease. 
 
We report a definite and probable stent thrombosis ST rate of 1.9% in the first year, 
rising to 2.2% over the course of the follow-up. While this is similar to that reported for 
other LMCA PCI cohorts [31, 252], it is twice the number reported in a multi-centre 
registry of ULMCA PCI [253]. There could be a few of reasons for this increased ST rate 
in our study compared to this registry, including: 1) significantly longer median stent 
length used in our study [253]; 2) our patients have significantly more comorbidity 
[254]. While LMCA bifurcation requiring a two-stent strategy may be a risk of ST [31, 
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77], we had a similar burden of distal LMCA disease and similar usage of the two stent 
approach compared to this multicentre registry. Despite using fewer DES in our cohort 
compared to the meta-analysis, we reported cases of very late ST (VLST), while they 
reported none. Unfortunately, we were unable to exclude premature cessation of 
DAPT in our patients. One other factor which may explain the significantly lower ST 
rate in this multi-centre registry is that the study authors may have under-reported ST 
in unexplained deaths [253]. 
3.3.3 Limitations 
 
Despite a similar median SS, diabetic patients had significantly more distal left main 
disease. Distal LMCA disease is a predictor of MACCE [26, 28, 71-77]. The SS 
incorporates the total burden of coronary disease and additional points are given for 
LMCA bifurcation disease and complexity [35]. In this way we have significant 
collinearity of data. So despite including the SS in the multivariate regression analysis, 
there may be significant confounding from distal LMCA disease.  
 
Selection bias was inherent in this retrospective study of a group of individuals for 
whom one can only presume CABG was not an option. Whether it is due to the 
acuteness of their presentation or high surgical risk, this heterogeneous study 
population would not be included in a randomised trial of ULMCA revascularisation. 
Considering the mode of presentation, this alone would bias the results in favour of 
those presenting free of cardiogenic shock. This is reflected in the significant 
differences between patients with and without cardiogenic shock. Therefore it was 
appropriate to consider these two groups separately for further analysis. While it is 
unavoidable for this type of study, by dividing the patients into subgroups, e.g. 
excluding cardiogenic shocked patients; it is possible to explore some research 
questions. If we are to consider a prospective registry examining this patient group, we 
should include strict exclusion and inclusion criteria. 
 
   122 
 
Missing data presents a specific confounding on the analysis of outcomes, in particular 
when considering that poor LV function is accepted as a significant factor predicting 
poor outcomes from revascularisation. While accepting this was unavoidable given the 
retrospective nature of the study, it is noted that similar studies of more robustly 
audited databases, such as the BCIS national database, the data here too were found 
wanting in a greater proportion of patients. Furthermore, other randomised trials have 
reported similarly high proportions of missing LV function data, up to a quarter in 
some instances [110]. Nevertheless, in order to diminish this confounding, we used 
multiple imputation. While this imputed data cannot be used to provide conclusions, 
we were able to confirm the findings from the initial analysis.  
 
The choice of composite outcomes could be argued lack specificity and may in fact be 
inaccurate. The inaccuracy relates to the follow-up, as the data were collected 
retrospectively and a proportion of the patients were followed up at district hospitals. 
However, every effort was made, as stated in the methods section to ameliorate this 
by gathering information from each hospital and GP practices. Furthermore, the 
specificity is directly related to the selection bias, e.g. measuring all cause death in 
older patients doesn’t necessarily examine the treatment effect of revascularisation. 
We addressed this issue earlier and by using two different composite end-points have 
provided alternative interpretations of outcomes. These two issues could easily be 
addressed by constructing a prospective registry with regular follow-up and 
independent review of end-points. Exclusion criteria should provide a study population 
which allows longer term follow-up where appropriate measures of treatment 
effectiveness can be examined. 
There may be significant confounding for the lack of data on medical management for 
these patients. The study sample was accrued over a number of years and during this 
time there were significant advances in medical therapy, so these were not taken into 
account. Nor is there any knowledge of whether medications were optimised during at 
follow-up. 
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There are hints that some of the practices at the LGI were not conforming to other 
centres, take for instance the use of large sized femoral catheters. In this way we 
should be cautious to generalise the findings of this study to the wider community. Of 
particular note is seemingly low numbers of repeat revascularisation, which is out of 
keeping with all published data. There could be a few reasons for this; 1) conservative 
management of subsequent coronary events, 2) recurrent MACCE events not being 
included, which is possible given the retrospective nature of this study. 
 
3.3.4 Conclusion 
 
This unique study population gives insight into the challenges of delivering ULMCA 
revascularisation for those patients who are not usually included in published studies 
and for whom CABG is not appropriate according to accepted guidelines/practice. Our 
study population is older, has more comorbidity and has a significantly different 
burden of coronary disease compared with currently published observational and 
randomised study populations. 
 
Patients with cardiogenic shock had poor outcomes which are consistent with findings 
from historical cardiogenic shock study cohorts, despite advancing PCI techniques. This 
probably reflects the limited progress in the management of cardiogenic shock rather 
than a failing of PCI revascularisation techniques.  
 
We have shown diabetes is independently associated with poor outcomes amongst 
patients with ULMCA disease. While risk factors, such as smoking and high cholesterol 
decline in the population, diabetes continues to increase amongst the more deprived 
[255]. The role of diabetes in cardiovascular disease is potentially confounded by the 
timing of diagnosis and initial management, which is often at the time of onset of 
clinically apparent coronary disease, such as presentation with an ACS.  
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Despite significant missing data, multiple imputation provided results which were 
consistent with other analyses. While future studies should improve the completeness 
of data collection, multiple imputation can be considered a useful tool in dealing with 
missing data.  
 
Finally, MACCE in our cohort was relatively high with a high mortality rate, repeat 
revascularisation represented less than 3.0% of all MACCE. This may reflect the 
conservative approach to further revascularisation. Patients and clinicians embark on 
treatment to achieve two goals, prognostic and symptomatic benefit. This 
retrospective study indicates that amongst this older group of patients, where 
prognostic benefit may be limited, a closer analysis of the symptomatic benefit is 
warranted with a prospective quality of life study. 
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4. Results chapter: Left main coronary bifurcation 
percutaneous coronary intervention 
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We demonstrated significant stenosis of the left main coronary bifurcation in 262 
patients.  In this analysis of outcomes from left main bifurcation percutaneous 
coronary intervention we excluded 27 patients presenting with cardiogenic shock, 
which is in keeping with the other studies of bifurcation PCI [106, 110, 114]. 
4.1 Patient characteristics 
 
We identified 162 patients with ‘True’ left main bifurcation disease compared with 63 
patients with ‘Non-true’ bifurcation disease. 
4.1.1 Demographics 
 
The ‘Non-true’ and ‘True’ bifurcation groups were equally matched for most baseline 
characteristics (Table 25). There was a preponderance of females in the ‘True’ 
bifurcation group, while age did not differ between the two groups. There was no 
significant difference in the median age for the ‘Non-true’ and ‘True’ bifurcation 
groups, 75.0 (21.0) years and 79.0 (14.0) respectively. Almost two-thirds of patients 
presented with an ACS in each group, with a significantly greater proportion of STEMI 
in the ‘Non-true’ compared to the ‘True’ groups, 17 (27.0%) vs. 24 (14.8%); p<0.05. The 
proportion of patients treated electively for stable angina was not significantly 
different between the groups and represented just over a third of all patients, 22 
(34.9%) in the ‘Non-true’ group compared with 55 (34.0%) in the ‘True’ group. 
 
Baseline comorbidity was similar with a significantly smaller proportion of patients 
with a history of previous MI in the ‘Non-true’ bifurcation group, 20 (31.7%), compared 
with the ‘True’ bifurcation group, 82 (50.6%); p<0.05. Close to a third of patients had 
missing LV function assessments, and for those with LV function, a third had moderate 
to severe LV impairment. Over a quarter of patients presented with diabetes in the 
‘Non-true’ and ‘True’ groups, 16 (25.4%) and 42 (25.9%) respectively. A little over 17.0% 
of all patients had a history of peripheral vascular disease (PVD), with no significant 
difference between the two groups. 
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Table 25: Patient characteristics in 225 patients with left main bifurcation disease  
 ‘Non-true’ bifurcation disease (n=63) ‘True’ bifurcation disease (n=162) p-value 
Median (IQR)Age 75.0 (21.0) 79.0 (14.0) p=NS 
Female Sex 12 (19.0%) 59 (36.4%) p<0.05 
Stable Angina at time of presentation 22 (34.9%) 55 (34.0%) p=NS 
NSTEMI at time of presentation 24 (38.1%) 83 (51.2%) p=NS 
STEMI at time of presentation 17 (27.0%) 24 (14.8%) p<0.05 
Cardiac arrest at presentation 3 (5.6%) 0 (0%) p=NS 
Hyperlipidaemia 31 (51.7%) 83 (53.5%) p=NS 
Diabetes 16 (25.4%) 42 (25.9%) p=NS 
Hypertension 27 (42.9%) 83 (51.2%) p=NS 
Current or ex-smoker 34 (58.6%) 76 (53.1%) p=NS 
COPD 7 (11.1%) 19 (11.7%) p=NS 
Previous Stroke 4 (6.3%) 21 (13.0%) p=NS 
Peripheral vascular disease 10 (15.9%) 29 (17.9%) p=NS 
Previous MI 20 (31.7%) 82 (50.6%) p<0.05 
Previous PCI 1 (15.9%) 31 (19.1%) p=NS 
Previous Cardiac surgery 3 (4.8%) 14 (8.6%) p=NS 
Renal Impairment 5 (7.9%) 16 (9.9%) p=NS 
Moderate to severe LV impairment* 13 (20.6%) 62 (38.3%) p=NS 
IQR: interquartile range; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; COPD: chronic obstructive pulmonary 
disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; LV: left ventricular; *missing values = 63 (28.0%) 
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4.1.2 Angiographic data 
 
There were significant differences in the burden of coronary disease between the two 
groups beyond the left main bifurcation (Table 26). We identified aorto-ostial disease in a 
slightly greater proportion of ‘Non-true’, 18 (28.6%), versus ‘True’ group patients, 36 
(22.2%); p<0.05. The median (IQR) SYNTAX score (SS) was significantly lower in the ‘Non-
true’ group, 25.5 (14.3) vs. 35.0 (14.0). Close to a third of ‘Non-true’ group patients, 18 
(29.0%), and almost two-thirds of patient with ‘True’ bifurcation disease, 98 (60.9%), were 
in the high SS tertile. A significantly smaller proportion of patients in the ‘Non-true’ group 
presented with left main (LM) +2 vessel disease (VD) and LM+3VD, 12 (19.0%), compared 
with 63 (38.9%) of ‘True’ bifurcation patients. An American Heart Association (AHA) Type C 
lesion classification for the left main bifurcation stenosis was given for half of all ‘Non-true’ 
bifurcation lesions, 31 (49.2%) compared with almost four-fifths, 127 (78.3%); p<0.05, in the 
‘True’ group. The right coronary artery (RCA) was significantly diseased in over half of 
patient with ‘True’ bifurcation disease, 92 (58.6%), which was a significantly greater 
proportion when compared with the ‘Non-true’ bifurcation cohort, 21 (34.4%); p<0.05. 
There was no significant difference in the proportion of patients with chronic total 
occlusions (CTO) in the ‘Non-true’, 9 (14.3%), and ‘True’, 28 (17.3%), bifurcation groups. 
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Table 26: Angiographic characteristics of 225 patients with left main bifurcation disease  
 ‘Non-true’ bifurcation disease (n=63) ‘True’ bifurcation disease (n=162) p-value 
Aorto-ostial lesion 18 (28.6%) 36 (22.2%) p=NS 
LM+1VD 23 (36.5%) 68 (42.0%) p=NS 
LM+2VD 6 (9.5%) 43 (26.5%) p<0.05 
LM+3VD 6 (9.5%) 20 (12.3%) p=NS 
AHA Type C lesion 31 (49.2%) 127 (78.3%) p<0.05 
Median SYNTAX score (IQR) 25.5 (14.3) 35.0 (14.0 ) p<0.05 
Lower SS tertile  ≤23 19 (30.6%) 9 (5.6%) p<0.05 
Intermediate SS tertile  23-32 25 (40.3%) 54 (33.5%) p=NS 
High SS tertile  ≥32 18 (29.0%) 98 (60.9%) p<0.05 
Dominant RCA 58 (95.1%) 152 (95.6%) p=NS 
Significant RCA disease 21 (34.4%) 92 (58.6%) p<0.05 
CTO present 9 (14.3%) 28 (17.3%) p=NS 
CTO of proximal/mid vessel segments  8 (12.7%) 28 (17.3%) p=NS 
LMCA: left main coronary artery; LM: left main; VD: vessel disease; SYNTAX: synergy between PCI with taxus and cardiac surgery; IQR: interquartile range; 
SS: SYNTAX score RCA: right coronary artery; CTO: chronic total occlusion 
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4.1.3 PCI procedure data 
 
Femoral access was favoured for the majority of patients in both groups, whereas 
radial access was used in just over a quarter of ‘True’, and a third of ‘Non-true’ left 
main bifurcation cases (see Table 27). There was a cross over from radial to femoral 
access in fewer than 5% of patients in both groups. A larger sized catheter, at least 7Fr, 
was favoured in 43 (68.2%) of ‘Non-true’ and 133 (82.1%) of ‘True’ bifurcation cases.  
There was significantly more use of the smaller 6Fr sheath in the ‘Non-true’ bifurcation 
group. An intra-aortic balloon pump (IABP) for inotropic support was required pre-PCI 
in 11 (6.8%) of patients with ‘True’ bifurcation disease and 2 (3.2%) patients with ‘Non-
true’ bifurcation disease. Numerically more patients with 'True', 7 (4.3%), than 'Non-
true', 1 (1.6%), bifurcation disease had an intra-aortic balloon pump insertion during 
PCI. Heparin was the preferred anticoagulant for two-thirds of patients in both groups. 
Heparin and Bivalirudin were used together in less than 3% of all cases.  
 
There was a significant difference in choice of bifurcation treatment strategies 
between the two groups. The single-stent strategy was employed in the majority of 
patients with ‘Non-true’ bifurcation disease, 53 (84.1%), whereas a two-stent strategy 
was preferred in the majority of ‘True’ bifurcation cases, 88 (53.4%); p<0.05. A similar 
proportion of patients in both groups had a final kissing balloon inflation, with 15 
(23.8%) of ‘Non-true’ bifurcation cases and 39 (24.2%) of ‘True’ bifurcation cases. 
While we report significant RCA disease in half of all patients, only 14 (6.2%) had a 
coronary intervention to this artery at the time of LMCA intervention, with no 
significant difference between the two groups. A drug-eluting stent (DES) was used in 
over 80% of all cases, including the use of 2nd generation DES in 45 (71.4%) of ‘Non-
true’ and 111 (68.5%) of ‘True’ bifurcation cases. Despite a numerically greater median 
(IQR) stent length for patients with ‘True’ bifurcation disease, there was no significant 
difference between the two groups. A larger proportion of 'True' bifurcation patients 
had rotational atherectomy to the LMCA than 'Non-true' bifurcation, 27 (16.7%) 
compared with only 4 (6.5%); p<0.05. Intravascular ultrasound was employed in 
significantly more patients with ‘Non-true’ bifurcation disease than those with ‘True’ 
bifurcation disease, 24 (38.1%) vs. 30 (18.5%) respectively. 
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Rotational atherectomy of the calcified LMCA was required in 31(13.8%) of all patients 
where femoral access was preferred in 26(83.9%) using a large sized sheath, greater 
than 7Fr, in 30(96.8%) of these cases.  
 
4.1.4 PCI complications 
 
There were fewer procedural complications in the ‘Non-true’ bifurcation groups, 9 
(14.2%), compared with 43 (26.5%) in the ‘True’ bifurcation group. Nevertheless, there 
was no significant difference between the two groups (see Table 28). Coronary 
complications, including coronary dissection/perforation/side branch occlusion, 
accounted for the majority of complications in the ‘True’ bifurcation disease group 
making up two-thirds of all the complications, whereas in the ‘Non-true’ group this 
represented fewer than half of all complications. The proportion of coronary dissection 
in patients with ‘True’ bifurcation disease, was more than twice that of patients with 
‘Non-true’ bifurcation disease, 17 (10.5%) vs. 3 (4.8%) respectively. Access site 
complications occurred in a similar proportion of patients in the two groups, 4 (5.6%) 
of ‘Non-true’ bifurcation disease and 7 (4.6%) of ‘True’ bifurcation disease (see Table 
29). 
 
 
Of the 31 patients who required rotational atherectomy, 7 (22.6%) suffered a 
procedural complication. Four patients had coronary dissections, of these one patient 
had an additional coronary perforation, and one other developed a cardiac arrest 
during the procedure. Of the two patients with coronary perforations, one resulted in 
a cardiac tamponade. Only one patient developed cardiogenic shock during PCI, while 
none suffered side branch occlusions, neither pulmonary oedema nor underdeployed 
stents were reported. Access site complications were limited to those treated by the 
femoral route. These complications included: 1 femoral artery dissection, two 
haematomas and one false aneurysm requiring injection.
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Table 27: PCI procedure details in 225 patients with left main bifurcation disease  
 ‘Non-true’ bifurcation disease (n=63) ‘True’ bifurcation disease (n=162) p-value 
Femoral access 39 (61.9%) 113 (69.8%) p=NS 
Radial Access 21 (33.3%) 44 (27.2%) p=NS 
Radial and Femoral access 3 (4.8%) 5 (3.1%) p=NS 
6 Fr catheters 16 (25.4%) 23 (14.2%) p<0.05 
7 Fr catheters 38 (60.3%) 111 (68.5%) p=NS 
8 Fr catheters 5 (7.9%) 22 (13.6%) p=NS 
IABP use pre – PCI 2 (3.2%) 11 (6.8%) p=NS 
IABP use during PCI 1 (1.6%) 7 (4.3%) p=NS 
Heparin 42 (66.7%) 108 (66.7%) p=NS 
Bivalarudin 23 (36.5%) 54 (33.3%) p=NS 
Abciximab 14 (22.2%) 47 (29.0%) p=NS 
Tirofiban 3 (4.8%) 4 (2.5%) p=NS 
2 stent strategies for LMCA bifurcation 10 (16.1%) 88 (53.4%) p<0.05 
Final kissing balloon 15 (23.8%) 39 (24.2%) p=NS 
DES use (patient level data) 55 (87.3%) 135 (84.4%) p=NS 
1st generation DES 10 (15.9%) 24 (14.8%) p=NS 
2nd Generation DES 45 (71.4%) 111 (68.5%) p=NS 
Median (IQR) total stent length 30.0 (22.3) 42.0 (26.0) p=NS 
Rotational atherectomy 4 (6.5%)) 27 (16.7%) p<0.05 
IVUS 24 (38.1%) 30 (18.5%) p<0.05 
OCT 0 (0%) 0 (0%) p=NS 
Operator reported unsuccessful PCI 0 (0%) 5 (3.1%) p=NS 
PCI: percutaneous coronary intervention; IABP – intra-aortic balloon pump; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial 
infarction; Fr: french size; IABP: intra-aortic balloon pump; LMCA: left main coronary artery; IVUS: intravascular ultrasound; OCT: optical coherence 
tomography 
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Table 28: Procedural complications in 225 patients with left main bifurcation disease  
 ‘Non-true’ bifurcation disease (n=63) ‘True’ bifurcation disease (n=162) p-value 
Coronary dissection 3 (4.8%) 17 (10.5%) p=NS 
Coronary perforation 0 (0%) 5 (3.1%) p=NS 
Cardiac tamponade 0 (0%) 2 (1.2%) p=NS 
Cardiogenic shock developing during procedure 1 (1.6%) 5 (3.1%) p=NS 
Pulmonary oedema 0 (0%) 1 (0.6%) p=NS 
Cardiac arrest 0 (0%) 1 (0.6%) p=NS 
Propagation of thrombus 2 (3.2%) 3 (1.9%) p=NS 
Side branch occlusion 1 (1.6%) 5 (3.1%) p=NS 
Stroke 1 (1.6%) 0 (0%) p=NS 
Underdeployed stent 1 (1.6%) 3 (1.9%) p=NS 
Emergency CABG 0 (0%) 1 (0.6%) p=NS 
CABG: coronary artery bypass surgery 
 
Table 29: Access site complications in 225 patients with left main bifurcation disease  
 ‘Non-true’ bifurcation disease (n=63) ‘True’ bifurcation disease (n=162) p-value 
Retroperitoneal bleed 0 (0%)  1 (0.6%) p=NS 
Surgical intervention 0 (0%) 1 (0.6%) p=NS 
Arterial dissection 0 (0%) 1 (0.6%) p=NS 
Arterial haemorrhage 1 (1.6%) 4 (2.5%) p=NS 
False aneurysm requiring thrombin injection 1 (1.6%) 0 (0%) p=NS 
False aneurysm requiring compression 1 (1.6%) 0 (0%) p=NS 
False aneurysm conservative management 1 (1.6%) 0 (0%) p=NS 
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4.2 Outcomes 
 
The median (IQR) follow-up of all patients with left main bifurcation disease was 642 (1069) days with a 
mortality rate of 28.4% over this period. The crude 30-day mortality rate was 4.9 % and the one-year 
mortality rate was 15.1%. A breakdown of all MACCE events during the study follow-up is shown in Table 
30. The overall MACCE rate for the entire follow-up period was 37.3%, and the 30-day MACCE rate was 
5.8%. There was significantly less MACCE over the follow-up period for the ‘Non-true’ bifurcation group, 15 
(23.8%), compared with the ‘True’ bifurcation group, 69 (42.6%). There were no repeat revascularisations 
in patients with ‘Non-true’ bifurcation disease, 0 (0%), whereas 10 (14.5%) patients with ‘True’ bifurcation 
disease underwent further unplanned coronary revascularisation.  
Myocardial infarction (MI) occurred in 10.2% of patients for the entire follow-up. 2.2% of all patients 
suffered either a definite or probable ST, all of these were in the ‘True’ left main bifurcation disease group. 
Early and late stent thrombosis (ST) rates were 1.8 % and 0.4% respectively, while there were no reported 
very late ST (VLST) for either group. 
 
 
4.2.1 Survival Analysis 
 
Unadjusted Kaplan-Meier survival analysis showed a significantly worse outcome for patients with ‘True’ 
left main bifurcation disease over 642 (1069) days follow-up (figure 12). After adjustment for baseline 
clinical and procedural characteristics, which are considered in the directed acyclic graph, we found that 
there was a two fold increase in the risk of MACCE in patients with ‘True’ bifurcation disease, [aHR 2.0; 95% 
Confidence Interval (CI), 1.1-3.6; p<0.05] (Table 31). Other covariates which were independently associated 
with MACCE include: significant right coronary artery (RCA) disease [aHR 1.8; 95% CI, 1.1-2.9; p<0.05], 
diabetes [aHR 1.7; 95% CI, 1.1-2.7; p<0.05] and peripheral vascular disease [aHR 1.7; 95% CI, 1.0-2.8; 
p<0.05].  
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Table 30: MACCE in 225 patients with left main bifurcation disease  
 ‘Non-true’ bifurcation disease (n=63) ‘True’ bifurcation disease (n=162) p-value 
All-cause death 11 (17.5%) 53 (32.7%) p<0.05 
Cardiac Death 3 (4.8%) 33 (20.4%) p<0.05 
MI 5 (7.9%) 18 (11.1%) p=NS 
Repeat revascularisation 0 (0%) 11 (14.7%) p<0.05 
Stroke 0 (0%) 2 (1.2%) p=NS 
Definite/Probable ST 0 (0%) 5 (3.1%) p=NS 
MACCE 15 (23.8%) 69 (42.6%) p<0.05 
MACCE: major adverse cardiac and cerebrovascular events; MI: myocardial infarction; ST: stent thrombosis 
 
 
Table 31: Independent predictors of MACCE  over long term follow-up in 225 patients with left main bifurcation disease 
Covariate aHR (95%CI) p-value 
‘True’ left main bifurcation disease 2.0 (1.1-3.6) p<0.05 
Significant RCA disease 1.8 (1.1-2.9) p<0.05 
Peripheral vascular disease 1.7 (1.0-2.8) p<0.05 
Diabetes 1.7 (1.1-2.7) p<0.05 
 
MACCE: major adverse cardiac and cerebrovascular events; aHR: Adjusted Hazard ratio; CI: confidence interval; RCA: right coronary 
artery 
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Figure 12: Kaplan-Meier estimates of survival to MACCE in 162 patients with ‘true’ and 63 patients with ‘non-true’ left main bifurcation disease 
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4.3 One-stent vs Two-stent strategies 
 
A separate analysis of 162 patients with ‘True’ bifurcation disease was made 
comparing 74 patients treated with a single stent strategy to 88 patients treated with a 
two-stent strategy. 
 
4.3.1 Patient characteristics 
 
The cohort treated with a two-stent strategy were significantly older than those 
treated with a single stent strategy, median (IQR) 81.0 (11.0) years old vs. 75.5 (20.0) 
years old; p<0.05 (see Table 32).  Approximately two-thirds of patients presented with 
an acute coronary syndrome (ACS) with no significant difference between the two 
groups. Those patients treated with a single stent strategy had a numerically higher 
proportion of patients who had a previous MI at presentation, 43 (58.1%) vs. 38 
(43.2%), but this was not significantly different between the two groups. Those treated 
with a two-stent strategy had significantly more chronic obstructive pulmonary disease 
(COPD), 16 (18.2%) vs. 3 (4.1%); p<0.05. They were also more likely to suffer from 
hypertension, 50 (56.8%) vs. 31 (41.9%); p<0.05. There were no other significant 
differences between the groups for comorbidity. 
  
4.3.2 Angiographic details 
 
Aorto-ostial disease was present in over a quarter of patients treated in the single 
stent group and a fifth of those in the two stent group with no significant difference 
between the two groups (see Table 33). The median (IQR) SYNTAX score was 
significantly higher in the single stent group. Despite proportionately more patients in 
the higher SS tertile for those treated with a single stent, there was no significant 
difference between the treatment groups for the three SYNTAX tertile groups. The 
right coronary artery was the dominant vessel in over 90.0% of patients and was 
significantly diseased in over half of patients in both treatment groups. Chronic total 
occlusions (CTO’s) were present in 17 (23.0%) patients treated with a single stent 
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strategy and only 12 (13.6%) of patients treated with the two-stent strategy. 
Multivessel disease, LM+2VD and LM+3VD, was present in half of the patients in the 
single stent groups and only a third of patients in the two stent group. There were a 
significantly larger proportion of patients with LM+2VD in the single stent group, 26 
(35.1%) vs. 17 (19.3%); p<0.05, than in the two stent group. 
 
4.3.3 PCI procedural data 
 
The femoral route was preferred in over two-thirds of patients, with no significant 
difference between the groups, 47 (67.1%) in the single stent group and 59 (72.0%) in 
the two stent group (see Table 34). Larger sized catheters, 7Fr and 8Fr, were preferred 
in the two stent group, 77 (95.1%) vs 52 (70.3%); p<0.05. Heparin use was not 
significantly different between the two groups. However, the two stent group had 
significantly higher Bivalirudin use, 35 (42.7%) vs. 16 (22.9%); p<0.05. Final kissing 
balloon inflations were employed in almost a third of patients in the two stent group 
and just 11.6% of patients in the single stent group. Drug-eluting stents were used in 
the majority of patients, 136 (84.0%), with significantly more DES used in the two stent 
group, 74 (90.2%), compared with 53 (75.7%) in the single stent group. In the light of 
this, we found a significantly greater use of second generation DES used in the two 
stent group, over three-quarters, compared with just over half in the single stent group.  
The ‘Trouser, legs and seat’ two-stent strategy was preferred in the majority of 
patients, 28 (31.8%), while the T-stent was the second most commonly employed two-
stent technique, used in 24 (27.3%) of patients. The 'Shotgun' method was the next 
most common with 21 (23.9%) of patients treated using this strategy, see Table 35. 
The V-stent and Culotte were used in equal frequency, 7 (8.0%), while the ‘T and small 
protrusion’ technique was used in a single patient. It is not known whether some 
patients treated with these two stent techniques had failed a provisional single stent 
approach. 
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Table 32: Patient characteristics in 162 patients with ‘true’ left main bifurcation disease  
 Two stent strategy (n=88) Single stent strategy (n=74) p-value 
Median (IQR)Age 81.0 (11.0) 75.5 (20.0) p<0.05 
Female Sex 32 (36.4%) 27 (36.5%) p=NS 
Stable Angina at time of presentation 28 (31.8%) 26 (35.1%) p=NS 
NSTEMI at time of presentation 50 (56.8%) 33 (44.6%) p=NS 
STEMI at time of presentation 10 (11.4%) 15 (20.3%) p=NS 
Cardiac arrest at presentation 0 (0%) 0 (0%) p=NS 
Hyperlipidaemia 45 (51.1%) 39 (52.7%) p=NS 
Diabetes 26 (29.5%) 17 (23.0%) p=NS 
Hypertension 50 (56.8%) 31 (41.9%) p<0.05 
Current or ex-smoker 39 (44.3%) 36 (48.6%) p=NS 
COPD 16 (18.2%) 3 (4.1%) p<0.05 
Previous Stroke 13 (14.8%) 8 (10.8%) p=NS 
Peripheral vascular disease 13 (14.8%) 16 (21.6%) p=NS 
Previous MI 38 (43.2%) 43 (58.1%) p=NS 
Previous PCI 16 (18.2%) 15 (20.3%) p=NS 
Previous Cardiac surgery 5 (5.7%) 8 (10.8%) p=NS 
Renal Impairment 9 (10.2%) 7 (9.5%) p=NS 
Moderate to severe LV impairment* 32 45.7%) 29 (52.7%) p=NS 
IQR: interquartile range; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; COPD: chronic obstructive pulmonary 
disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; LV: left ventricular; *missing values = 35 (22.9%) 
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Table 33: Angiographic characteristics of 162 patients with ‘true’ left main bifurcation disease  
 Two stent strategy (n=88) Single stent strategy (n=74) p-value 
Aorto-ostial lesion 17 (19.3%) 19 (25.7%) p=NS 
LM+1VD 40 (45.5%) 28 (37.8%) p=NS 
LM+2VD 17 (19.3%) 26 (35.1%) p<0.05 
LM+3VD 10 (11.4%) 10 (13.5%) p=NS 
AHA Type C lesion 62 (91.2%) 65 (95.6%) p=NS 
Median SYNTAX score (IQR) 34.0 (11.0) 40.5 (18.0) p<0.05 
Lower SS tertile  ≤23 5 (5.7%) 4 (5.4%) p=NS 
Intermediate SS tertile  23-32 34 (39.1%) 20 (27.0%) p=NS 
High SS tertile  ≥32 48 (55.2%) 50 (67.6%) p=NS 
Dominant RCA 81 (93.1%) 70 (97.2%) p=NS 
Significant RCA disease 47 (55.3%) 44 (61.1%) p=NS 
CTO present 12 (13.6%) 17 (23.0%) p=NS 
CTO of proximal/mid vessel segments  12 (13.6%) 17 (23.0%) p=NS 
LMCA: left main coronary artery; LM: left main; VD: vessel disease; SYNTAX: synergy between PCI with taxus and cardiac surgery; IQR: interquartile range; 
SS: SYNTAX score RCA: right coronary artery; CTO: chronic total occlusion 
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Table 34: PCI procedure details in 162 patients with ‘true’ left main bifurcation disease  
 Two stent strategy (n=88) Single stent strategy (n=74) p-value 
Femoral access 62 (70.5%) 51 (68.9%) p=NS 
Radial Access 23 (26.1%) 21 (28.4%) p=NS 
Radial and Femoral access 3 (3.4%) 2 (2.7%) p=NS 
6 Fr catheters 5 (5.7%) 18 (25.7%) p<0.05 
7 Fr catheters 68 (78.2%) 44 (62.9%) p<0.05 
8 Fr catheters 14 (16.1%) 8 (11.6%) p=NS 
IABP use pre – PCI 6 (6.8%) 4 (5.4%) p=NS 
IABP use during PCI 3 (3.4%) 5 (6.8%) p=NS 
Heparin 54 (61.4%) 54 (73.0%) p=NS 
Bivalarudin 37 (42.0%) 17 (23.0%) p<0.05 
Abciximab 21 (23.9%) 26 (35.1%) p=NS 
Tirofiban 2 (2.3%) 2 (2.7%) p=NS 
Final kissing balloon 30 (34.1%) 9 (12.3%) p<0.05 
DES use (patient level data) 80 (90.9%) 56 (75.7%) p<0.05 
1st generation DES 10 (11.4%) 14 (18.9%) p=NS 
2nd Generation DES 70 (79.5%) 42 (56.8%) p<0.05 
Median (IQR) total stent length 45.0 (24.0) 34.5 (23.0) p=NS 
Rotational atherectomy 14 (16.3%) 13 (17.8%) p=NS 
IVUS 14 (15.9%) 17 (23.0%) p=NS 
OCT 0 (0%) 0 (0%) p=NS 
Operator reported unsuccessful PCI 2 (2.3) 2 (2.7%) p=NS 
PCI: percutaneous coronary intervention; NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; Fr: french size; IABP: 
intra-aortic balloon pump; LMCA: left main coronary artery; IVUS: intravascular ultrasound; OCT: optical coherence tomography 
 
 
 
   142 
 
Table 35: Two stent strategies used in 88 patients with ‘true’ left main bifurcation disease 
 Two stent strategy (n=88) 
T-Stent 24 (27.3%) 
V-stent 7 (8.0%) 
Trouser legs and seat 28 (31.8%) 
Culotte 7 (8.0%) 
TAP 1 (1.1%) 
Shotgun 21 (23.9%) 
TAP: T and small protrusion 
 
 
 
4.3.4 Procedural complications 
 
Procedural complications occurred in 19 (21.6%) patients in the two stent group and 24 (32.4%) patients in 
the single stent group with no significant difference between the groups (p=NS). There was a fourfold 
higher rate of side branch occlusion in the single stent group (see Table 36). Coronary dissection was by far 
the commonest complication in 7 (8.0%) patients in the two stent group and 10 (13.5%) patients in the 
single stent group. Only one patient in the single stent group underwent emergency bypass. Cardiogenic 
shock developed in 3 (4.1%) patients in the single stent group and 2 (2.3%) patients in the two stent group. 
All of these patients with cardiogenic shock, apart from one patient in the two stent group, required intra-
aortic balloon pump insertion.  
There was a single retroperitoneal bleed in the two stent group (see Table 37) however; there were no 
significant differences between the two groups for the incidence of arterial access site complications. 
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Table 36: Procedural complications in 162 patients with ‘true’ left main bifurcation disease  
 Two stent strategy (n=88) Single stent strategy (n=74) p-value 
Coronary dissection 7 (8.0%) 10 (13.5%) p=NS 
Coronary perforation 2 (2.3%) 3 (4.1%) p=NS 
Cardiac tamponade 2 (2.3%) 0 (0%) p=NS 
Cardiogenic shock developing during procedure 2 (2.3%) 3 (4.1%) p=NS 
Pulmonary oedema 1 (1.15) 0 (0%) p=NS 
Cardiac arrest 0 (0%) 1 (1.4%) p=NS 
Propagation of thrombus 2 (2.3%) 1 (1.4%) p=NS 
Side branch occlusion 1 (1.1%) 4 (5.4%) p=NS 
Stroke 0 (0%) 0 (0%) p=NS 
Underdeployed stent 2 (2.35) 1 (1.4%) p=NS 
Emergency CABG 0 (0%) 1 (1.4%) p=NS 
CABG – coronary artery bypass grafting 
 
Table 37: Access site complications in 162 patients with ‘true’ left main bifurcation disease  
 Two stent strategy (n=88) Single stent strategy (n=74) p-value 
Retroperitoneal bleed 1 (1.1%) 0 (0%) p=NS 
Surgical intervention 0 (0%) 1 (1.4%) p=NS 
Arterial dissection 0 (0%) 1 (1.4%) p=NS 
Arterial haemorrhage 1 (1.1%) 3 (4.1%) p=NS 
False aneurysm requiring thrombin injection 0 (0%) 0 (0%) p=NS 
False aneurysm requiring compression 0 (0%) 0 (0%) p=NS 
False aneurysm conservative management 0 (0%) 0 (0%) p=NS 
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4.3.5 Outcomes 
 
The median (IQR) follow-up of the patients with ‘True’ bifurcation disease was 603 
(1077) days. The overall mortality rate for the follow-up period was 32.7%. The crude 
30-day mortality rate was 6.2%, and the one-year mortality rate was 17.2%. Table 38 
shows a breakdown of all MACCE during the study follow-up. The MACCE rate for the 
overall follow-up was 41.4%, where death makes up 76.8% of all MACCE. The MACCE 
rate at 30 days was 7.4% consisting of a high proportion of cardiac deaths. Cardiac 
deaths made up two-thirds of all MACCE at one month, 58.5% of all MACCE at one 
year and 47.8% for the entire follow-up period. Patients treated with a single stent 
strategy had a higher MACCE rate compared with those treated with a two-stent 
strategy, 38 (51.4%) vs. 31 (35.2%). At one year we report a repeat revascularisation 
rate of only 3.1%, and for the entire follow-up period, this was 4.9%. Myocardial 
infarction occurred in 11.1% of all patients for the entire follow-up. Definite and 
probable ST rates are reported in this analysis at a rate of 3.1%, with 3 (3.4%) cases of 
ST in the two stent group and 2(2.7%) cases in the single stent group. The early and 
late ST rates are 2.5% (4 cases) and 0.6% (1 case) respectively. No very late stent 
thrombosis was reported. 
 
 
4.3.6 Survival analysis 
 
While there seems to be a nominal advantage in survival from a two stent strategy 
when assessing the separation of the Kaplan-Meier curves in figure 13, this is not 
evident with unadjusted survival analysis. After adjustment for baseline clinical and 
procedural characteristics, we found that peripheral vascular disease [aHR 1.9; 95% CI, 
1.1-3.3; p<0.05] and diabetes [aHR 1.7; 95% CI, 1.0-2.9; p<0.05] were independently 
associated with MACCE (see Table 39). 
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Table 38: MACCE in 162 patients with ‘true’ left main bifurcation disease  
 Two stent strategy (n=88) Single stent strategy (n=74) p-value 
All-cause death 23 (26.1%) 30 (40.5%) p=NS 
Cardiac Death  13 (14.8%) 20 (27.0%) p=NS 
MI 7 (8.0%) 11 (14.9%) p=NS 
Repeat revascularisation 4 (4.5%) 7 (9.5%) p=NS 
In-stent restenosis 7 (8.0%) 4 (5.4%) p=NS 
Stroke 2 (2.3%) 0 (0%) p=NS 
Definite/Probable ST 3 (3.4%) 2 (2.7%) p=NS 
MACCE 31 (35.2%) 38 (51.4%) p<0.05 
MACCE: major adverse cardiac and cerebrovascular events; MI: myocardial infarction; ST: stent thrombosis 
 
Table 39: Independent predictors of MACCE  over long term follow-up in 162 patients with ‘true’ left main bifurcation disease 
Covariate aHR (95%CI) p-value 
Peripheral vascular disease 1.9 (1.1-3.3) p<0.05 
Diabetes 1.7 (1.0-2.9) p<0.05 
 
MACCE: major adverse cardiac and cerebrovascular events; aHR: Adjusted Hazard ratio; CI: confidence interval;  
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Figure 13: Kaplan-Meier estimates of survival to MACCE in patients with 'true' bifurcation disease treated with a single or two stent strategy 
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4.4 Summary 
 
4.4.1 Key results  
 
In this analysis of patients with left main coronary artery bifurcation disease, the 
presence of ‘True’ bifurcation disease was associated with a two-fold increase in the 
risk of MACCE over long-term follow-up. Other factors independently associated with 
MACCE include the presence of significant right coronary artery disease, peripheral 
vascular disease and diabetes. 
A separate analysis of patients with ‘True’ bifurcation disease identified peripheral 
vascular disease and diabetes as independent predictors of MACCE over long-term 
follow-up. Unadjusted survival analysis showed while there appears to be a separation 
of the Kaplan-Meier survival curves for the two stent strategy and single stent strategy, 
that there was no significant difference in unadjusted survival when comparing 
patients treated with a single or two-stent strategy. 
 
4.4.2 Discussion 
 
In order to study long-term outcomes from ULMCA bifurcation disease, and given the 
known association of cardiogenic shock with early mortality [256-259], we did not 
include patients with cardiogenic shock in this analysis. This methodology is in keeping 
with the study design of prospective left main bifurcation studies and other bifurcation 
studies where patients with cardiogenic shock were excluded [106, 110]. 
 
The MACCE rate in this study population was 13.1% at 30 days and 26.2% at 1 year, 
which is similar to that reported in registries of LMCA PCI with first generation DES [21], 
while it is almost twice the MACCE found in other LMCA PCI registries of 1st generation 
DES which include close to 80.0% distal LMCA disease [22, 23, 26]. However, the 
burden of coronary disease may not be comparable as these studies do not specify the 
Medina class of LMCA bifurcation disease, nor do they use the SYNTAX score to 
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quantify associated coronary involvement. Our MACCE rate seems to be comparable 
with the treatment of complex LMCA bifurcations [73].  
 
 
We found a significant association between ‘True’ left main bifurcation disease and 
MACCE. There is a known association between significant distal LMCA disease and 
poor long-term outcomes [78]. While ‘True’ coronary bifurcations have worse 
outcomes when compared to 'Non-true' [260], no study has demonstrated this within 
the LMCA bifurcation. Other studies of left main bifurcation disease inform us that the 
greater the burden of atheroma at the bifurcation, the worse the long-term outcomes 
[78, 96]. However, this is the first study reporting outcomes in ‘True’ versus ‘Non-true’ 
left main bifurcation disease using the Medina classification of bifurcation disease [104, 
107, 114]. While other studies of LMCA disease demonstrate a prevalence of 'True' 
LMCA bifurcation in around one third of all patients, our study reports almost half all 
patients have ‘True’ LMCA bifurcation stenosis [61, 90, 114, 261]. Similar to our study, 
these studies did not use QCA to assess the size of the SB and the severity of disease in 
this vessel, while IVUS use was limited to a between one and two thirds of patients in 
two of these studies only. While there is a more than two fold increase in MACCE for 
patients with ‘True’ left main bifurcation disease in our study, they have a more than 5 
fold greater proportion of cardiac death, repeat revascularisation and stent thrombosis. 
 
The presence of RCA disease was associated with a nearly two-fold increase in the risk 
of MACCE.  While this supports the notion that total coronary disease burden 
contributes to poor outcomes in LM revascularisation [155, 213], more specifically 
significant RCA stenosis is predictive of worse outcomes from surgical revascularisation 
for LM disease [78]. Incomplete revascularisation of the RCA at the time of LMCA 
revascularisation may account for the association with poor outcomes. A number of 
factors may contribute to incomplete revascularisation. We describe an older cohort of 
patients with a median age of 78.0(16.0) years compared with other observational 
[113-115, 127, 261] or randomised trials [61, 117] reporting on outcomes from LMCA 
bifurcation PCI. While some studies report exclusively on patients with stable or 
unstable angina [113, 114, 117], others include less than a third [61, 127, 261] or close 
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to half of patient of patients presenting with ACS [115]. Our cohort of patients has the 
largest proportion, two-thirds, presenting with an acute coronary syndrome when 
compared with these studies with a larger proportion of patients with STEMI on 
presentation than any of these studies. National BCIS data have displayed a similar 
proportion of stable to ACS for all PCI [262]. Taken together, this preponderance of 
ACS in an older cohort may lead to selective revascularisation [170] and may have led 
to the incomplete revascularisation of the RCA. Indeed, residual coronary disease is a 
significant factor in determining outcomes from coronary revascularisation [9, 156-
158]. However, while we failed to revascularise the RCA in only 14 (6.2%) of our 
patients, the other study reporting RCA disease as a predictor of poor outcomes, failed 
to declare the number of unrevascularised RCAs [78]. Given the small number it is not 
certain that incomplete revascularisation of the RCA is the mechanism for poor 
outcomes. 
 
 
Compared with other studies of LMCA bifurcation disease, our study cohort has a 
similar burden of diabetes [113-115, 261], yet only one other study has demonstrated 
the association between diabetes and poor outcomes in distal LMCA disease [115]. 
While the burden of diabetes in our cohort is similar to that reported for this 
retrospective study by Palmerini et al [115], they failed to demonstrate this association 
after propensity-adjusted Cox regression analysis. This was mainly due to significant 
differences between groups with respect to comorbidity and coronary disease burden. 
In our study after multivariate regression analysis, correcting for coronary disease 
burden and comorbidity, we found the presence of diabetes was associated with 
almost twice the risk of adverse long-term outcomes in patients with ULMCA 
bifurcation disease. While Palmerini et al’s and our study were not designed to 
examine the outcomes between diabetic and non-diabetic patients, the choice of 
outcome measures may account for the conflicting results. While we used MACCE they 
used a composite of cardiac death and MI; MACCE would encompass the multi-organ 
effects of diabetes, while cardiac death and MI would be a measure of the cardiac 
specific effects of the PCI. 
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There was a two-fold increased risk of MACCE in patients with peripheral vascular 
disease (PVD). PVD is associated with an increased risk of coronary artery disease [263, 
264], and is an independent predictor of poor long-term outcomes following 
revascularisation [137, 228, 265]. While our cohort had less PVD compared to other 
published registries of LMCA PCI [72, 73], only one other LMCA PCI registry has 
reported PVD as an independent predictor of worse outcomes [37]. However, in this 
study, patients had almost twice the burden of PVD compared with our study patients. 
We did not find a significant difference in the prevalence of PVD between the ‘True’ 
and ‘Non-true’ groups, indeed no study has demonstrated an association between PVD 
and the burden of coronary disease. PVD is a marker of whole body atherosclerosis, 
and in this context is associated with MACCE in our population. 
 
 
In the separate analysis of patients with ‘True’ left main bifurcations, we showed no 
difference in outcomes for single and two stent strategies. There is conflict in the 
available evidence supporting either a single or two stent strategies in the treatment 
of LMCA bifurcation disease.  No randomised trials have compared single to two stent 
strategies for ‘True’ LMCA bifurcation PCI; while observational studies may report 
unequally matched treatment groups. Some studies have reported favourable 
outcomes from a single-stent strategy [90, 112, 115, 127] . Criticisms of these studies 
include: a) unequally matched groups with significantly more ‘True’ bifurcation disease 
in the two stent group [90, 112], or b) a lack of reporting atheroma burden in the left 
main bifurcation [115, 127], or c) significant differences in the burden of comorbidity 
between treatment groups, such as more diabetic patients in the single stent group 
compared to the two stent group [115]. Similarly, studies which report no difference 
between the stent strategies have inherent issues [113, 114, 261, 266]. These issues 
include: a) the inclusion of up to 20% of patients with a protected left coronary 
circulation [113], b) there may be a mismatch between the treatment groups with 
more ‘true’ bifurcation disease in the two stent group [113, 114, 266], c) they include 
only a third of patients with ‘true’ left main bifurcation disease [261], d) there may be 
significant differences in accepted practice between the treatment groups, such as 
significantly fewer final kissing inflations in the single stent group compared with the 
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two stent group [114]. To our knowledge this is the first study reporting outcomes 
from a two stent versus single-stent strategy in ‘True’ left main bifurcation disease, 
other studies have considered culotte versus double kiss crush and another considered 
culotte versus T-stenting [111, 267]. Yet our findings should be considered with 
caution, the study is underpowered and this is reflected in the unadjusted survival 
curves. There appears to be a nominal advantage from a two stent strategy, yet the 
unadjusted survival analysis did not show significant differences. While our findings 
seem to suggest a provisional strategy could be considered up front for all patients, we 
await the result of the EBC MAIN study which will examine this question [106]. 
 
While we show equal outcomes from two and single stent procedures, there may be 
considerable crossover between treatment groups. In our cohort, it could be presumed 
that almost two thirds of our patients treated with a two stent procedure, including 
the ‘Trouser, legs and seat’/ ‘V-stent’/ ‘Shotgun’, were treated electively, while those 
treated with a ‘T-stent’/’Culotte’/’TAP’ may have crossed over from a provisional single 
stent procedure to a two stent procedure [92].  The ‘Crush’ and ‘Culotte’ techniques 
were employed in over 85.0% of patients treated with an elective two stent strategy in 
the Nordic and BBC ONE studies of coronary bifurcations [82, 83, 268], while the 
‘Culotte’ technique was preferred in the  EBC TWO study of large coronary bifurcation 
disease [110]. After intention to treat analysis they concluded that a single stent 
technique was superior to a these two stent strategies for complex coronary lesions, 
however these studies include fewer than 5.0% of patients with LMCA disease. The ‘T-
stent’ and ‘Crush’ were preferred in over 70.0% of patients treated with two stents in 
retrospective studies of LMCA bifurcation PCI [22, 114, 115]. While these studies 
suggest equal outcomes from two or single stent procedures for the LMCA bifurcation, 
the crossover from a single to two stent procedure due to SB stenosis may be as high 
as 16% for these patients [82]. While in the BBC ONE trial crossover was allowed when 
the side branch was compromised, we report 4 times as many SB occlusions in the 
single stent cohort [82].  It is therefore not clear from these studies, nor our data, 
whether equal outcomes from single or two stent strategies were confounded by 
considerable crossover. The only randomised trial of PCI for LMCA bifurcation disease 
suggested that the double kiss crush was superior to the ‘Culotte’ for LMCA bifurcation 
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disease [117]. It is therefore not known which elective two stent procedure is 
preferable for the LMCA bifurcation. Yet the protocol for the EBC MAIN study, which 
will examine single stent vs two stent procedures for LMCA bifurcations, limit 
operators to a choice of either ‘Culotte’, ‘Minicrush’ (the double kiss variety), ‘T-
stenting’ or ‘TAP’ [106]. While our data cannot be analysed on an intention to treat 
analysis, they suggest that other two stent techniques, such as the ‘Trouser, legs and 
seat’/’V-stent’/’Shotgun’, should be included in a randomised study against the single 
stent technique. 
 
While it is known that PCI of the distal LMCA carries a higher risk of ST compared to 
other LMCA lesions [127], our study demonstrates a numerically more definite or 
probable ST in the ‘True’ bifurcation group compared to the ‘Non-true’ LMCA group, 
3.1% vs 0.0, however this was not statistically significant. The ST rate for ‘True’ left 
main bifurcation disease in our study was three times the rate  reported for all other 
PCI [69, 269], yet it was similar to that reported in other left main bifurcation PCI 
studies [114, 127].  Furthermore, while other studies report a greater risk of ST 
amongst patients treated with a two stent strategy compared with a single stent 
strategy [127, 261], we found no difference between the single and two stent 
treatment groups with respect to ST rates. Other studies confirm our findings that the 
ST rate is similar for single and two stent groups, however while we report on ‘True’ 
LMCA bifurcation disease, these studies report both ‘True’ and ‘Non-true’ [113, 114].  
 
 
 
IVUS guided PCI was not associated with better outcomes in our study. Only one study 
suggests a specific IVUS measurement, the minimum luminal area (MLA) of the 
polygon of confluence, may be predictive of long term outcomes following LMCA 
bifurcation PCI [101], while other evidence suggests there is no significant 
improvement in outcomes from IVUS guided LMCA PCI [270].  While SB stenosis at the 
distal LMCA is predictive of poor outcomes [96], IVUS is superior to angiography in 
delineating the LMCA bifurcation disease into ‘Non-true’ or ‘True’ bifurcation disease 
[89].  In this way IVUS might influence the PCI management strategy. We report double 
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the rate of use of IVUS for ‘Non-true’ compared with ‘True’ bifurcation patients. The 
benefit of using IVUS in the ‘Non-true’ group may lie in confirming the lack of 
obstructive atheroma in the SB [89], where this modality may be used to assess the 
appropriateness of a provisional single stent strategy  while ‘True’ bifurcation disease 
would motivate the operator to consider an elective two stent approach. The 
operators in our study may well have used IVUS to identify adverse features, such as 
acute bifurcation angle, which may predict carina shift and SB occlusion [103]. Indeed 
for patients with ‘True’ bifurcation disease, IVUS was employed in greater numbers 
amongst those treated with a single-stent compared with the two-stent group, albeit 
this was not statistically significant. In another retrospective study, IVUS was favoured 
in patients for whom an elective two-stent strategy was preferred to a provisional 
single-stent to treat ‘True’ LMCA disease; it is not clear whether the IVUS findings 
influenced the choice of stent strategy [114]. Yet, we used IVUS in only 24.0% of all our 
patients, while other LMCA bifurcation PCI studies report IVUS use in over two thirds 
of patients [90, 112, 114, 127].  While IVUS seems to be employed selectively in our 
study this practice does not seem to be consistent with other observational studies [90, 
112, 127], nor is it in agreement with the EBC recommendation to use IVUS in all LMCA 
bifurcation PCIs [271]. Indeed beyond the assessment of SB involvement, additional 
advantages of IVUS in bifurcation PCI include: 1) determining the main and sidebranch 
vessel reference diameters, 2) assessing adequate stent expansion, 3) assessment of 
the sidebranch ostium post PCI and 4) excluding stent edge dissections. There seems 
to be evidence indicating the data from the IVUS influenced the choice of stent 
strategy in our study population. Indeed this influence has been studied for other 
diagnostic modalities, such as pressure wire [272]. While there is no proven outcome 
benefit from IVUS use in LMCA PCI, our study suggests that management strategies are 
influenced by the data gathered through IVUS, so further studies designed to quantify 
this influence is warranted.  
 
 
While rotational atherectomy of the ULMCA is considered ‘off-label’ [273-275], there is 
evidence of improved outcomes in this subgroup of patients [276]. We report 
rotational atherectomy of the ULMCA bifurcation in 31 (13.8%) of the overall cohort. 
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However, a recent analysis of the use of rotational atherectomy in the UK national 
database has found that rotational atherectomy was used to treat the LMCA in only 
5.5% of all LMCA PCI [276], and other studies have shown it is a safe option [277].  In 
younger observational cohorts, less than half the proportion of patients with LMCA 
disease required rotational atherectomy [32, 43], with even lower usage rates amongst 
LMCA bifurcation registries [112]. Our older cohort of patients may be expected to 
have more calcified lesions than the younger patients reported in other studies [278-
280], which may account for this increased usage. 
 
While coronary rotational atherectomy is associated with a two-fold greater risk of 
complications compared with standard PCI, we report an incidence of double that 
number, 22.6% vs. 9.7% [276]. Over half of our reported complications were coronary 
dissections, 4(12.9%), while other data suggest the risk of coronary dissections from 
rotational atherectomy could be as low as 2.0% to 6.0% [276, 281-287]. Indeed the risk 
of coronary dissection after rotational atherectomy is lower than for standard PCI 
[288-290]. There could be various mechanisms for this increased number of dissections 
in our cohort, including an older cohort compared with other studies or the concurrent 
use of balloon angioplasty. Additionally one has to consider there is a small pool of 
operators who perform rotational atherectomy, indeed there is a possibility that these 
represent the complications of a single operator. One other consideration would be 
that of operators with lack of experience, such as registrar operators. These 
considerations though would be difficult to assess given the lack of identification of 
operators in our data. 
 
Nearly three times as many patients with ‘True’ than ‘Non-true’ bifurcation disease 
were treated with rotational atherectomy.  Side branch occlusion rates in our study 
were numerically higher amongst ‘True’ left main bifurcations; however, none were 
reported for patients treated with rotational atherectomy. While there was no 
statistically significant difference in our study, there is evidence from other studies 
that debulking of bifurcation lesions results in less SB occlusion from main vessel 
across side branch stenting [274, 283]. More patients with ‘True’ bifurcation disease 
treated with a single stent suffered SB occlusion than the two stent group, 5.4% vs. 
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1.1%. However, this was not statistically significant. While 16 patients had rotational 
atherectomy and single stent treatment, none suffered SB occlusion. SB occlusion is a 
recognised complication of bifurcation PCI and may occur in up to 8.0% of all cases [80, 
291-293]. It is commonly due to carina shift after main across side branch stenting 
[103]. While some studies suggest that ‘True’ bifurcations are at risk of side branch 
occlusion [260, 291, 294], other studies have found no difference in side branch 
occlusion rates comparing ‘True’ to ‘Non-true’ bifurcations [293]. Our study suggests a 
trend to more SB occlusion from the single-stent strategy in ‘True’ LMCA bifurcation 
disease but not after rotational atherectomy; while this is hypothesis generating the 
number of patients in our study are too small to draw conclusions. 
 
 
A third of patients in the two-stent group and only and eighth of those treated with a 
single stent had final kissing balloon (FKB) inflations; however the lack of use of FKB’s 
was not associated with poor outcomes. FKB inflations are recommended for 
provisional single stenting when the SB requires further ballooning [295], indeed it 
may be required in less than a third of these patients [82, 114]. The data suggest 
potential benefit from the use of final kissing balloons as a routine strategy in single 
stent procedures of the LMCA bifurcation. For LMCA bifurcation studies with high FKB 
inflations, over 50.0%, in the single stent group, they report better outcomes from the 
single stent compared with the two stent technique, despite FKB inflations in over 90.0% 
of those treated with two stents [73, 90, 115, 127]. While in other studies where FKB 
inflations were used in less than a third of patients treated with a single stent, they 
found no difference in outcomes [113, 114]. These studies suffer from confounding 
due to the difference in Medina class of bifurcation involvement, indeed after 
matching the benefit of FKB’s seem to extend only to patients treated with a two stent 
strategy [115].  Yet there is conflict in the data examining FKB in single stent treatment 
of LMCA bifurcation disease, with some reporting benefit [115], while others report no 
benefit in the routine FKB inflations for a single stent in the LMCA bifurcation [296]. 
These studies report almost double the FKB usage compared with our study and were 
undertaken amongst ‘Non-true’ and ‘True’ LMCA bifurcation lesions. Questions remain 
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regarding the benefit of routine FKB inflations for a single stent strategy in ‘True’ 
bifurcation disease.  
 
 
 
We report a similar rate of arterial access complications, only 4.9%, compared with 
other LMCA PCI registries [297], and we report an equal incidence of complications 
between ‘True’ and ‘Non-true’ cohorts. This is surprising given that the femoral route 
was used for almost two thirds of our patients with a slightly higher frequency 
amongst those with ‘True’ bifurcation disease. Femoral access is associated with worse 
outcomes from LMCA PCI [297]. The radial route has been used successfully for left 
main bifurcation PCI [297], however the  femoral route seems to be the preferred 
access for patients with ‘True’ left main bifurcation stenosis [114, 298]. In these studies 
the femoral route was preferred for elective two-stent strategies. We found no 
difference in access site preference for one or two stent strategies; femoral access was 
used in over two thirds of patients in both groups. The size of catheter used may have 
influenced the choice of access, close to 80.0% of all our patients were treated using at 
least a 7Fr catheter. While the 6Fr catheter can be used successfully for treating left 
main bifurcations [297], for those treated with an elective two stent strategy, larger 
catheters have been preferred in the past [298]. Current randomised studies seem to 
suggest a trend to using 6Fr catheters for elective two stent procedures in up to two 
thirds of patients [110]. While larger catheters allow the option of using kissing stents, 
more conventional two stent strategies can be performed with a 6Fr catheter even 
when kissing balloons are used. Amongst the ‘True’ bifurcation group those treated 
using a two stent technique were more likely to have larger catheters compared with 
the single stent group. However, due to lack of knowledge of intention to treat, it is 
not known the number of patients treated as a provisional single stent strategy with a 
view to possible conversion to a two stent strategy. In spite of the larger sized 
catheters and preference for femoral access amongst the two stent group, there was 
no significant difference in access site complications between the one and two stent 
groups. 
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Notably, while early expert consensus suggested that ‘True’ left main bifurcation 
disease should be considered a strong indication for a two stent strategy [119], the 
most recent consensus remains deliberately ambiguous in the light of observational 
non-randomised data and pending the results of EBC MAIN [271] . The only 
randomised trial assessing ‘True’ LMCA bifurcation disease compared the Culotte to 
double kiss crush, both two stent strategies [117]. However the question of whether a 
provisional single stent or two stent strategy for the treatment of ‘true’ bifurcation 
disease has not been assessed in a randomised trial. Our study therefore sheds some 
light on the problem given some obvious limitations.  
 
4.4.3 Limitations 
 
Our study suffers from considerable confounding for a number of reasons. While there 
were a significantly greater proportion of patients with a past medical history of 
myocardial infarction amongst the ‘True’ LMCA bifurcation group, the ‘True’ and ‘Non-
true’ bifurcation groups were otherwise equally matched with regards to comorbidity. 
Missing LV function, on almost a third of patients, would act as a confounder given the 
greater number of patients in the ‘True’ group with previous myocardial damage.  
 
Given that all cause death makes up three quarters of the MACCE, age may be 
considered a confounder as patients treated with a two stent strategy were 
significantly older than those treated with a single stent strategy. One other study 
showed that despite patients treated with a single stent being older patients with 
greater comorbidity they had better outcomes [115]. However, in this study the 
treatment groups differed with respect to the extent of LMCA bifurcation disease. 
 
 
In the analysis of ‘True’ bifurcation disease, patients treated with a single stent had a 
significantly greater median SS compared with patients in the two stent group. The 
greater SS is mainly accounted for by the associated coronary vessel disease, LM+2VD 
and LM+3VD, where half of patients in the single stent group had associated coronary 
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disease as opposed to only a third of those in the two stent group. In contemporary 
registries up to 80% of patients with LMCA bifurcation disease are reported to have 
LM+2VD and LM+3VD [112, 113]. In another study, patients had worse outcomes from 
a two stent strategy in the context of significantly more mulitvessel disease as 
compared to the single stent group [112]. Patients with a greater SYNTAX score 
generally do worse [55]. The higher SYNTAX score for patients with ‘True’ bifurcation 
disease in our study is not accounted for alone by the burden of atheroma around the 
LMCA bifurcation. A ‘True’ left main bifurcation stenosis contributes only 2 points to 
the SYNTAX score when compared with a 'Non-true' lesion [35, 299].Another study 
which report no difference in outcomes for single and two stent strategies, have 
treatment groups which are matched for SYNTAX scores and where the SS was in the 
low-intermediate tertiles [114]. Despite the criticism that the groups differed with 
regards to coronary disease burden, in the multivariate analysis, SS was not an 
independent predictor of poor outcomes. 
 
 
Future studies examining the PCI strategy for distal LMCA disease should be designed 
to reduce the confounding created by this associated multivessel disease. Indeed the 
EBC MAIN study excludes patients with a SS of greater than 32 [106]. However, bearing 
in mind that we treated significantly older patients with more extensive coronary 
disease, the data should be applied cautiously to the ‘real world’ patient cohorts. 
Distal left main disease is associated with a greater burden of multivessel disease [62, 
300-302]  and indeed this is the case for ‘True’ left main bifurcation disease, more so 
than ‘Non-true’ bifurcation disease. We report significantly more multivessel disease, 
LM +2VD and LM+3VD, amongst the ‘True’ bifurcation cohort compared with the ‘Non-
true’ cohort. However, other studies of PCI for unselected distal LMCA disease have 
reported associated multivessel coronary disease in up to four-fifths of patients [113, 
115], twice the proportion in our study. They show no difference in the burden of 
coronary disease between the 'True’ and 'Non-true' groups [72]. Despite this 
association with multivessel disease, after multivariate analysis including the SS, we 
can conclude that the association of 'True' LMCA bifurcation disease with poor 
outcomes were independent of the greater coronary disease burden. 
   159 
 
 
Despite only a numerically greater median stent length for the ‘True’ group, given the 
significant differences in coronary disease burden between the ‘True’ and ‘Non-true’, 
one cannot ignore possible confounding. We did not report the coronary territory 
involved in ST, other LM PCI studies have suggested the risk of ST may be related to the 
treatment of extensive coronary disease beyond the LMCA [127]. 
 
 
Prospective trials, such as the BBC ONE and Nordic trials include clear study treatment 
protocols which allow the identification of treatment crossover due to an unsuccessful 
stent strategy [83]. In this respect, while our retrospective study reports equal 
outcomes from a two stent vs single stent treatment for the LMCA, for those patients 
treated with ‘T-stent’/’Culotte’/’TAP’ strategies, there may have been considerable 
crossover from a provisional single stent to a T-stent strategy. In the EBC II trial the 
crossover was up to 16% [110]. Other confounders of an intention to treat analysis 
would include the lack of QCA data to confirm the size of the SB, while the viability of 
the subtended myocardial bed was unknown for a number of patients. 
 
 
While we report MACCE, including death, MI, repeat revascularisation and stroke, we 
did not report on TLR due to a lack of lesion-level outcome data. TLR in the stented left 
main bifurcation is reported in up to a fifth of patients over long term follow-up [127], 
so it remains an important determinant of outcomes. However, restenosis after LMCA 
bifurcation PCI was commonly asymptomatic and was often diagnosed after routine 
angiographic follow-up [190]. Only a small number of our patients suffered repeat 
revascularisations, while MACCE was mainly driven by death. In this older cohort it 
could be suggested that a lack of access to revascularisation procedures may have led 
to an underreporting of TLR  .   
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4.4.4 Conclusions 
 
This study cohort is older and has more extensive coronary disease than study 
populations included in current published data from which LMCA bifurcation PCI 
guidelines have been drawn. This study is the first to show that ‘True’ LMCA 
bifurcation disease is associated with worse outcomes following PCI. Diabetes is 
associated with a two-fold increase in the risk of poor outcomes in patients with LMCA 
bifurcation disease, albeit patient-level rather than lesion-level outcomes. Our study 
sample is representative of current clinical practice, which include high risk patients 
with complex coronary lesions. These data highlight the challenges facing both 
clinicians and researchers.  
So while our data support the notion that a single or two-stent strategy is acceptable 
for the treatment of ‘True’ LMCA bifurcation disease, given the lack of lesion-level 
outcomes, including TLR, this is hypothesis generating rather than conclusive. Future 
research to assess single vs. two stent strategies for ‘True’ LMCA bifurcation disease 
should include a more specific outcome measure and the selection of patients with 
limited associated coronary disease to minimise confounding. The challenge, therefore, 
would be to design a study which can answer the narrow question of how to treat the 
LMCA bifurcation while acknowledging that the typical patient presenting with LMCA 
bifurcation disease would usually have extensive coronary disease and may well be 
older with more comorbidity. These patients, therefore, may not be appropriately 
managed with CABG.  While we await the results of the EBC MAIN study, our findings 
seem consistent with the EBC recommendations for treating LMCA bifurcations. 
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5. Results chapter: Octogenarians with Left main coronary 
artery disease 
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We identified 154 octogenarians who presented with unprotected left main coronary 
artery (ULMCA) disease, the numbers of octogenarians treated increased year on year 
(see table 40). It is known that amongst an unselected group of octogenarians treated 
with PCI, cardiogenic shock is the single greatest predictor of in-hospital death, with a 
risk greater than five fold compared with other patients [1, 126, 303]. For the following 
analysis of long term outcomes amongst octogenarians, 15 patients presenting with 
cardiogenic shock were excluded and here follows the analysis of outcomes amongst 
139 octogenarians following left main coronary intervention.  
Up to three quarters of patients with LMCA disease have concomitant multi-vessel 
coronary artery disease [151]. There is increasing recognition that incomplete 
revascularisation of all diseased coronary arteries in multi-vessel disease is associated 
with increased mortality [156-158]. However, complete revascularisation is less 
commonly achieved in patients with anatomically more complex disease [47, 155]. If 
one considers that as one approaches the 8th decade the prevalence of LMCA disease 
is over 25% [151, 304],[305],[306], even up to 40% in one study [153], and it often 
presents with concomitant multivessel coronary disease [151], then the elderly would 
be at risk of incomplete revascularisation [170, 206]. 
The residual SYNTAX score (rSS) is a quantitative and reproducible measure of the 
severity and complexity of residual coronary disease after PCI, which is predictive of 
long term clinical outcomes in younger populations [47, 167]. Patients with rSS >8 have 
higher all-cause mortality at long term follow-up [155] and are at increased risk of 
recurrent ischaemic events [167]. In patients who receive PCI for ULMCA disease, rSS is 
a prognostic discriminator and has been identified as an independent predictor of 
cardiac mortality at two years [168]. However, the patients included in this study were 
relatively young (mean age 71 years) and the results may not be applicable to older 
individuals. A recent study of less than 100 patients suggested that residual coronary 
disease was associated with poor outcomes in octogenarians presenting with ACS 
[170]. This study did not assess patients with LMCA disease exclusively, with less than a 
third of patients had LMCA disease. 
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5.1 Patient characteristics 
5.1.1 Demographics 
 
Of 139 octogenarians (median age 84.0 [IQR 5.0] years; 40.7% female), over two thirds 
(67.1%) presented with an acute coronary syndrome, 12.1% of whom had STEMI 
(Table 41). Over half of patients 78 (56.1%) presented with a history of some form of 
cardiovascular disease including 21 (15%) with peripheral vascular disease, 16 (11.4%) 
with a history of stroke, 62 (44%) patients had a history of previous MI, while 25 
(17.9%) had previous PCI and 4(2.9%) patients had a history of previous cardiac surgery. 
No patients were found to have a protected left coronary circulation. There were 26 
(18.6%) patients with diabetes and nearly half of patients, 69 (49.3%) were treated for 
hypercholesterolaemia. Other significant comorbidity in this study cohort includes 14 
(10.1%) patients with renal impairment and 4 out of 10 patients had a history of 
smoking. While the median EuroSCORE (IQR) was 10.4 (11.8), there were 19 patients 
with a EuroSCORE of less than 5.0. The decision for PCI over surgery was not available 
in the retrospective data enquiry. 
 
The patients were ordered by rSS and divided into equal tertiles, the rSS score 
corresponding to the separate groups was used to describe the categories by rSS 
groupings. There were no significant differences in comorbidity between the three 
tertiles. 
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Table 40: Number of unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) in octogenarians per calendar year 
Year Number of ULMCA PCI %DES 
 
2005 6 50% 
2006 10 80% 
2007 10 30% 
2008 22 36.4% 
2009 17 82.4% 
2010 24 100% 
2011 27 88.9% 
2012 32 96.9% 
2013 (up to March) 6 100% 
 
ULMCA – unprotected left main coronary artery; PCI – percutaneous coronary intervention; DES – drug eluting stent 
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Table 41: Baseline clinical characteristics for 139 octogenarians, for the all patients and residual SYNATX score tertiles, rSS≤8, rSS>8-17 and rSS≥17 
Variable All patients (n=139) rSS≤8 (n=48) rSS >8-17   (n= 44) rSS >17 (n=47) p-value 
Median Age (IQR) 84.0 (5.0) 84.0 (5.0) 84.0 (4.0) 85.0 (6.0) NS 
Female sex 57 (40.7%) 19 (39.6) 16 (36.4%) 22 (46.8%) NS 
Stable angina 46 (32.9%) 16 (33.3%) 14 (31.8%) 16 (34.0%) NS 
NSTEMI 76 (54.3%) 27 (56.3%) 25 (56.8%) 24 (51.1%) NS 
STEMI 17 (12.1%) 5 (10.4%) 5 (11.4%) 7 (14.9%) NS 
Previous MI 62 (44.3%) 21 (43.8%) 16 (36.4%) 25(53.2%) NS 
Previous cardiac surgery 4 (2.9%) 1 (2.1%) 1 (2.3%) 2 (4.3%) NS 
Previous PCI 25 (17.9%) 10 (20.8%) 6 (13.6%) 9 (19.1%) NS 
Hypertension 77 (55.0%) 27 (56.3%) 23 (52.3%) 27 (57.4%) NS 
Peripheral vascular disease 21 (15.0%) 6 (12.5%) 6 (13.6%) 9 (19.1%) NS 
Chronic Lung disease 13 (9.3%) 4 (8.3%) 5 (11.4%) 4 (8.5%) NS 
Previous CVA 16 (11.4%) 2 (4.2%) 7 (15.9%) 7 (14.9%) NS 
Renal impairment 14 (10.1%) 5 (10.4%) 6 (13.6%) 3 (6.4%) NS 
Diabetes 26 (18.6%) 8 (18.2%) 9 (19.1%) 9 (19.1%) NS 
Hyperlipidaemia 69 (49.3%) 25 (55.6%) 17 (38.6%) 27 (60.0%) NS 
Ex or current smoker 56 (40.0%) 20 (45.5%) 13 (37.1%) 23 (52.3%) NS 
Median logistic EuroSCORE (IQR) 10.4 (11.8) 10.0 (13.0) 11.5 (10.5) 10.4 (12.2) NS 
 
IQR – interquartile range; MI – myocardial infarction; PCI – percutaneous coronary intervention; CVA – cerebrovascular accident 
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5.1.2 Angiographic data 
 
Over 60% of the cohort had ‘true’ bifurcation disease of the LMCA (medina 
1,1,1/0,1,1/1,0,1) (Table 42). The median SS was 32.0 (IQR 12.8) with almost half 
(47.1%) of patients falling within the high SS group (SS ≥33) (see figure 14). Over a 
third of patients, 53 (34.1%), had at least 2 other coronary vessels with a significant 
stenosis in addition to the diseased LMCA, where the RCA had a significant stenosis in 
over half of patients, 73 (52.1%). Chronic total occlusions (CTO) were present in 21 
(15.0%) patients, and involved the proximal to mid coronary artery segments in all but 
one patient. 
 
There were significant differences with respect to coronary disease burden for the 
three tertiles of residual SS. For patients with an rSS>17, none had a baseline of SS≤22, 
while half of all patients in the rSS≤8 and rSS <8-17 tertiles had a baseline SS ≤ 22.  Only 
10.4% of patients with a rSS≤8 had a SS≥33, consequently those patients within the 
rSS>17 tertile had significantly greater baseline SS. Almost three quarters of patients in 
the rSS≥17 group had ‘True’ LMCA bifurcation disease, while this was the case in less 
than half of the patients with rSS≤8. Over a quarter of patients in the rSS≥17 tertile had 
a CTO, while only one patient had a CTO in the rSS≤8 tertile. Close to half of patients in 
the rSS≤8 tertile had LMCA+1VD, while more than half of patients in the rSS≥17 group 
had at least 2 vessels disease in addition to the LMCA. 
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Figure 14: Synergy between percutaneous coronary intervention with TAXUS and Cardiac Surgery (SYNTAX) Score 
tertiles in 139 Octogenarians. Patients were divided into low (SYNTAX score ≤22), intermediate (SYNTAX score 
=23-32) and high (SYNTAX score ≥33) tertiles.
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Table 42: Baseline angiographic features for 139 octogenarians, for the all patients and residual SYNATX score tertiles, rSS≤8, 
rSS>8-17 and rSS≥17 
Variable All patients 
(n=139) 
rSS≤8 (n=48) rSS >8-17   (n= 
44) 
rSS >17 (n=47) p-value 
Median SS (IQR) 32.0 (12.8) 25.0 (11.8) 31.0 (8.0) 45.0 (14.5) <0.001 
Lower tertile ≤ 22 23 (16.4%) 19 (39.6%) 4 (9.1%) 0 (0%) <0.001 
Intermediate tertile 23-32 50 (35.7%) 24 (50.0%) 22 (50.0%) 4 (8.5%) <0.001 
High tertile ≥33 66 (47.1%) 5 (10.4%) 18 (40.9%) 43 (91.5%) <0.001 
LMCA bifurcation disease 109 (78.4%) 35 (72.9%) 35 (79.5%) 39 (83.0%) NS 
True LMCA Bifurcation disease * 84 (60.0%) 23 (47.9%) 26 (59.1%) 35 (74.5%) <0.05 
LMCA + 1 vessel 53 (37.8%) 22 (45.8%) 18 (40.9%) 13 (27.7%) <0.05 
LMCA + 2 vessels 34 (24.3%) 5 (10.4%) 13 (29.5%) 16 (34.0%) <0.05 
LMCA + 3 vessels 19 (13.6%) 3 (6.3%) 4 (9.1%) 12 (25.5%) <0.05 
Significant RCA disease 73 (52.1%) 15 (33.3%) 25 (56.8%) 33 (70.2%) <0.05 
Dominant RCA 132 (94.3%) 45 (95.7%) 41 (93.2%) 46 (97.9%) NS 
All CTO’s 21 (15.0%) 1 (2.1%) 8 (18.2%) 12 (25.5%) < 0.05 
Proximal to mid vessel CTO’s 20 (14.3%) 1 (2.1%) 8 (18.2%) 11 (23.4%) <0.05 
 
SS- SYNTAX score; IQR – Interquartile range; LMCA – left main coronary artery; RCA – right coronary artery; CTO – chronic total occlusion, *True 
left main bifurcation disease denotes (medina 1,1,1/0,1,1/1,0,1) 
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5.1.3 PCI procedural data 
 
Almost three quarters of procedures were performed via the femoral artery with the 
radial and femoral artery employed in only 3 cases. Larger sized catheters were 
favoured, the 7 French (Fr) or 8Fr sized catheters were used in over 80.0% of patients 
(Table 43). The IABP was employed in a small number of patients, in 6 patients it was 
inserted prior to the PCI while in 5 patients the need arose during the angioplasty to 
insert the IABP. Unfractionated heparin was used in over two thirds of patients, while 
Bivalarudin was used in the rest.  The additional use of intravenous IIb/IIIa-inhibitors 
was required in a quarter of patients. Rotational atherectomy was employed in a large 
proportion of patients, up to a fifth (27 cases) of patients. All rotational atherectomy 
was performed through a 7/8Fr catheter with all but 4 cases performed from the 
femoral access site. For LMCA bifurcation disease, a single stent strategy was 
undertaken in over half of the cases. While the median baseline SS was 32.0 (IQR 12.8) 
and the median residual rSS 13.0 (IQR 12.0), the median Delta SS was 20.0 (IQR 8.75). 
There was a significant positive correlation between the baseline SS and the rSS 
(Pearson’s correlation coefficient 0.86, p<0.001), see figure 15. 
There was no significant difference in the access site used for each of the three rSS 
tertiles as well as the preference for larger sized catheters in over 80.0% of patients. 
While the use of drug eluting stents (DES) was favoured in 4 out of 5 patients overall, 
only two thirds of patients in the highest rSS tertile, rSS≥17, received a DES. Compared 
with the rSS≥17 tertile, DES usage was significantly higher in the rSS≥8 and rSS >8-17 
tertiles, 91.7% and 86.4% respectively. Median stent lengths did not differ between 
the three rSS tertiles; however there was a small but insignificant difference in the 
median Delta SS across the rSS tertiles.   
While there was no significant relationship between access site and ‘true’ bifurcation 
disease X2 (2, N = 139) = 2.76, p =0.25; there was a significant relationship between 
‘true’ bifurcation disease and the use of at least 7Fr guide catheters, X2 (1, N = 139) = 
10.243, p =0.001. Furthermore, there is a significant relationship between the use of at 
least 7Fr guide catheters and the use of femoral access, X2 (2, N = 139) = 30.34, p 
<0.001). 
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Table 43: Percutaneous coronary intervention (PCI) procedural details for 139 octogenarians, for the all patients and residual 
SYNATX score tertiles, rSS≤8, rSS>8-17 and rSS≥17. 
Variable All patients 
(n=139) 
rSS≤8 (n=48) rSS >8-17   (n= 44) rSS >17 (n=47) p-value 
Femoral access 101 (72.1%) 35 (72.9%) 32 (72.7%) 34 (72.3%) NS 
Radial Access 35 (25.0%) 13 (27.1%) 11 (25.0%) 11 (23.4%) NS 
Radial and Femoral access 3 (2.1%) 0 (0%) 1 (2.3%) 2 (4.3%) NS 
6 Fr Catheter  25 (17.9%) 9 (18.8%) 7 (15.9%) 9 (19.1%) NS 
7 Fr Catheter 89 63.6%) 32 (66.7%) 28 (63.6%) 29 (61.7%) NS 
8 Fr Catheter 22 (15.7%) 7 (14.6%) 8 (18.2%) 7 (14.9%) NS 
IABP Pre – PCI 6 (4.3%) 0 (0%) 3 (6.8%) 3 (6.4%) NS 
IABP During PCI 5 (3.6%) 3 (6.4%) 1 (2.3%) 1 (2.1%) NS 
Unfractionated Heparin 92 (65.7%) 30 (62.5%) 28 (63.6%) 34 (72.3%) NS 
Bivalarudin 47 (33.6%) 17 (35.4%) 16 (36.4%) 14 (29.8) NS 
Abciximab 28 (20.0%) 9 (18.8%) 12 (27.3%) 7 (14.9%) NS 
Tirofiban 7 (5.0%) 1 (2.1%) 1 (2.3%) 5 (10.6%) NS 
Rotational atherectomy 27 (19.3%) 7 (14.6%) 9 (20.9%) 11 (23.4%) NS 
Single stent to LMCA bifurcation 79 (56.4%) 26 (54.2%) 23 (52.3%) 30 (63.8%) NS 
DES used 113 (80.7%) 44 (91.7%) 38 (86.4%) 31 (66.0%) <0.05 
Median total stent length (IQR), mm 35.5 (23.3) 38.5 (22.8) 34.0 (27.0) 36.0 (28.0) NS 
Median rSS (IQR) 13.0 (12.0) 5.0 (3.0) 13.0 (4.0) 24.0 (13.0) <0.001 
Median deltaSS (IQR) 20.0 (8.75) 20.0 (8.5) 20.0 (7.0) 17.5 (8.0) <0.001 
Fr – French size; PCI – percutaneous coronary intervention; IABP – intra-aortic balloon pump; LMCA – left main coronary artery; DES – drug 
eluting stent; rSS – residual SYNTAX score; IQR – interquartile range; deltas – delta SYNTAX score 
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Figure 15: Correlation between the baseline and residual SYNERGY between Percutaneous Coronary Intervention with Taxus and 
Cardiac surgery (SYNTAX) Score. The baseline score is presented on the x-axis and the residual SYNATAX score on the y-axis. The paired 
scores are presented for the 139 octogenarians with unprotected left main coronary artery (ULMCA) disease. Each point on the graph 
may represent more than 1 value. SS- baseline SYNTAX score; rSS – residual SYNTAX score 
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5.1.4 PCI procedural complications 
 
Procedural complications occurred in 9 (6.5%) patients, with 4 coronary perforations 
resulting in 2 cardiac tamponades, with cardiogenic shock in 1 of these patients (Table 
44). Cardiogenic shock occurred in 3 additional patients. Of the 27 patients who were 
treated with rotational atherectomy, 2(7.4%) suffered a coronary perforation. All 
coronary perforations occurred in patients treated for LMCA bifurcation disease, 
4(4.8%). Other procedural complications include 1 (0.7%) cerebrovascular accident 
(CVA) and 1 (0.7%) sidebranch occlusion. 
 
5.1.5 Arterial access complications 
 
Arterial access site complications occurred in 7 (5.0%), comprising 3 haemorrhages 
requiring blood transfusion and 1 which required surgical intervention (Table 45). All 
complications occurred in patients treated through the femoral artery and all occurred 
with catheters of at least 7Fr in size. Of the 27 patients treated with rotational 
atherectomy, 3(11.1%), suffered an access site complication. A chi-square test of 
independence was performed to examine the relation between all procedural and 
access site complications and rotational atherectomy. The relation between these 
variables was not significant, X2 (1, N = 139) = 0.001, p =0.97.  
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Table 44: Post-procedure complications for 139 octogenarians, for the all patients and residual SYNATX score tertiles, rSS≤8, 
rSS>8-17 and rSS≥17 
Complications All patients (n=139) rSS≤8 (n=48) rSS >8-17  (n= 44) rSS >17 (n=47) p-value 
Cardiac Tamponade 2 (1.4%) 2 (5.4%) 0 (0%) 0 (0%) NS 
Cardiogenic shock 4 (2.9%) 2 (5.4%) 1 (1.6%) 1 (2.6%) NS 
Coronary perforation 4 (2.9%) 3 (8.3.%) 0 (0%) 1 (2.7%) NS 
CVA – infarct 1 (0.7%) 0 (0%) 1 (1.6%) 0 (0%) NS 
Sidebranch occlusion 1 (0.7%) 0 (0%) 1 (1.6%) 0 (0%) NS 
SYNTAX -Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Score;  rSS – residual SYNTAX score, 
CVA – cerebrovascular accident 
 
Table 45: Arterial complications reported for 139 octogenarians, for the all patients and residual SYNATX score tertiles, rSS≤8, rSS>8-17 
and rSS≥17 
Arterial complication All patients 
(n=139) 
rSS≤8 (n=48) rSS >8-17 (n= 44) rSS >17 (n=47) p-value 
Retroperitoneal bleed 0 0 0 0 p=NS 
Surgical intervention 1 (0.7%) 0 0 1 (2.1%) p=NS 
Arterial dissection 1 (0.7%) 1 (2.1%) 0 0 p=NS 
Arterial occlusion 0 0 0 0 p=NS 
Arterial haemorrhage 3 (2.2%) 1 (2.1%) 1 (2.3%) 1 (2.1%) p=NS 
False aneurysm requiring thrombin injection 1 (0.7%) 1 (2.1%) 0 0 p=NS 
False aneurysm requiring compression 1 (0.7%) 1 (2.1%) 0 0 p=NS 
False aneurysm conservative management 0 0 0 0 p=NS 
 
NSTEMI: non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; rSS – residual SYNTAX score 
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5.2 Outcomes 
 
Over a median follow-up of 654 (IQR 1041) days, there were 43 (30.7%) deaths.  At 30 
days, the mortality rate was 5.0% and at one year it was 11.4%.  Table 46 shows a 
breakdown of all the MACCE events during the study follow-up. The MACCE rate for 
the overall follow-up was 38.1%, where death accounts for up to 81.1% of all MACCE. 
The MACCE rate at 30 days was 5.0%. Cardiac deaths accounted for over 85% of all 
MACCE at 1 month, 48.0% at 1 year and 35.8% for the entire follow-up period. The 
proportion of non-cardiac cause of death rose steadily from 14.3% at 1 month, to 25.0% 
at 1 year and 55.8% for the entire follow-up. At 1 year we report a repeat 
revascularisation rate of 2.9% and 5.8% over the entire follow-up period. No patients 
received repeat revascularisation with CABG, while further PCI was performed in the 
lower, middle and upper rSS tertiles in 3 (6.3%), 3 (4.5%) and 3 (6.4%) of patients 
respectively. Myocardial infarction occurred in 8.6% of patients for the entire follow-
up. Definite and probable ST rates are reported in this analysis. The early and late ST 
rates are 1.4% (2 patients) and 0.0% (0 patients) respectively, with a VLST rate of 0.7 % 
(1 case). 
5.2.1 Survival analysis 
 
Unadjusted survival was worse for patients with an rSS in the upper tertile (figure 16 
and 17). After adjusting for mode of presentation, co-morbidity (renal impairment, 
diabetes, previous cardiac surgery, previous myocardial infarction, previous PCI, 
peripheral vascular disease) and PCI strategy, the only variable independently 
associated with all cause death was SS [aHR 1.04, 95% CI 1.02-1.07, p=0.002]. 
Regression analyses were repeated after replacing SS with collinear variables including 
rSS, true left main stem coronary artery disease, significant right coronary artery 
disease and presence of a chronic total occlusion. After adjustment, rSS [aHR 1.03; 95% 
CI, 1.00-1.06; p=0.04] and true bifurcation LMCA disease [aHR 3.41; 95% CI, 1.31-8.83; 
p=0.01] were independently associated with all cause mortality, while ‘True’ LMCA 
bifurcation disease [aHR 2.78; 95% CI, 1.5-5.2; p=0.001] was independently associated 
with MACCE.  
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Table 46: MACCE  at 30 days, 1 year and overall follow-up reported for 139 octogenarians, for the all patients and residual SYNATX 
score tertiles, rSS≤8, rSS>8-17 and rSS≥17 
 0-30 days 1 year Overall follow-up 
All-cause death 7 (5.0%) 16 (11.5%) 43 (30.9%) 
Cardiac Death 6 (4.3%) 12 (8.6%) 19 (13.7%) 
MI 0 7 (5.0%) 12 (8.6%) 
Repeat revascularisation 0 4 (2.9%) 8 (5.8%) 
Stroke 0 0 3 (2.6%) 
Definite/Probable ST 2 (1.4%) 2 (1.4%) 3 (2.6%) 
MACCE 7 (5.0%) 25 (18.0%) 53 (38.1%) 
 
MACCE: major adverse cardiac and cerebrovascular events; MI: myocardial infarction; ST: stent thrombosis 
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Figure 16: Unadjusted Kaplan-Meier estimates of survival from all-cause death in 139 Octogenarians with rSS ≤ 8; rSS >8-17 and rSS≥17. 
 
Figure 17: Unadjusted Kaplan-Meier estimates of survival from all-cause death in 139 octogenarians with rSS 0-17 and rSS>17
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5.3 Summary 
5.3.1 Key results 
 
In this retrospective analysis of octogenarians treated with ULMCA PCI, we found that 
patients with incremental levels of residual coronary disease, as calculated from the 
residual Syntax score (rSS), were at greater risk of mortality over long-term follow-up. 
Each 10 unit increase in rSS was associated with a 3% increase in all-cause mortality. 
The thirty day and 1 year survival of patients within our cohort of octogenarians 
treated with ULMCA PCI is similar to other non-randomised studies of revascularisation 
amongst octogenarians despite significant comorbidity [152, 307]. Whilst one year 
survival amongst this aged population approached 90% and at about 2 years, was 77%, 
we found that, in addition, the Syntax score (SS) was significantly associated with poor 
long term outcomes. Furthermore, the presence of ‘True’ LMCA bifurcation disease 
was associated with a three-fold increase in risk of death after a median follow-up of 
645 (IQR 1041) days. 
 
5.3.2 Discussion 
 
Our study population had a similar prevalence of comorbidities and burden of 
coronary disease compared with other reported registries of octogenarians treated 
with ULMCA PCI [126, 141, 143, 144, 308]. Elderly patients are more likely to present 
with complex, multivessel coronary disease [304, 309, 310]. This increased burden of 
atheroma in the elderly, which includes distal LMCA disease and multivessel disease, is 
confirmed by other observational studies of LMCA disease revascularisation in 
octogenarians [39, 146, 307].  Using the SS to quantify the atheroma burden, we can 
report a higher median baseline SS than those reported in randomised trials [47, 61].  
 
In keeping with other observational studies, LMCA bifurcation disease was associated 
with poor outcomes [78]. Using the Medina classification of bifurcation disease, our 
study is the first to report this association with ‘True’ LMCA bifurcation disease 
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amongst octogenarians receiving PCI for LMCA disease. Despite a similar proportion of 
patients with LMCA bifurcation disease, our patients tended to have a provisional 
single stent when compared with younger study cohorts [31, 61]. It is not certain if the 
provisional single stent is inferior to the two stent strategies for treatment of the 
LMCA bifurcation disease [77, 113, 115]. Indeed, for the treatment of ‘True’ LMCA 
bifurcation disease, a provisional single stent would leave the large SB stenosis 
untreated. While poor outcomes from LMCA bifurcation revascularisation are driven 
by repeat revascularisation [115, 117], only 4.3% of our patients suffered repeat 
revascularisation. However, as LMCA bifurcation disease is associated with extensive 
coronary disease, repeat revascularisation was a major determinant of poor outcomes 
in these studies. 
 
We reported almost twice the burden of residual coronary disease compared with 
other randomised studies [155, 167]. In our study rSS and SS were strongly correlated: 
we observed greater residual coronary disease in patients with higher baseline SS. This 
finding differs from that reported in the SYNTAX trial [155], in which there was no 
correlation between rSS and SS. In keeping with the design of this trial, complete 
revascularisation was achieved in almost 60% of patients in SYNTAX [155], whereas 
complete revascularisation was achieved in only 4.3% of patients in our observational 
study. Accordingly, median delta SS did not differ across the rSS tertiles confirming a 
tendency for selective rather than complete revascularisation in our series and this 
explains the significant collinearity of the SS with other measures of coronary disease, 
such as the rSS and distal LMCA involvement. 
 
Selective revascularisation in the elderly has been reported in other studies [170, 206].  
Over two thirds of our patients presented with an ACS compared with only 50-55% in 
other registries of octogenarians with ULMCA PCI [143, 144, 308] , while this is similar 
to UK national revascularisation trends [311]. Elderly patients are less likely to have 
access to revascularisation compared with younger patients [206, 207]. Octogenarians 
are more likely to receive treatment for unstable syndromes than stable angina when 
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compared with younger patients [126, 130, 133, 146], indicating a possible preference 
to manage stable symptoms conservatively for this age group. While haemodynamic 
compromise has been implicated in poor outcomes from revascularisation of ACS in 
the elderly [131] we excluded patients presenting with cardiogenic shock. Less 
extensive revascularisation and increasing rSS following the treatment of ACS in 
octogenarians has been associated with poor outcomes [170]. Nevertheless, ACS on 
presentation was not associated with poor outcomes. 
 
The presence of a chronic total coronary occlusion is a major factor in failing to achieve 
complete revascularisation by PCI [312]. CTOs were more prevalent and tended to be 
left untreated in our patients when compared with a younger LMCA study cohort [61]. 
However, we were unable to assess whether CTO revascularisation was appropriately 
deferred due to lack of myocardial viability or ischaemia. 
 
Diabetic patients tend to have more extensive coronary disease, indeed this has been 
confirmed amongst older patients with diabetes [313-315]. As a consequence of this, 
diabetic patients are at increased risk of incomplete revascularisation [316]. While we 
report a similar incidence of diabetes as reported in other non-randomised studies 
amongst octogenarians undergoing revascularisation [130, 141, 307], diabetes was not 
independently associated with adverse long-term outcomes in our cohort. Diabetes is 
implicated in excess cardiovascular deaths amongst the elderly [317]. Thus older 
patients with diabetes suffer excess mortality compared with older patients without 
diabetes [318]. Evidence suggests that tight glycaemic control amongst patients with 
established cardiovascular disease does not prevent excess cardiovascular deaths, and 
may in fact be harmful [319]. It is rather the macrovascular sequelae rather than the 
diabetes per se which is associated with poor outcomes. So within a cohort with a 
significantly high burden of established coronary disease, such as ours, there is no 
excess risk associated with diabetes following revascularisation. 
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Octogenarians suffer more complex coronary disease than younger patients, including 
more bifurcation disease [320] and more calcified lesions [278-280, 321]. Calcified 
lesions are identified as a major factor leading to selective revascularisation [322], and 
are markers of poor prognosis following revascularisation [323]. Rotational 
atherectomy was required to treat the LMCA in almost a fifth of our patients, while it is 
used in less than half the proportion of younger patients with LMCA disease [32, 43].  
 
Octogenarians are more likely to suffer complications following PCI [1, 133], making 
clinicians less likely to consider complex revascularisation strategies [206]. The overall 
rate of complications amongst our cohort was 11.5 %; over half of these are related to 
coronary complications with the remaining related to access site complications. There 
are a number of factors potentially relating to this increased risk of complications. 
Compared with published data, we employed rotational atherectomy in nearly twice 
the proportion of octogenarians treated for all coronary artery lesions [141] and those 
treated for LMCA disease [39]. It is known that the elderly suffer an increased risk of 
procedural complications from standard PCI, including the use of rotational 
atherectomy, when compared with younger cohorts [133]. Due to the need for larger 
sized catheters, rotational atherectomy is often performed from the femoral route. All 
rotational atherectomy in our cohort was performed from the femoral access. Despite 
this, it should be noted that rotational atherectomy for LMCA disease  can be 
performed from radial access using catheters no larger than 6Fr, thus offering an 
alternative approach with similar success rates [277].  
 
Femoral artery access was favoured in close to three quarters of our patients, whereas 
in other reported studies of octogenarians the radial artery route was used in up to 
90.0% of patients [39]. While the transradial approach is favoured by patients and 
clinicians alike due to reduced discomfort and less complications, there is a greater risk 
of failure of the transradial approach in the elderly [324].  Due to age related 
progression of vascular disease including increased tortuosity of the subclavian artery, 
unfolding of the aorta, dilation of the aortic root, less compliant vasculature with 
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increased atherosclerosis and calcification, the femoral route may be preferred [325, 
326]. Evidence supports the use of the radial access in the context of STEMI, with 
fewer bleeding complications and improved survival compared with femoral access 
[250, 327, 328]. However, these trials include younger patients, fewer females and the 
LMCA was treated in only 1.0% of the population. There are significant benefits of 
radial access in the elderly [329, 330], however these data suffers from selection bias, 
where patients with greater clinical risk, such as cardiogenic shock, received femoral 
access [329]. Radial access is a viable option for LMCA PCI, there is only one 
observational study of access site use in octogenarians with LMCA disease, the findings 
suggest a 98.0% PCI success rate with fewer complications from the radial access [331].  
 
This study cohort had a large burden of peripheral vascular disease, similar to the 
levels reported in other observational studies of coronary revascularisation in the 
elderly [39, 126, 141]. The burden of peripheral vascular disease is significantly higher 
amongst the elderly revascularisation population compared with younger patients 
[126, 129, 133, 141, 142]. Indeed the prevalence of peripheral vascular disease in 
octogenarians is more than twice that of younger patients [332], and is strongly 
correlated with coronary artery disease [333]. While the presence of peripheral 
vascular disease indicates widespread macrovascular disease, it has implications for 
the management of coronary disease in the elderly due to and increased risk of access 
site complications [133]. 
 
Women have smaller calibre vessels [334], present later with coronary artery disease 
[335] and consequently have greater clinical risk due to comorbidity. We report a 
greater proportion of female patients than found in randomised studies of ULMCA 
revascularisation [1, 59-61, 141, 213]. Given the survival bias due to significantly 
greater life expectancy for females in the overall population [121], it is unsurprising 
that we report a greater proportion of female patients than amongst the younger 
populations of randomised studies of ULMCA revascularisation.  However, it is a similar 
prevalence to that reported in registries of revascularisation among the elderly, where 
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more women are represented [130, 131, 133, 141, 142, 303]. The combination of 
smaller coronary arteries and greater comorbidity also contributes to the increased 
risk of procedural complications [133]. 
 
In this cohort there seems to be a preference for the use of larger catheters for the 
treatment of ‘true’ left main bifurcation disease. While the treatment of ‘True’ LMCA 
bifurcation disease may necessitate the use of a two stent approach through a larger 
sized catheter, a provisional single stent technique could be performed through a 6Fr 
sheath [336]. Femoral access may be preferred when using larger sized catheter as 
there is a greater risk of radial artery spasm and greater long term occlusion rates. A 
single stent technique was favoured in up to three quarters of our patients with LMCA 
bifurcation disease, which is a significantly greater proportion of patients when 
compared with other studies reporting on LMCA bifurcation PCI in the elderly [39]. 
While in the Rodes-Cabau study they report taking a provisional single stent approach 
in over 80.0% of LMCA bifurcations, a sidebranch stent was required in over 90.0% of 
these patients. While we used at least 7Fr sized catheters in over four fifths of patients, 
there was a significant association between larger sized catheters using femoral access 
and ‘True’ left main bifurcation disease. So while the femoral route was preferred in 
our data set, and with IABP use in 7.9% of patients, it may be assumed that the radial 
route could have been considered in the over 90.0% of patients.  
 
Bearing in mind the greater burden of peripheral vascular disease in octogenarians, the 
greater use of radial access for LMCA PCI may reduce the risk of complications 
amongst octogenarians. Despite a higher incidence of radial and brachiocephalic trunk 
anatomical tortuosity compared to younger subjects, similar success rates for PCI with 
low procedural complication rates are found even among the elderly [337, 338]. 
However this will be limited by the need for larger sized catheters employed for LMCA 
bifurcation PCI, rotational atherectomy and a greater proportion of female patients 
with smaller calibre radial arteries.  
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Despite a significantly higher number of females in this older cohort compared with 
other studies due to survival bias, gender was not identified as an independent 
predictor of worse outcomes. There is a gender-based difference in clinical outcomes 
from revascularisation which is pronounced in younger populations, with worse 
outcomes for women [206]. This gender-based difference in outcomes disappears 
amongst the elderly [307, 339].  It is not clear why these differences disappear, 
however, our data supports the findings that older female patients are at no greater 
risk of worse outcomes than men. 
 
While death made up almost two thirds of all MACCE at 1 year and over 80.0% for the 
median follow-up, we report a repeat revascularisation rate of only 2.8% at 1 year and 
5.9% over the median follow-up. It is known that poor outcomes from LMCA PCI are 
predominantly driven by repeat revascularisations in all major randomised controlled 
trials [47, 59, 60]. When compared with other observational studies of DES 
revascularisation in octogenarians, our repeat revascularisation rate is similar or 
slightly higher [303, 340], including a registry of ULMCA PCI in octogenarians [39]. The 
failure to use DES in a fifth of our patients may be causally linked to the risk of repeat 
revascularisation [341].  Older patients are less likely to receive DES, yet they are still 
likely to benefit from a DES compared with BMS [342, 343].   
 
In this older cohort, with more baseline and residual coronary disease compared with 
the SYNTAX trial patients [155], we did not observe a difference in the risk of repeat 
revascularisation across the rSS groups. It should be noted that in our cohort all repeat 
revascularisation was performed in the context of subsequent acute coronary events 
rather than stable angina. The younger cohorts studied in the randomised trials seem 
to be at greater risk of repeat revascularisation [47, 59, 60].  This greater risk may in 
part be due to the difference in the pathology of the atheroma. Despite a greater 
burden of coronary disease in older age, the plaque morphology is more stable than in 
younger patients [321], and thus the older patient is less likely to re-present with 
further acute coronary events. In this way, while it is known that coronary 
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revascularisation offers greater gains in survival for the elderly than young [130], 
revascularisation also seems to offer a more robust form of treatment for the elderly. 
 
5.4.3 Limitations 
 
While there were 19 patients who may be considered low risk for CABG, a EuroSCORE 
of less than 5.0, we were unable to ascertain the reason for choosing PCI over CABG. 
One may therefore speculate that additional unmeasured confounders may account 
for this decision, such as frailty. Indeed frailty is linked with increased mortality 
following CABG [344, 345], and is a predictor of worse prognosis for patients with 
cardiovascular disease [346-349]. Other unmeasured confounders which should be 
considered include presentation with heart failure and dementia. While we have 
previously discussed the missing LV function, it is a major predictor of poor prognosis 
in the elderly [350, 351]. 
 
This observational study suffers from inherent limitations including referral and 
selection biases. More so amongst elderly patients, selection bias may play a huge 
impact on outcomes from observational studies of revascularisation [206]. The elderly 
patients who eventually have revascularisation represent those most likely to benefit 
from the procedure. While clinical judgement would no doubt result in a selection bias 
for patients included in this analysis, there is additional bias with regards to the 
decision to provide limited revascularisation in some patients. As this was a 
retrospective study we were unable to determine the revascularisation strategy on a 
per-patient level, and so can only speculate reasons for failure to achieve complete 
revascularisation in the majority of patients. However, elderly patients are at greater 
risk of selective revascularisation [171], which may account for over 15.0% of CTOs 
being left unrevascularised. While the rationale for this is not recorded, we also do not 
have the data describing the complexity of these lesions so can’t make reasonable 
speculation about these lesions. While the techniques for CTO revascularisation have 
improved, these lesions remain difficult to treat and with high associated risk.  
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Our data lack functional lesion assessment, while rSS is an anatomical assessment of 
untreated coronary disease and does not necessarily imply functionally incomplete 
revascularisation Clinicians are more inclined to demonstrate lesion ischaemia, using 
fractional flow reserve (FFR), to assess appropriate revascularisation in multivessel 
disease [352, 353]. Functional lesion classification could change the SS for up to a third 
of patients and thus lead to a change in management decisions, from CABG to PCI and 
vice versa [354]. This would result in a change in SS and rSS.  However, no study has 
demonstrated an advantage of functional complete revascularisation over anatomical 
complete revascularisation in multivessel disease [355].  Indeed, while we await the 
results of the SYNTAX II and FAME 3 studies which will assess the FFR guided 
revascularisation of multivessel disease, these studies will not include patients with left 
main disease [356, 357]. Similarly, as information on myocardial viability was 
unavailable we are unable to exclude the possibility that stenoses in vessels 
subtending non-viable myocardial segments may have been appropriately left 
untreated. 
In an ideal world we should study the benefits of revascularisation in the elderly in a 
randomised controlled trial. Yet there are limited opportunities for this as most RCT’s 
exclude long lived individuals. One other possibility is to introduce a control from the 
population using actuarially predicted survival as a control. One argument against this 
would be that it doesn’t offer any reliable comparator for patients treated for this 
medical condition. This cohort with LMCA disease, suffered an ACS in about two thirds 
and had significant comorbidity. So any comparison to a predicted survival would not 
give a true reflection of the benefit or harm of the treatment. Therefore we did not 
consider it a useful exercise. It should be imperative that the cardiology community 
studies this group of patients in an RCT in the near future.  
5.4.4 Conclusions 
 
While several recently published studies have attempted to identify a cohort of 
patients with LMCA disease who could appropriately be treated with PCI, the 
proportion of octogenarians included in these studies is low. Nevertheless, we have 
demonstrated that amongst a high surgical risk cohort of octogenarians with LMCA 
   186 
 
disease, survival can be similar if not better than other reported studies of 
revascularisation in octogenarians [307].  
 
Bearing in mind the sample size and reduced statistical power, we are therefore 
limited in our capability of detecting clinically relevant factors associated with poor 
outcomes in revascularisation of octogenarians with LMCA disease. Yet we identified a 
few factors associated with poor outcomes which seem to be congruent with 
published studies. 
Baseline coronary disease burden, measured by the SS, is associated with poor 
outcomes in octogenarians with ULMCA disease. While octogenarians suffer from 
selective revascularisation, octogenarians in our real-world series had levels of residual 
disease more than twice those reported in randomised studies of ULMCA 
revascularisation [155, 167]. Incremental residual coronary disease among 
octogenarians who received ULMCA PCI was significantly associated with mortality. 
Currently, we are unable accurately determine the benefit octogenarians would 
receive from more complete revascularisation, however further studies designed to 
quantify this are warranted. While we have applied an anatomical quantification of 
incomplete revascularisation, future studies should be designed with functional 
classification of completeness of revascularisation.  
 
Furthermore, while repeat revascularisation remains a significant factor limiting the 
use of PCI for LMCA disease, we have found a very low repeat revascularisation rate 
amongst elderly patients despite the large burden of residual disease; this is probably 
related to the more stable nature of plaque disease in the elderly [321]. The main 
discriminator of outcomes in our study is mortality, rather than repeat 
revascularisation as we find in the younger trial populations. Thus in future 
consideration needs to be given to assessing outcomes including measures of quality 
of life given the high burden of comorbidity in this population. 
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While this study demonstrates an association between residual coronary disease and 
poor prognosis, we cannot conclude that increasing degrees of completeness of 
revascularisation in octogenarians would result in an improved prognosis. There is 
obviously a selection bias which would indicate that clinicians applied clinical 
judgement in assessing individuals for further revascularisation as well as in making 
decisions regarding which lesions were treated. Thus a risk-benefit analysis, balancing 
the increased risks of revascularisation against prognostic gains and quality of life gains, 
should be analysed in future studies. Quality of life is an important outcome measure 
in the success of revascularisation in patients with limited life spans [358].  
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6. Result chapter: Longitudinal health related quality of life 
outcomes of management in a prospective cohort with left 
main coronary disease  
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6.1 Introduction 
Physician-oriented measures of revascularisation, including traditionally reported  
outcome measures, such as MACCE and mortality, describe the natural history of the 
pathophysiological processes as well as treatment effects [180]. These outcome 
measures inform treatment decisions of perceived prognostic benefit [69, 299]. Yet 
while mortality is an indisputable measure of prognosis; the composite outcome, 
MACCE, may not be as accurate. Due to binary censorship of MACCE, one may ascribe 
a minor MI as an equal outcome to a disabling stroke. In this way, for the treatment of 
LMCA disease, while PCI may be considered non-inferior to CABG on the basis of 
mortality [59, 60], for more extensive coronary disease, PCI is considered inferior to 
CABG on the basis of excess repeat revascularisations despite a higher risk of stroke 
with CABG [47, 215]. Only one recently published study found a greater risk of stroke 
with PCI compared to CABG for the treatment of LMCA disease [60]. These outcome 
measures inform the risk-benefit analysis for each patient when deciding between 
either PCI or CABG [47, 229]. In the case of high risk patients, where revascularisation 
may offer no prognostic benefit, these outcome measures do not inform us of 
symptomatic benefit to the patient. However, there also needs to be clarity on the 
benefit of revascularisation for symptom management as well. The problem of course 
is the significant placebo effect from undergoing a ‘procedural’ treatment. For less 
severe stable coronary disease, revascularisation with PCI offers no benefit over 
medical management for symptoms when employing a ‘sham’ procedure [359].  
 
Observational data though suggest increasing proportions of patients are having PCI 
rather than CABG for coronary disease [360]. These include patients with high surgical 
risk, such as the elderly [360, 361] and others with more complex coronary disease 
[362], such as LMCA disease [2]. Revascularisation decisions are therefore not solely 
based on improving traditional outcome measures, such as mortality, but rather 
symptomatic improvement. There is a need for data which inform this management 
approach.  
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Quality of life outcome measures may nuance the risk-benefit analysis. Quality of life 
outcomes amongst patients with coronary disease are predictive of poor outcomes, 
such as death [363, 364], repeat revascularisation [365, 366] and hospitalisation [367]. 
Poor quality of life outcomes within the first year predicts mortality up to a decade 
following revascularisation [368], even extending to the elderly [369-371]. Several 
studies have compared quality of life outcomes in patients treated with coronary 
revascularisation using PCI or CABG [372-385], however the results are conflicting with 
some reporting no difference [377, 383, 386, 387], while other studies report greater 
benefit from CABG [376, 380-385, 388]. These observational studies compare patients 
with varying degrees of severity of coronary disease and apart from the SYNTAX trial; 
none of these studies includes a large cohort of patients with LMCA disease.  
 
While it is known that CABG improves angina compared to medical management in 
patients with LMCA disease [389], there is only one study comparing QOL outcomes 
from CABG or PCI in patients with LMCA disease [390]. This study was an inadequate 
examination of QOL as it failed to assess the known longitudinal changes in QOL by 
using only a single time point measure. HRQOL changes have never been described 
over a 1 year longitudinal study in patients with left main coronary artery disease 
comparing patients who are medically managed to those undergoing revascularisation 
with CABG or PCI [377, 388, 390, 391]. 
 
6.2 Methods 
6.2.1. Study design 
 
This pilot study of comparative, prospective, longitudinal quality of life outcomes in 
patients with left main coronary disease, who are referred for consideration for 
revascularisation, was conducted at a single tertiary cardiac centre in the United 
Kingdom. The study narrative would describe the process of referral, the consideration 
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for revascularisation, the study recruitment process and the follow-up of QOL 
outcomes using repeated measure questionnaires over 1 year follow-up.  
 
6.2.2. Public consultation 
 
In accordance with the principles laid out in the UK Policy Framework for Health and 
Social Care Research [392] , we conducted a public consultation of the research project. 
It is recommended that patients, service users and the public be involved, where 
appropriate, in the design, management and conduct of research. Patient and public 
involvement in decision-making is regarded as a key feature of the provision and 
development of good quality health care [393]. The General Medical Council requires 
doctors to “work in partnership with patients, sharing with them the information they 
will need to make decisions about their care” [394]. A Patient and Public consultation 
was held with the West Yorkshire Cardiovascular Network Patient and Public group on 
the 6th September 2013. This consultation process informed the study design, 
implementation and the recording of outcome measures. 
 
6.2.3. Patient recruitment  
 
All patients referred to the Leeds General Infirmary (LGI) for consideration for LMCA 
revascularisation would be approached for consent to the prospective study. Patients 
would be identified after:  
(i) review at the weekly multi-disciplinary team (MDT) coronary 
revascularisation meeting held on Wednesdays, or 
(ii) outpatient referral to a named interventionalist/surgeon, or  
(iii) emergency revascularisation for LMCA disease.  
It is suggested by the European Society of Cardiology (ESC) that all patients considered 
for revascularisation of complex coronary disease, including LMCA disease, be 
discussed by the MDT or ‘heart team’ [299]. Guidelines suggest the MDT comprise 
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non-interventionalist cardiologists, interventional cardiologists and cardiothoracic 
surgeons [395]. For those patients discussed at the LGI weekly MDT, they were 
referred in the following ways: 
1) Elective patients referred from the district general hospitals were discussed at 
their local MDT meeting and then referred to a named surgeon/coronary 
interventionalist at the Leeds General Infirmary.  
2) Urgent admissions to the Leeds General Infirmary were discussed at the multi-
disciplinary team meeting. 
 
Treatment decisions were often made in the MDT meeting but for the purposes of 
recruitment to the study, all angiograms were first reviewed by a senior coronary 
interventionalist to confirm LMCA disease; patients were then approached by a 
member of the research team for informed consent. Elective patients referred to the 
LGI MDT were approached for consent at the time of admission for revascularisation to 
the LGI, while in-patients were approached for consent soon after MDT decisions of 
care.  
 
For patients referred to a named interventionalist/surgeon, correspondence was sent 
to either the LGI LCMA revascularisation clinic or to the individual 
interventionalist/surgeon’s clinic from a referring cardiologist. The treating 
surgeon/cardiologist would inform the research team of patients they felt were 
appropriate for inclusion in the study. Informed consent was obtained from patients 
admitted at the time of their procedure, in practical terms it was accepted this could 
occur about 1 week either side of the procedure. In the case of medically managed 
patients consent was obtained soon after the management decision was made either 
on the ward or in the clinic.  
Patients admitted as an emergency often had treatment in their best interest, but 
where possible discussions between the interventional cardiologist and on-call surgeon 
were documented. These patients were approached for consent soon after their 
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procedure, usually the following day once they have been identified from angiographic 
review.  
Recruitment of the prospective quality of life cohort began in March 2013, where the 
first 103 patients were included in this pilot study. Documents approved for the 
recruitment and collection of data include the Patient information leaflet (PIS) 
(appendix 1), consent form (appendix 2) and letter to the GP.  
Inclusion and exclusion criteria 
All patients with significant LMCA disease were invited to participate in the study, 
where significance was defined as a greater than 50.0% diameter angiographic stenosis 
of the LMCA. All patients presenting with ACS where the significant LMCA lesion was 
either the culprit or bystander lesion were included. Further diagnostic tests, including 
IVUS/OCT/pressure wire study of the LMCA were left to the discretion of the treating 
clinician. Patients managed with revascularisation, including PCI or CABG, as well as 
those for optimal medical treatment only, were invited. The only exclusion included 
patients with a lifespan of less than 90 days due to a significant life-threatening co-
morbidity. 
 
6.2.4. Follow-up 
 
Prospective patients had a planned telephone or clinic follow-up conducted at 6 
months post-procedure and then yearly. HRQOL questionnaires were completed by 
patients at the following time points to allow for longitudinal analysis: 
• Within 1 week of the procedure (either PCI or CABG) or at the time of consent for 
medically managed patients: MacNew [66] and Brief illness perception [70] 
questionnaires were administered.  
• 1 Month post-procedure: MacNew and Brief illness perception were posted. 
• 6 month post-procedure/recruitment: MacNew and Brief Illness perception were 
posted. 
• 1 year post-procedure/recruitment: MacNew and Brief Illness perception were 
posted. 
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The HRQOL measures include the combined questionnaires for use at 1 week prior, 1, 
6 and 12 months post-procedure, a sample questionnaire can be found in appendix 3.  
The baseline questionnaire was issued to assess the HRQOL prior to treatment. 
However, when considering the event of patients presenting as an emergency, it was 
agreed by all investigators that the questionnaire would remain valid if administered 
within the first 1 week of the revascularisation procedure. It was felt that patients 
could still reflect on their premorbid state.  
 
 
6.2.5. Questionnaires 
 
The MacNew questionnaire 
The MacNew questionnaire evaluates how emotional, physical and social functioning is 
affected by coronary disease and is therefore applicable to this research [196, 396]. 
Various studies have confirmed the validity, reliability and reproducibility of the 
MacNew questionnaire [397-399]. The questionnaire consists of 27 questions using 
multiple choice answers along a seven-point Likert-type response scale, where only 
one answer is allowed. The mean global score is a sum of all the scores divided by the 
number of questions.  A mean subscale score for the three domains (social, physical 
and emotional) is similarly a sum of the scores divided by the number of questions 
aggregated to assess a particular domain [195]. 
The MacNew compares favourably to the other quality of life questionnaires 
commonly used to assess outcomes in coronary disease [379, 400, 401]. Questionnaire 
completion rates are higher than comparative questionnaires and the aggregated 
score is a valid and repeatable measure of quality of life [196], while its specificity for 
ischaemic heart disease has been confirmed [402].The MacNew mean global score is 
predictive of measurable clinical end-points: a relatively low mean score it is predictive 
of mortality in patients with coronary artery disease undergoing revascularisation 
[363]; while a comparatively high mean global score is associated with a decreased risk 
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of rehospitalisation over long term follow-up amongst patients following an MI [403]. 
Despite this, longitudinal studies in patients with left main coronary disease are limited.  
 
Brief illness perception 
Awareness of patients beliefs about an illness allows us to interpret self-reported 
quality of life outcomes as well as giving us an understanding of their behaviours [404]. 
Patients form cognitive and emotional representations of the illness in response to 
signs and symptoms leading to a change in coping behaviours. These beliefs/ideas 
about an illness are formed around five components which help them interpret their 
experiences and allow them to develop coping mechanisms [405]. They form ideas 
about the nature or identity (the label a patient uses to describe the illness or 
symptoms), time-line (‘how long will my illness last’), consequences (‘how does this 
impact on my life’), cause (what are the causal factors), and control/cure (feasibility of 
control or cure of the illness). Additional domains are measured by the BIP 
questionnaire including the emotional representations of the illness and illness 
coherence, and control/cure is separately assessed as treatment control and personal 
control [406].  
The Brief Illness Perception (BIP) questionnaire assesses these components on a Likert 
scale where an increase in the score over time represents an increase in the domains 
measured [197]. It uses a single item scale, in the form of a question, to assess 
perceptions on a continuous linear scale rated 0-to-10. It assesses illness 
representations in the following domains: 
• Cognitive illness representations: consequences (Question 1); timeline (Question 2), 
personal control (Question 3), treatment control (Question 4), and identity 
(Question 5).  
• Emotional representations: concern (Question 6) and emotions (Question 8). 
• Illness coherence/comprehensibility (Question 7). 
• Causal attribution: This open-ended question asks the patient to list the three most 
important causal factors in their illness (Question 9).  The unique patient responses 
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should be grouped into categories specific to the causality of coronary artery 
disease; e.g. hereditary, lifestyle, stress, comorbidity. 
 
The BIP scale been shown to be predictive of poor outcomes, return to work, in 
patients following an MI [407]. Patients' beliefs that an MI will have long term negative 
impact can predict prolonged sick leave and greater levels of disability [408, 409]. 
Functional capacity in relation to return to work has been linked to causal attributions 
[410], the effect of which can be measured many years after the event [411]. Causal 
attributions contribute to changes in lifestyle behaviour after an MI [412], so effective 
interventions have been developed to promote positive lifestyle changes. Those 
patients with the strongest ideas concerning consequences, high scores for personal 
control and who attribute causation to lifestyle are more likely to attend rehabilitation 
programmes [413]. 
BIP interventions have been developed to influence these patterns of cognitive and 
emotional attributions following an MI and have been shown to improve angina and 
result in less time off work [407, 414]. Longitudinal studies are required to examine the 
change of illness perception following revascularisation procedures, none of which 
have been performed to date in a cohort of patients with left main coronary disease.  
6.2.6. Ethics 
Ethics approval was sought for the prospective study of patients treated with Left Main 
Coronary Artery revascularisation, the application was made in November 2012 and 
the study received approval in December 2012 (see appendix 5). An amendment to the 
application to allow the collection of quality of life measures using questionnaires was 
granted in December 2012.  The application included provision for the study of 
prospective patients with quality of life questionnaires and for long term telephone or 
clinic follow-up for a period of ten years. Data would be held for 10 years. Prospective 
recruitment commenced in March 2013 and in April 2013 the first patient was 
recruited with HRQOL measures.  
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6.2.7. Data handling 
Data storage 
A bespoke database was designed with the consultation of all stakeholders. The 
database platform was then created on the Google™ Structured Query Language (SQL) 
platform by Mr R. Gillott, with constant clinical input from all members of the research 
team. The database is hosted on the NHS secure N3 network which allows multicentre 
recruitment and data input over all IT platforms. Security includes password protected 
accounts, data encryption and pseudonymised patient data using sequentially 
allocated patient identifiers (PatID’s). The database platform was available in a 
rudimentary form by December 2012 with further ongoing modifications continuing 
based on research requirements. 
Weekly research committee meetings, chaired by the Chief Investigator Prof 
Sivananthan, were held to discuss the design of the database and ongoing data entry. 
Our aim was to integrate automated EuroSCORE, SYNTAX score, eGFR/BMI calculators 
into the design. The platform could be used in the cathlab for the direct input of data 
by cathlab staff. 
The database set out to include a robust drug history including use of anti-anginals at 
the time of the procedure and through the entire follow-up.  
Database management is administered through a central management structure 
including the Chief investigator and database manager, Mr. Richard Gillott. 
Applications can be made to the research committee for research purposes. Individual 
password protected accounts are assigned to those involved in recruitment and data 
entry. 
 
Data collection 
Baseline clinical and demographic data were collected from medical case notes and 
referral correspondence. Procedural details were collected from the bespoke in-house 
procedural database, Cardiobase™. Where additional patient data were required GP 
summaries were collected including complete drug histories at baseline and at 1 year 
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follow-up. Specifically, baseline, prior to revascularisation, and 1 year medication lists 
were assessed to determine the change anti-anginals over the course of follow-up. A 
change in medication was noted as increased or reduced dose of anti-anginals 
including beta-blockers, calcium channel blockers, Ivabradine or Ranolazine.  All data 
was entered prospectively at the time of the procedure, or at the time of consent. The 
data was regularly audited to ensure data completeness of the minimum dataset BCIS 
data fields. All cause mortality was tracked through linkage to the Office of National 
Statistics (ONS) using the NHS number.   
Data completion was reviewed on a regular basis, but remained an issue due to delays 
in the database completion. While the database existed in a rudimentary form from 
December 2012, data entry was encouraged early on despite incomplete data fields. 
Many of these unfilled fields were then revisited at a later date during a separate data 
review. 
 
6.2.8. Statistical methods 
 
Statistical analysis was performed with IBM SPSS statistics version 20 (IBM Corporation, 
NY, USA). Baseline characteristics were described using numbers and percentages for 
categorical data and means and standard deviations (SD) or medians and interquartile 
ranges (IQR) for normal and non-normally distributed continuous variables. Categorical 
data were compared using a Pearson Chi-squared test or the ANOVA for more than 2 
groups comparisons. Continuous variables were compared using one way ANOVA for 
normally distributed variables and the Kruskal-Wallis test for non-normally distributed 
data. 
 
Longitudinal analyses are preferred for the analysis of changes over time [415]. 
Repeated measures analysis of variance (ANOVA) general linear model was applied to 
quality of life measures over the 4 time points to detect significant changes, this has 
the advantage over multiple T-tests as this could lead to type 1 error. However, for 
patients with only 2 time point measures present, due to missed time point sampling, 
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a paired T-test was applied to these 2 time points over the entire study cohort. An 
analysis thereof is presented separately. Individual predictors of health related quality 
of life at 1 year were determined by single variable linear regression analysis of 
variables related to presentation, comorbidity and treatment modality. A significance 
level, p value <0.1 was accepted and these variables were entered into a multivariate 
general linear regression model with stepwise removal of variables.  
 
Multilevel modelling using linear mixed models were constructed in SPSS (SPSS 22.0; 
SPSS, Inc; Chicago). Mixed models analysis includes both random, the general 
variability within patients, and fixed effects, treatment or management used, in the 
analysis. These are analysed in a hierarchical way, which allow estimates for the means 
between upper levels, or treatment groups, with correlated measurements amongst 
the lower levels for each upper level group. We will use linear growth curves to assess 
variances, where the lowest levels of observation are the repeated measures and the 
predictor variable will be time [377, 416].Growth curves have the advantages over 
repeated measures ANOVA where it allows the inclusion of all cases despite a single 
missing measure by using maximum likelihood. Where we have unequal spacing of 
QOL measures we are able to use time as a predictor variable.  Other predictor 
variables were identified based on their possible effect on HRQOL, this was through 
the use of a directed acyclic graph. We identified predictor variables from a literature 
review of studies of QOL in revascularisation including: demographic data (gender, 
age)[417-419] socioeconomic data (indices of multiple deprivation score)[379, 417, 
420], presentation type (STEMI, NSTEMI, stable angina), comorbidity (renal 
dysfunction, diabetes, previous cardiac surgery or PCI, LV impairment). The predictor 
variables were added in a sequential way to determine the final growth model. 
 
Bivariate correlation was performed using the Pearson Product Moment Correlation 
(PPMC) to establish possible causal links between two continuous variables. A high 
correlation was defined as a R2 value between 0.5 to 1.0 or -0.5 to 1.0; a medium 
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correlation was defined as a R2 value between 0.3-.05 or -0.3 to 0.5, while a low 
correlation was defined as a R2 value between 0.1 to 0.3 or -0.1 to -0.3. 
Sample size calculation 
In order to compare the MacNEW global score means of the three separate treatment 
groups using repeated measures analysis, the number required in each group is given 
by the equation:  
𝑛 = ƒ(∝, 𝛽) ∙
2𝛾
𝛿
 
Where:  
∝ is the significance level ( using a two sided test) – i.e the cut-off for considering the 
result as statistically significant. 
1-β is the power of the test 
ƒ(∝,β) is the value calculated from α and β – given in the table below 
𝛿 is the smallest difference in means that one would regard as being important to be able 
to detect, based on previous studies a difference on 0.5 in the global mean score at 1 
year was correlated with poor long term outcomes [363]. 
𝛾 is the standard deviation of the global mean score, this is estimated from previous 
studies to be ±1.0 [363] 
ƒ(∝,β) for the most commonly used values for ∝ and β: 
 
∝ 
β 
0.05 0.1 0.2 0.5 
0.05 13.0 10.5 7.9 3.8 
0.01 17.8 14.9 11.7 6.6 
 
An online calculator was used to determine the sample size for the study population 
given probability of type 1 error (a) of 0.05, power (1-β) of 0.1, difference between the 
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means of 0.5 and the expected background standard deviation of 1.0 (derived from 
previous studies) [421]. The sample size required per group is given as 77. 
6.3. Funding 
Ongoing funding for the research fellow salary was provided by a local research fund 
for 12 months and further funding continued for 6 months through the support 
through the LTHT. Additional funds for the licensing and printing of quality of life 
questionnaires was provided for by the School of Healthcare, University of Leeds, 
under the administration of Professor Felicity Astin.  The study was adopted onto the 
NIHR CRN portfolio and a research nurse, employed by the NIHR, provided support for 
the consenting of patients. Furthermore, a data clerk and the database manager were 
provided similarly through the NIHR CRN portfolio. 
6.4. Results 
Recruitment to the prospective left main registry commenced in March 2013, while 
the first patient recruited for the HRQOL study was recruited in April 2013. A total of 
103 patients completed 1 year follow-up in May 2015, ongoing recruitment continues. 
This analysis included the first 103 patients who completed one year follow up, 
recruitment continues, and is for review in this thesis alone. It provides pilot data to 
identify possible issues with recruitment thus allowing a feedback loop to improve 
recruitment and follow-up. 
Baseline characteristics 
This cohort of patients represents a heterogeneous group including patients 
considered for medical management, left main coronary artery (LMCA) percutaneous 
coronary intervention (PCI) and CABG. While the overall cohort of patients had a 
median age of 69.0 (IQR 14.0), the patients treated with LMCA PCI were significantly 
older than patients treated with CABG and those medically managed (table 47).  It 
should be noted that of the patients treated for STEMI, the left main coronary artery 
was not the culprit vessel for these patients. The PCI group had the largest proportion 
of female patients, a third, compared with the medically manged, 15.0%, and CABG 
groups, 23.3%. Significantly more patients with STEMI were treated with CABG as 
compared to the PCI cohort. 
   202 
 
 
   203 
 
Table 47: Baseline characteristics 
Baseline characteristics Overall cohort Medically managed 
(n=20) 
PCI (n=35) CABG (n=48) p-value 
Median Age(IQR), years 69.0 (14.0) 69.5 (22.0) 76.0 (20.0) 66.0 (9.0) <0.001 
Female Gender 24 (23.3%) 3 (15.0%) 13 (37.1%) 8 (16.7%) NS 
NSTEMI 51 (49.5%) 8 (40.0%) 18 (51.4%) 25 (52.1%) NS 
STEMI 18 (17.5%) 7 (35.0%) 2 (5.7%) 9 (18.8%) <0.05 
Stable Angina 34 (33.0%) 5 (25.0%) 15 (42.9%) 14 (29.2%) NS 
Renal Impairment 8 (7.8%) 1 (5.0%) 4 (11.4%) 3 (6.3%) NS 
Diabetes 28 (27.1%) 8 (40.0%) 8 (22.9%) 12 (25.0%) NS 
Peripheral vascular disease 11 (10.7%) 4 (20.0%) 3 (8.6%) 4 (8.3%) NS 
Previous CVA 8 (7.8%) 2 (10.0%) 3 (8.6%) 3 (6.3%) NS 
Hypercholesterolaemia 54 (52.4%) 11 (55.0%) 11 (31.4%) 32 (66.7%) NS 
Previous MI  22 (21.6%) 8 (40.0%) 7 (20.0%) 7 (14.6%) <0.05 
Previous PCI 18 (17.5%) 4 (20.0%) 7 (20.6%) 7 (14.6%) NS 
Previous Cardiac surgery 8 (7.8%) 3 (15.0%) 4 (11.4%) 1 (2.1%) NS 
Protected 8 (7.8%) 3 (15.0%) 4 (11.4%) 1 (2.1%) NS 
Chronic lung disease 12 (11.7%) 3 (15.0%) 3 (8.6%) 6 (12.5%) NS 
Ex or current smoker 54 (52.4%) 9 (45%) 18 (51.4%) 27 (56.3%) NS 
Pulmonary hypertension  6 (5.8%) 1 (5.6%) 3 (11.1%) 3 (6.3%) NS 
Poor mobility 6 (5.8%) 2 (10.0%) 2 (5.7%) 2 (4.3%) NS 
Median(IQR) SYNTAX score     NS 
Cardiogenic shock 1 (1%) 0 1 (2.9%)  NS 
CABG – coronary artery bypass surgery; PCI- percutaneous coronary intervention; IQR – interquartile range; NSTEMI – non-ST elevation myocardial 
infarction; STEMI – ST elevation myocardial infarction; CVA – cerebrovascular accident; MI – myocardial infarction; SYNTAX - Synergy Between 
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery 
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Surgical procedure details 
CABG procedural data reflected current standard accepted practice, with over 80% of 
patients treated with a LIMA graft (table 48). Over 80% of patients required 
revascularisation of at least one other vessel and almost two thirds, 64.5%, required 
multivessel revascularisation with at least two vein grafts. Only two patients were 
treated with off-pump bypass and only one required circulatory support with an intra-
aortic balloon pump during the operation. 
PCI procedure details 
Almost half of all patients treated had distal LMCA disease, while over a third had 
treatment of the ostium and body (table 49). Up to 20.0% of patients had rotational 
atherectomy during the procedure and almost half, 42.8%, had some form of 
intravascular imaging to aide the procedure. The femoral access route was favoured 
and larger sized catheters, 7Fr, in over 45.0%. 
Anti-anginal medication 
Full medication history was documented for 91 patients, and of these, the vast 
majority (48), reported no change in anti-anginal dose over the course of 1 year. 
However, 30 patients had an increase in anti-anginals while only 13 patients were 
taking fewer anti-anginals at the end of the 1 year follow-up. No patient within the 
medically managed group had a reduction in anti-anginals, while 10 patients had an 
increase in the anti-anginals over the course of follow-up.  There was no significant 
difference between the treatment groups when considering a dose increase or no 
change vs reduced dose. 
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Table 48:CABG procedural details (n= 48) 
 Numbers (%) Missing data 
Number (%) 
LIMA 40 (83.3%) 6 (12.5%) 
RIMA 1 (2.1%) 6 (12.5%) 
Three Vein Grafts 9 (18.8%) 6 (12.5%) 
Two Vein Grafts 13 (27.1%) 6 (12.5%) 
One vein Graft 18 (37.5%) 6 (12.5%) 
Unrevascularised vessels –surgical report 5 (10.4%) 9 (18.8%) 
AoV surgery (None=0/Tissue=1/Mechanical =2) 1 (2.1%) 7 (14.6%) 
MV Surgery (None=0/Tissue=1/Mechanical =2) 0 (0%) 7 (14.6%) 
Off-pump 2 (4.2%) 6 (12.5%) 
Cardioplegia (Cold, Antegrade, Intermittent) 32 (66.7%) 6 (12.5%) 
IABP used 1 (2.1%) 6 (12.5%) 
Inotropes 3 (6.3%) 9 (18.8%) 
Pacing 3 (6.3%) 6 (12.5%) 
Bypass time (minutes) 93.0 [IQR 44.0] 11 (22.9%) 
Cross clamp time (minutes) 49.0 [IQR 35.5] 11 (22.9%) 
BMI 27.5 [IQR 7.6] 9 (18.8%) 
Vasoconstrictors 0 (0%) 9 (18.8%) 
Complications 2 (4.2%) 6 (12.5%) 
CABG – coronary artery bypass surgery; LIMA – left internal mammary artery; RIMA – right internal 
mammary artery; IABP – intra-aortic balloon pump; BMI – body mass index 
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Table 49: Percutaneous coronary intervention (PCI) procedural details (n=35) 
 Number (%) Missing (%) 
Femoral access 14 (40.0%)  
Radial Access 13 (37.1%)  
Radial and Femoral access 4 (11.4%)  
6 Fr Sheath 15 (42.8%)  
7 Fr Sheath 16 (45.7%)  
Heparin use 14 (40.0%) 4 (11.4%) 
Bivalarudin only 16 (45.7%) 4 (11.4%) 
Rotational atherectomy 7 (20.0%) 4 (11.4%) 
Intravascular ultrasound 13 (37.1%) 4 (11.4%) 
Optical coherence tomography 2 (5.7%) 4 (11.4%) 
LMCA ostium/body treated 12 (34.2%) 5 (14.3%) 
Distal LMCA treated 17 (48.6%) 5 (14.3%) 
DES used 30 (85.7%) 4 (11.4%) 
BMS used 1 (2.9%) 4 (11.4%) 
Fr – French size; PCI – percutaneous coronary intervention; LMCA – left main coronary artery; DES – drug eluting stent; IQR – interquartile 
range; DES – drug eluting stent; BMS – bare metal stent 
 
Table 50: Completed Questionnaires 
 Baseline 1 month 6 months 1 year 
Number 
(%) 
Missing 
(%) 
Deaths (%) Number 
(%) 
Missing 
(%) 
Deaths (%) Number 
(%) 
Missing 
(%) 
Deaths (%) Number 
(%) 
Missing 
(%) 
Deaths (%) 
Medical 
Management 
17 (85.0%) 3 (15.0%) 1 (5.0%) 13 (65.0%) 7 (35.0%) 3 (15.0%) 10 (50.0%) 10 (50.0%) 3 (15.0%) 9 (45.0%) 11 (55.0%) 3 (15.0%) 
PCI 30 (85.7%) 5 (14.3%) 1 (2.9%) 25 (71.4%) 10 (28.6%) 1 (2.9%) 23 (65.7%) 12 (34.3%) 1 (2.9%) 21 (60.0%) 14 (40.0%) 2 (5.7%) 
CABG 41 (85.4%) 7 (14.6%) 0 38 (79.2%) 10 (20.8%) 0 40 (83.3%) 8 (16.7%) 1 (2.0%) 37 (77.1%) 11 (22.9%) 1 (2.0%) 
Total 88 (85.4%) 15 (14.6%) 2 (1.9%) 76 (73.8%) 27 (26.2%) 4 (3.9%) 73 (70.9%) 30 (29.1%) 5 (4.9%) 67 (65.0%) 36 (35.0%) 6 (5.8%) 
CABG – coronary artery bypass surgery; PCI- percutaneous coronary intervention; 
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Patient and public consultation 
Following the consultation process with the West Yorkshire Cardiovascular Network 
Patient and Public group consultation process in September 2013, we received a letter 
with the following: 
- The group felt that ‘quality of life is the single most important indicator’ for patients 
who survive the initial procedure 
- Their consensus opinion was that the components of MACCE should not be 
considered as equal. 
- They also felt that stroke should be weighted more heavily than the risk of MI or 
repeat revascularisation, however 
-The severity of each MACCE event should be measured individually, that is, for an MI 
which results in the need for CABG should carry more weight than a simple TIA/Stroke 
from which a patient makes a full recovery. 
HRQOL outcomes 
Completed questionnaires were included in the analysis; completion rates for the 
overall study population were over two thirds at each time point (table 50). Close to 
85.0% of patients completed questionnaires at pre-intervention/baseline with equal 
rates of completion for each category of management. There was a significant and 
continued fall in completion rates down to two thirds at 1 year follow-up. The greatest 
fall in questionnaire completion rates occurred amongst the medically managed group 
with less than half completing 1 year questionnaires. Amongst 17 medically managed 
patients who completed the baseline questionnaire, there were 4 deaths within the 
first year of the follow-up. The PCI group too saw a fall in questionnaire completion 
rates down to 60.0% at 1 year. Amongst the 30 patients in the PCI group who 
completed the baseline questionnaire, there was only 1 death within the first year of 
follow-up. Patients who underwent CABG had the smallest fall in completion rates 
down to 77.1% at 1 year, with only 1 death amongst these patients over the course of 
the first year of follow-up.   
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While we did not record the patient’s reason for not completing the initial 
questionnaire for the study, no patients refused on the basis of language difficulty. All 
patients were given baseline questionnaires either prior to treatment or within 1 week 
of receiving treatment. In the case of medically managed patients, they were given the 
baseline questionnaires at the time of assessment in the clinic, only 15.0% of all 
patients failed to complete the baseline questionnaires. Of the patients who had 
completed the initial baseline questionnaire, we compared those who completed the 1 
year questionnaire to those who did not (table 51).  Patients presenting with STEMI 
were more likely to fail to complete all their questionnaires. While patients treated by 
CABG were more likely to complete their questionnaires over 1 year follow-up. 
Medically managed patients as well as those with diabetes were more likely to fail to 
complete all questionnaires. There was no difference in age or indices of multiple 
deprivation scores for patients who did and did not complete the questionnaires. 
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Table 51:Comparison of patients who failed to completed the 1 year questionnaire 
 Missing questionnaire Completed questionnaire p-value 
Age 69.0 (10.0) 68.0 (12.0) NS 
Male gender 21 (75.0%) 49 (81.7%) NS 
Median Indices of multiple deprivation scores 27.0 (36.1) 12.0(20.0) NS 
CABG 8 (28.6%) 33 (55.0%) p<0.05 
Medically managed 9 (32.1%) 8 (13.3%) p<0.05 
PCI 11 (39.3%) 19 (31.7%) NS 
Previous CABG 3 (10.7%) 4 (6.7%) NS 
Stable 5 (17.9%) 23 (38.3%) NS 
STEMI 9 (32.1%) 7 (11.7%) p<0.05 
NSTEMI 14 (50.0%) 30 (50.0%) NS 
Chronic lung disease 2 (7.1%) 7 (11.7%) NS 
CVA 3 (10.7%) 4 (6.7%) NS 
Diabetes 11 (39.3%) 11 (18.3%) p<0.05 
Chronic kidney disease 1 (3.6%) 6 (10.0%) NS 
Recent MI 14 (50.0%) 27 (45.0%) NS 
Previous MI 9 (32.1%) 11 (18.6%) NS 
Previous PCI 5 (17.9%) 10 (16.7%) NS 
Ex or current smoker 16 (59.3%) 30 (50.8%) NS 
CABG – coronary artery bypass grafting, PCI – percutaneous coronary intervention, CVA – cerebrovascular accident,, MI – myocardial infarction 
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MacNEW 
Global scores 
Mean (SD) MacNew global scores were calculated for each group of patients at 
baseline, 1 month, 6 months and 1 year. A one-way repeated measures analysis of 
variance (ANOVA) of the change in quality of life was calculated for a change in global 
MacNEW scores for the three groups (table 52).  
The mean longitudinal MacNEW global score for completed questionnaires in the 
overall population show a trend to increase over time (figure 18). The paired sample T-
test for baseline and 1 months mean global scores did not show a significant change in 
QOL (4.1 ±1.3 vs. 4.4 ±1.1; p = 0.88), however there was a significant increase from 
baseline to 6 months (4.1 ±1.3 vs. 5.3 ±1.2, p<0.001) which was maintained to 1 year 
(4.1 ±1.3 vs. 5.3±1.2, p<0.001) .   
Subgroup analysis using paired T-tests revealed medically managed patients 
experienced no change in QOL over the course of the year. Patients managed with 
revascularisation, PCI and CABG, had significant improvements in QOL at 6 months 
(p<0.05 and p<0.001, respectively) and a year (p<0.005 and p<0.001, respectively) 
when compared to baseline scores (figure 19). 
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Table 52:MacNEW global scores over 1 year follow-up for all patients 
 Baseline 1 month 6 months 1 year 
All patients 4.33 (IQR1.81) 4.59 (IQR 1.59) 5.41 (IQR 1.69) 5.52 (IQR 1.45) 
Medical Management 
(IQR) 
4.33 (IQR 1.70) 4.78 (IQR 1.10) 5.13 (IQR 1.77) 4.33 (IQR 1.74) 
PCI 4.36 (IQR 1.41) 4.37 (IQR 1.57) 4.89 (IQR 1.59) 5.48 (IQR 1.57) 
CABG 4.11 (IQR 2.08) 4.75 (IQR 1.59) 5.85 (IQR 1.23) 5.89 (IQR 1.28) 
CABG – coronary artery bypass surgery; PCI- percutaneous coronary intervention; IQR – interquartile range 
 
 
Figure 18: The scatter plot with linear regression prediction line of 95% confidence interval of the scores of  
global MacNew scores for time points: baseline (0 months), 1 month, 6 months and 12 months. 
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Figure 19: The scatter plot with linear regression predication line of 95% confidence interval of scores of  
global MacNew for patients treated with CABG, PCI and medical management of left main coronary artery  
disease for time points: baseline (0 months), 1 month, 6 months and 12 months. 
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Generalised linear model analysis 
A one-way repeated measures analysis of variance (ANOVA) was conducted to 
evaluate if there was a significant change in the global MacNEW score over the period 
of one year for completed questionnaires at all time points up to 1 year (n=45). The 
results of the ANOVA indicated a significant change in quality of life over the four time 
points [Wilks’ Lambda = 0.52, F(3, 42) = 12.89, W2 = 0.48, p<0.001] but there was no 
significant difference between groups. Comparisons for the overall cohort indicated a 
significant pairwise difference in score was found between all time-points except 
between baseline and 1 month and between 6 months and 1 year. The QOL over the 
first and second time points did not significantly change. Between the management 
groups there was no significant difference between baseline HRQOL scores; however 
there was a significant difference between CABG and the medically managed groups 
over 1 year follow-up. There was no significant difference between PCI and the 
medically managed groups, or between PCI and CABG over 1 year follow-up. 
All patient factors, management and MACCE were assessed in a general linear 
regression analysis to determine predictors of HRQOL outcomes. The HRQOL outcomes 
were used as the dependent variable. When predicting quality of life scores at 1 year  
it was found that elective procedures (β = -0.27, p < .05), previous MI (β = 0.28, p < .05), 
baseline quality of life scores (β= 0.35, p < .001) and CABG (β=0.45, p<0.001) were 
significant predictors of improved quality of life scores. Predictors of poor quality of 
life scores included previous cardiac surgery (β=0.40, p<0.001) previous CVA (β=0.27, 
p<0.05) and presentation with a STEMI (β=0.32, p<0.05). The overall model fit was R2 = 
0.63. 
Mixed model analysis 
Using multilevel analysis we identified three significant models. Firstly, data were 
converted to the long format. We used an unconditional means model, using a 
constant term only, to examine individual variation in the outcome without regard to 
time (n=98). This would allow the assessment of the amount of variation in the intra- 
and inter- individual levels. We found the intra-class correlation co-efficient (ICC), 
which describes the amount of variance in the outcome due to inter-individual 
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differences, to be 0.55/(0.96 + 0.55) = 0.36, which suggests that about 36% of the total 
variation in the global MacNew score was due to inter-individual differences. If the ICC 
is above 0.25, this indicates a better performance from growth curve models when 
compared with ANOVA [422]. 
Predictor variables were entered into the model sequentially. After each step, we 
assessed the goodness of fit by the difference in the deviance (-2*loglikelihood) 
between the sequential models. The best fitting model is determined by the lowest -
2*loglikelihood.   As a starting point we used the unconditional means model to 
describe and partition the variation across the 98 patients [423]. Then we proceeded 
to add time, thus constructing an unconditional growth model [424] and finally 
explanatory variables were identified and added to the model sequentially to fit an 
advanced model based on these possible predictor variables. The mixed model analysis 
is described in table 53, with the final best fitting model presented in the right hand 
column. Recent MI, within 90 days, CABG treatment and time, comparing all time 
points to the 1 year global mean MacNew score, significantly contributed to the model.  
   215 
 
Table 53: Variables included in progressive stages of the model 
Explanatory variables Unconditional means 
model estimate (SE) 
Unconditional growth 
model estimate (SE) 
Final model Estimate 
(SE) 
Fixed    
Constant 4.80(0.09)  5.29 (0.12)  3.64(0.15) 
Time  -1.00 (0.16)  0.47(0.06) 
Recent MI    0.52 (0.17) 
CABG treatment   -0.36 (0.17) 
    
-2*loglikelihood (IGLS) 946.7 828.2 816.1 
    
All effects significant. SE – standard error 
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MacNEW domain scores 
The questionnaire assesses the three major health related quality of life domains, the 
physical, emotional and social domains. The emotional, physical and social domain 
scores show a trend to improve over the 4 time points (figure 20). A one way repeated 
measures analysis of variance was conducted for all three domains over all time points. 
The emotional domain showed significant improvement in scores over the course of 1 
year, Wilk’s Lambda = 0.65, F(3, 50) = 9.13, W2 = 0.35, p<0.001. Pairwise comparisons 
showed significant difference across all time points except between 1 month follow-up 
when compared with either baseline or 6 month follow-up.  
Similar improvement in scores were found after analysis of the physical domain scores 
[Wilk’s Lambda = 0.11, F(3, 38) = 105.73, W2 = 0.89, p<0.001] and social domain scores 
[Wilk’s Lambda = 0.45, F(3, 42) = 16.9, W2 = 0.55, p<0.001] over the course of one year. 
Pairwise analysis revealed no significant change between baseline and 1 month scores 
and between 6 month and 1 year scores for both domains.  
Medically managed patients did not experience an increase in emotional domain 
scores over 1 year, while patients treated with PCI or CABG did experience a 
progressive improvement in scores (figure 21). All treatment groups showed an 
increase in the physical domain (figure 22). The medically managed group was the only 
treatment group which showed no improvement in social domain scores (figure 23). 
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Figure 20: Change in MacNew score for emotional, physical and social domains over time points baseline,  
1 month, 6 months and 12 months.  
 
 
 
 
 
 
Figure 21: Changes in MacNew emotional domain score for the overall patient cohort and for each treatment  
group over 1 year follow-up. PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting.  
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Figure 22: Changes in MacNew physical domain score for the overall patients cohort and for each treatment group  
over 1 year follow-up. PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting. 
 
 
 
 
 
Figure 23: Changes in MacNew social domain score for the overall patients cohort and for each treatment group  
over 1 year follow-up. PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting.
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Brief illness perception scores  
The BIP questionnaire uses eight questions to assess illness comprehensibility, 
cognitive and emotional representations. Cognitive representations include 
consequences (Item 1- greater the score the worse the outcome) , timeline (Item 2- 
greater the score the worse the outcome), personal control (Item 3- greater the score 
the better the outcome), treatment control (Item 4 - greater the score the better the 
outcome), and identity (Item 5 - greater the score the worse the outcome). Two of the 
items assess emotional representations including concern (Item 6 - greater the score 
the worse the outcome) and emotions (Item 8 - greater the score the worse the 
outcome). One item assesses illness comprehensibility (Item 7 - greater the score the 
better the outcome). Causal representation is assessed by an open-ended response 
item, the patient is asked to list the three most important causal factors in their illness 
(Item 9). 
All completed BIP questionnaires, n=41, were assessed across 4 time points for the 9 
questions. Each domain was assessed for the overall cohort and management groups 
using the median scores for each time point (figures 24-31). Repeated measures 
analysis of variance was used to assess change in scores for the overall, PCI and CABG 
managed cohorts over 1 year for each of the domains. Only 3 medically managed 
patients completed questionnaires over all 4 time points, so are not analysed 
separately. There were significant improvement in the median scores over time for the 
following domains including, consequences [Wilk’s Lambda = 0.41 F(3, 38) = 18.2, W2 = 
0.89, p<0.001] (figure 24), personal control [Wilk’s Lambda = 0.61 F(3,39) = 8.5, W2 = 
0.39, p<0.001] (figure 26), identity [Wilk’s Lambda = 0.74 F(3, 40), W2 = 0.26, p<0.05] 
(figure 28), concern [Wilk’s Lambda = 0.52 F(3, 40) = 12.5, W2 = 0.48, p<0.001] (figure 
29) and emotions [Wilk’s Lambda = 0.75 F(3, 40) = 4.6, W2 = 0.26, p<0.05] (figure 31). 
However, there was a significant decline in median scores over time for treatment 
control [Wilk’s Lambda = 0.69 F(3,38) = 5.6, W2 = 0.31, p<0.05] (figure 27). The 
domains illness comprehensibility and timeline were not found to be significantly 
changed over the 4 time points. Visually medically managed patients did not have a 
significant change in consequence scores over time. 
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Figure 24: : BIP consequence score for the overall cohort for each treatment group over 1 year.  
PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting.  
 
 
 
 
 
  
Figure 25: BIP timeline score for the overall cohort for each treatment group over 1 year.  
PCI – percutaneous coronary intervention; CABG – coronary artery bypass grafting 
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Figure 26: BIP personal control score for the overall cohort for each treatment group over 1 year follow-up. 
PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting. 
 
 
 
 
 
Figure 27: BIP treatment control score for the overall cohort for each treatment group over 1 year follow-up. 
PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting. 
 
 
   222 
 
 
Figure 28: BIP identity for the overall cohort for each treatment group over 1 year follow-up.  
PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting. 
 
 
 
 
  
 
Figure 29: BIP illness concern for the overall cohort and for each treatment group over 1 year  
follow-up. PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting. 
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Figure 30: BIP illness comprehensibility for the overall cohort and for each treatment group over 1 year 
 follow-up. PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting. 
 
 
 
 
  
Figure 31: BIP emotions for the overall cohort and for each treatment group over 1 year follow-up. 
PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting. 
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Pearson product-moment correlation coefficient was computed to assess the 
relationship between the mean global MacNew scores and the 8 components of the 
brief illness perception questionnaire. There were negative correlations between 
global MacNew scores and patient illness perceptions of consequences (r = -0.7, n = 
268, p <0.00), timeline (r = -0.22, n = 263, p <0.000), identity (r = -0.573, n = 270, 
p<0.000), illness concern (r = -0.572, n = 270, p <0.000) and emotional 
representation (r = -0.622, n = 267, p <0.000). Scatterplots summarise the results 
(Figure 32-36). Increase in scores for these five patient perceptions were correlated 
with lower global MacNew scores.  
 
There were positive correlations between global MacNew scores and patient illness 
perceptions of personal control (r = 0.353, n = 266, p <0.000), treatment control (r = 
0.177, n = 267, p <0.005), and coherence (r = 0.199, n = 270, p<0.005). Scatterplots 
summarise the results (Figures 37-39). Increase in scores for these three patient 
perceptions were correlated with higher global MacNew scores. 
 
Pearson product-moment correlation coefficients were computed to assess the 
relationship between each of the three MacNew quality of life domains and the 8 
components of the brief illness perception questionnaire. Positive correlations 
between the social MacNew domain and patients perception of personal control (r = 
0.333, n = 264, p <0.000), treatment control (r = 0.147, n = 264,p <0.05) and illness 
coherence (r = 0.172, n = 267, p =0.005); while negative correlations were found with  
patients perception of  consequences (r = -0.722  , n = 265 , p <0.000), timeline (r =-
0.197, n = 263, p <0.005), identity (r = -.524 , n = 267, p <0.000), illness concern (r = -
0.533, n = 267, p <0.000) and emotional representation (r = -0.507, n = 267, p 
<0.000).  
 
Positive correlations between the physical MacNew domain and patients perception 
of  personal control (r = 0.320,n = 260, p <0.000); while negative correlations were 
found with  patients perception of  consequences (r = -0.618, n = 261, p <0.000), 
identity (r =  -0.431, n = 263, p <0.000), illness concern (r= -0.468,n = 263, p<0.000) 
and emotional representation (r = -0.379, n = 263, p <0.000).  
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Positive correlations between the emotional MacNew domain and patients 
perception of personal control  (r = 0.299, n = 264, p <0.000), treatment control (r = 
0.155, n = 264, p <0.05) and illness coherence ((r =0.198, n =267, p <0.005); while 
negative correlations were found with  patients perception of consequences              
(r = -0.518, n = 265  , p <0.000), timeline (r = -0.127, n = 260, p <0.05), identity (r = -
0.405, n = 267, p <0.000), illness concern (r =  -0.510, n = 267, p <0.000) and 
emotional response (r = -0.685, n = 267, p <0.000).
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Figure 32: Correlation of global MacNew score with patient perception of illness consequences 
 
 
 
  
Figure 33: Correlation of global MacNew score with patient perception of disease timeline 
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Figure 34: Correlation of global MacNew score with patient perception of increasing personal identity 
 
 
 
 
Figure 35: Correlation of global MacNew score with patient perception of illness concern
   228 
 
 
Figure 36: Correlation of global MacNew score with patient perception of emotional representation of illness 
 
 
 
Figure 37: Correlation of global MacNew score with patient perception of personal control 
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Figure 38: Correlation of global MacNew score with patient perception of treatment control 
 
 
Figure 39: Correlation of global MacNew score with patient perception of illness coherence
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MACCE outcomes 
Over 1 year follow-up there was a total of 6 acute coronary syndromes, 3 patients required 
further revascularisation (table 54). The 1 year mortality rate for the entire cohort was 5.8%, 
including 3 deaths within the medically managed group, 2 patients treated with PCI and 1 
patient who had CABG.  Univariate linear regression analysis did not reveal a correlation of 
MACCE and mean global MacNew scores  over 1 year  follow-up [β =-0.16, p=0.19], nor was 
MACCE identified as a predictor variable in the best fitting growth model for global mean 
MacNew scores.   
Follow-up continued for the entire cohort until completion of all 1 year questionnaires for 
all patients, the median follow-up was 502 (286) days (table 55). MACCE recorded for this 
period include 1 further ACS within the PCI patient cohort, 1 patient treated with PCI initially 
suffered a repeat revascularisation, while 1 patient failed medically management and 
converted to a revascularisation strategy. There was 1 additional CVA within the CABG 
managed group and no further deaths were recorded. 
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Table 54: MACCE over 1 year follow-up 
MACCE Medical Management (%) PCI (%) CABG (%) 
ACS 2 (10.0%) 3 (8.6%) 1 (2.1%) 
Repeat revascularisation 2 (10.0%) 0 1 (2.1%) 
CVA 0 1 (2.9%) 0 
Death 3 (15.0%) 2 (5.7%) 1 (2.1%) 
CABG – coronary artery bypass surgery; PCI- percutaneous coronary intervention; MACCE – major 
adverse cardiac or cerebrovascular event; ACS – acute coronary syndrome; CVA – cerebrovascular 
accident 
 
 
 
Table 55: MACCE over median follow-up 502 (IQR 286) days 
MACCE Medical Management, n(%) PCI, n(%) CABG, n(%) 
ACS 2 (10.0%) 4 (11.4%) 1 (2.1%) 
Repeat revascularisation 3 (15.0%) 1 (2.9%) 1 (2.1%) 
CVA 0 1 (2.9%) 1 (2.1%) 
Death 3 (15.0%) 2 (5.7%) 1 (2.1%) 
CABG – coronary artery bypass surgery; PCI- percutaneous coronary intervention; MACCE – major 
adverse cardiac or cerebrovascular event; ACS – acute coronary syndrome; CVA – cerebrovascular 
accident 
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6.5. Discussion 
 
Over 100 patients were recruited into the prospective Leeds left main stem registry. Whilst 
the aim was to follow-up all patients for 1 year completing 4 time point HRQOL 
questionnaires, we achieved a completion rate of 45% for all time points. The conventional 
general linear model therefore included data from only 45 patients and indicated serial 
improvements in quality of life from baseline up to 6 months, maintained up to 1 year, for 
the revascularisation treatment groups. The medically managed cohort did not show an 
improvement in quality of life scores.  Independent predictors of poor quality of life at 1 
year were a history of cardiac surgery, previous CVA and presentation with a STEMI. The 
best fitting linear growth model, 98 patients were included, indicated that quality of life 
improves significantly with time from baseline in patients treated with CABG. PCI was not 
identified as a predictor of improvement in QOL when compared with CABG. Recent MI, 
within 90 days, was identified as a significant predictor of improvement in QOL over 1 year. 
Published data indicate that mixed model analysis using the linear growth models provides a 
better fitting model than one-way repeated measures analysis of variance (ANOVA) due: (a) 
to the inclusion of a larger number of cases, where missing data are estimated with 
maximum likelihood, and (b) by allowing the construction of a growth curve using data 
collected at unequal time points [416, 425]. These are the first published data on repeated 
measures quality of life data for patients with LMCA disease which include medically 
managed patients as a comparator [390]. The SYNTAX study compared QOL outcomes in 
patients with multivessel disease treated with PCI or CABG using the linear growth model; 
however only 39.2% of study patients had LMCA disease and they did not include a 
medically managed cohort [377]. We did not show a significant difference in HRQOL 
outcomes between PCI and CABG, which is consistent with other studies comparing HRQOL 
outcomes for CABG and PCI used to revascularise LMCA disease [388, 390]. However, as we 
used the linear growth model, as opposed to a single time-point measure, we found there 
was a non-significant trend for better outcomes from CABG over 1 year follow-up.  
Quality of life is an important clinical measure of outcomes because of the increasing 
number of patients who could be treated with ULMCA PCI as a viable alternative to surgery 
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[299, 426]. In particular patients with low to intermediate burden coronary disease [59, 60, 
215, 252] and those with high surgical risk patients may benefit from PCI [69, 299]. The first 
study to report quality of life outcomes in patients with LMCA disease found no significant 
difference in HRQOL scores for both CABG and PCI treatment arms at a single time-point, 
measured at 6 months  [390]. While our results correlate with these findings and those from 
other studies of revascularisation [377], we analysed repeated measures of QOL. The 
repeated measures analysis of QOL is a more robust methodology employed in more recent 
studies comparing PCI to CABG [388, 391].  
We did not show a significant difference in QOL scores comparing PCI to CABG; CABG was a 
predictor of better QOL in the linear growth model and PCI was not. Furthermore, mean 
QOL scores for CABG seem to improve to a greater degree than PCI within 6 months, which 
is in contrast to other studies which show larger early gains in QOL from PCI up to 6 months 
post-procedure [379], which may be reversed at 1 year. Possible explanations for this 
include the unmeasured differences in the disease burden between the cohorts, the 
significantly older PCI cohort and possibly larger burden of incomplete revascularisation in 
the PCI cohort.  
Compared with our retrospective LMCA PCI cohort, this was a much younger overall cohort, 
where patients treated with PCI though were significantly older than the CABG and 
medically managed cohorts. Age was not identified as a predictor of poor QOL outcomes, 
which is consistent with other studies which show similar HRQOL outcomes amongst older 
and the younger patients up to 1 year [358, 390, 427, 428]. QOL scores did not improve 
significantly from 6 months to 1year following CABG, but were maintained, this too reflects 
a relatively younger study population compared with other studies which show a 
deterioration in QOL after 6 months in older patients following CABG [429]. The older PCI 
cohort similarly maintained the early gains in QOL up to 1 year. The early and sustained 
improvement in QOL becomes more relevant amongst those with relatively short life 
expectancy, while other outcomes measures, such as repeat revascularisation, may become 
less relevant in the elderly. 
For the overall study cohort, all subgroup domains of the MacNew questionnaire 
significantly improved over time, with the largest improvement in the physical domain after 
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6 months. Previous studies have shown that amongst patients treated with CABG the 
physical domain lags behind the other QOL domains [376]. Indeed the 6 month physical 
domain QOL scores seem to lag behind the other QOL health domains for patients with 
LMCA treated with both PCI and CABG [390]. Elderly patients tend to have worse physical 
domain scores which do not improve as much as other domains [390, 430, 431]. CABG 
represents a significant physical trauma; despite this we did not show a significant 
difference in the physical domain scores between the PCI and CABG cohorts, this is more 
than likely a consequence of the older PCI cohort.  
This is the first longitudinal study of brief illness perception questionnaires of patients with 
LMCA disease. All BIP questionnaire scores increased over time apart from treatment 
control, which showed a significant decline. Treatment control had a weak positive 
correlation with global MacNew scores. This knowledge has important practical implications 
for rehabilitation programmes and patient education; by improving the perception of 
treatment control one can potentially improve quality of life outcomes [432][407]. Strong 
negative correlations were found between the mean global MacNew scores and patients 
perceptions of consequences and emotional representations each accounting for 49.0% 
(r2=0.49) and 38.6% (r2=0.386) of the variability in the overall QOL scores respectively. While 
moderate negative correlations were found between the mean global MacNew scores and 
identity and illness concern. There was a weak positive correlation of the mean global 
MacNew score and perceptions of personal control, which accounted for only 12.4% of the 
variability in the score.  
Across social and physical domains of the MacNew score, patients’ perception of 
consequences had a strong negative correlation accounting for 52.1% of the variability in 
the social domain score and 38.1% in the physical domain score. MacNew physical and 
social domain scores had a moderate negative correlation with BIP emotional 
representations while in the emotional domain of the MacNew it had a strong negative 
correlation which accounted for 46.9% of the variability in these scores. Other BIP 
perception scores with a moderate negative correlation to the social and physical MacNew 
domain scores include identity and illness concern.  The physical and social MacNew 
domains were both found to have a moderate positive correlation with BIP personal control, 
while there was only a weak correlation with the emotional MacNew domains. The 
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emotional domain of the MacNew had no strong or moderate positive correlations with BIP 
scores. 
The perception of negative illness consequences was assessed with the first item in the 
questionnaire (see appendix), ‘how much does your illness affect your life?’ with higher 
scores indicating worse consequence. While the effect of BIP consequence on long term 
QOL outcomes has not been studied in LMCA disease, it was known that the immediate 
(<24hours) beliefs in unpleasant consequences following an MI are predictive of poor long 
term QOL [433]. However this study correlated only a single measure of illness beliefs with 
QOL while we have demonstrated significant improvements in the BIP consequence scores 
with longitudinal data analysis. Results from meta-analysis of all BIP published data have 
confirmed the strong negative correlation of QOL with BIP consequences  [434]. It is known 
that in-hospital interventions which are designed to change patients' illness perceptions can 
improve long term QOL and angina scores following an MI [414].  So while BIP consequence 
scores were not included in the best fitting predictive linear growth model of QOL, it may 
have contributed to the overall improvement in QOL scores over time. It is worth noting 
that medically managed patients had some observable improvement in the mean BIP 
consequence scores.  
Emotional representation was assessed with item 8 in the BIP questionnaire; ‘how much 
does your illness affect you emotionally? (E.g. does it make you angry, scared, upset or 
depressed)’ (see appendix). Strong correlation of BIP emotional representation with 
depression, QOL psychological and emotional domains have been demonstrated in meta-
analysis of the published brief illness perception data [434]. Patient emotional 
representations can identify cardiac patients at high risk of depression [435], while 
depressed patients are more likely to have poor QOL scores [436]. Interventions, such as 
CBT, which target changes in illness perceptions, can improve depression in cardiac patients 
[437, 438].   
While the angina scores were not directly assessed in this study, we were able to determine 
the change in anti-anginal therapy over the course of 1 year. There was no significant 
difference in anti-anginal therapy between groups, which probably reflects what is known 
from other studies comparing CABG to PCI in multivessel disease; there was no significant 
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difference in angina [377]. This is interesting as patients treated with CABG achieve 
significantly more complete revascularisation than those treated with PCI [155]. The 
benefits of complete revascularisation extend to generic QOL scores too; physical domain 
QOL scores show a greater improvement amongst patients with complete revascularisation 
compared to those with incomplete revascularisation [163]. It should however be noted 
that revascularisation was not guided by ischaemia testing in either treatment group [47]. 
However, it is not possible for us to interpret the burden of angina in our study, as drug 
therapy, acting as a surrogate, may not have been actively reviewed. Revascularisation is 
known to augment the relief of angina when added to medical therapy [439, 440], and may 
explain why none of the medically managed patients in this cohort had a reduced dose of 
anti-anginal medication.   
Independent predictors of poor quality of life scores at 1 year include a history of previous 
CABG. While this is the first reported analysis to show this association, previous cardiac 
surgery is well known predictor of mortality from subsequent surgical revascularisation 
[137]. This has implications in decision making, probably tipping the scales further in favour 
of PCI for this subgroup of patients. Indeed if there were patent grafts to the left coronary 
tree, this could confer protection when undertaking LMCA PCI.  
Previous CVA and presentation with STEMI were also identified as independent predictors 
of poor HRQOL outcomes. While a history of CVA has never been reported as a predictor of 
QOL in other revascularisation studies, the mechanism could simply be related to the level 
of baseline physical disability, depression, lack of social support [441]  or even marital status 
[442]. While only 17.5% of patients presented with STEMI and almost half with NSTEMI, 
STEMI was a predictor of poor QOL; this is in contrast to known data which show worse QOL 
outcomes in patients with NSTEMI compare with STEMI following revascularisation [443]. 
Nevertheless, we are unable to confirm whether the mechanism for this poor QOL outcome 
post STEMI is related to known psychosocial factors, such as depression [444]. 
The MACCE rate for PCI was similar to that reported for randomised studies of LMCA 
revascularisation, while the MACCE rate we report for CABG was half that reported in other 
studies [45, 61]. Similarly the MACCE rate we report for the medically managed group was 
almost half that reported by other studies [5, 6, 8, 445] , however our medically managed 
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cohort was significantly younger than included in these studies. MACCE was not however an 
independent predictor of HQOL outcomes, yet it is known that there are measurable 
changes in QOL scores in patients suffering MACCE events post-revascularisation [195]. 
Significant change in QOL scores could therefore identify significant MACCE, which may 
allow a more appropriate censorship of MACCE.  A ‘weighted’ MACCE if you like, where 
insignificant MACCE, determined by a minor reduction in QOL scores, are ignored. Thus, 
longitudinal change in HRQOL in combination with hard end-points, could inform patients 
and clinicians of the prognostic and symptomatic gains of various therapies. However, in 
order for this study to measure a change in QOL related to a specific MACCE event, the QOL 
questionnaires should be administered at the time of the new event, thus creating 
additional time-point measurements for these patients. The study design was therefore not 
capable of establishing a ‘weighted’ MACCE, which was one of the recommendations from 
the Patient and public consultation group. Another factor precluding this analysis would be 
the small numbers included in the study, with such a low MACCE rate; we would need a 
much larger study population. 
Questionnaire completion rates varied across the treatment groups with the medically 
managed group having the lowest completion rates across the year of follow-up. Poor 
completion rates for questionnaires are similar to those found in other studies of QOL [446, 
447], yet the factors related to this were not assessed. Death accounted for over a third of 
the missing questionnaires amongst the medically managed group. Indeed it is well 
documented in other studies that patient attrition due to the disease process results in a 
decline in completion rates over time [416, 446]. Other factors given are poor socio-
economic status, older age and foreign or socially isolated groups [447]. However, other 
studies report higher questionnaire completion rates amongst older patients, 71.0% for 
those over 75 years old and only 66.7% for those under 75 years old [390]. In previous 
chapters we have demonstrated that the cohort of patients treated with LMCA PCI at our 
institution is older than the published data, however this prospective study cohort, median 
(IQR) age of 69.0 (14.0) years old, was younger than the retrospective cohort, median (IQR) 
age of 75.0 (18.0) years old. Furthermore, there was no difference in age between the 
missing and completed QOL questionnaire groups. Neither did we report a significant 
difference in socio-economic status between those with missing and completed 
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questionnaires. There were significantly more STEMI patients who did not complete the 
questionnaires. STEMI patients treated at our institution are recovered from a wide 
geographical area, and they are then repatriated to their respective district hospitals soon 
after treatment. This may account for the low completion rate despite posting 
questionnaires to these patients. Possible mechanisms may include the lack of routine 
clinical follow-up with the sponsored research site, such as routine outpatient clinic visits. 
We also found that patients with diabetes were less likely to complete all questionnaires; 
the mechanism for this is unclear. 
6.6. Limitations  
 
Issues with recruitment are a source of potential bias in this study. This prospective study 
intends to describe the QOL outcomes amongst all patients with LMCA disease; however we 
were unable to recruit all patients diagnosed at our institution. From the conception of this 
study we anticipated issues relating to recruitment and attempted to negate these using 
various strategies. Patients admitted as emergencies overnight were often repatriated to 
the district hospitals prior to recruitment. Our strategy involved communicating actively 
with clinical staff which would alert the research team to potential patients within the 
department prior to their discharge. To enhance inclusion of all patients diagnosed with 
LMCA disease, we invited referrals to the Leeds MDT.  We presented an outline of the study 
at the regional commissioning group meeting in September 2012. Furthermore, the study 
design and ethics application made possible the recruitment from multiple centres. Despite 
this we were unable to recruit additional centres to the study due to concerns raised by the 
research committee about loss of Comprehensive Local Research Network (CLRN) funding 
and the already stretched technical support staff.  Direct referrals from the district hospitals 
to a named surgeon continued which therefore bypassed discussion at the MDT and led to 
missed recruitment. A further source of potential bias includes the unknown numbers of 
patients diagnosed at the district general hospitals who were medically managed. Despite 
encouraging referral, without a multicentre study design a number of medically managed 
would have been missed. Due to small numbers of medically managed patients we are 
unable to assess factors associated with poor QOL.  
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A major limitation of this study is that we did not provide comparative coronary disease 
burdens for each treatment group. There were obvious differences between groups with an 
older PCI cohort compared to the CABG group. This introduces potential confounding, 
disease burden and indeed the residual disease burden significantly affects the QOL 
outcomes [155].  
While we included recognised predictor variables in developing the linear growth model, 
possible confounding factors not measured include: emotional/mood status [442], 
educational level [417], cognitive impairment [448-450], living environment [451], ischaemic 
burden [452], the requirement for social support[431]. All these are known predictors of 
poor QOL, and thus contribute to the overall causative psychological model. 
At most this study provides a snapshot in terms of QOL outcomes. It is known that over 
longer term follow-up, up to 3 years, QOL scores seem to deteriorate amongst the elderly 
[453]. Older patients though are underrepresented in HRQOL studies [358]. Yet for these 
elderly patients, HRQOL is particularly relevant given their relatively short life expectancy. 
For the elderly, traditional measures of outcome, such as MACCE, becomes less relevant. 
We should consider extending the use of QOL questionnaires up to 3 years following 
revascularisation with appropriate strategies to deal with the with poor questionnaire 
completion rates found amongst the elderly [447].  
‘Missingness’ is correlated with outcomes and missing questionnaires introduce extreme 
bias to the data, cautious interpretation of the available data is warranted [446].  The bias is 
proportional to (a) the difference in mean QOL scores between those who have completed 
the questionnaires and those who have not (one assumes they have completed the 
questionnaire), and to (b) the proportion of non-responders. If  we compare two treatments, 
A and B,  in a randomised clinical trial using overall QOL scores; the proportion of patients 
who completed all questionnaires, in treatment arm A would be given by ‘A’, while those 
who did not would be ‘1-A’.  The mean scores for patients who completed the 
questionnaires, the A ‘comp’ group, is given by ῡAcomp; while the mean scores for those 
who did not complete the questionnaires, the A ‘incomp’ group is given by, ῡAincomp; 
assuming they had responded.  Thus the mean score for all patients in treatment group A 
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would be ῡA = A.ῡAcomp + (1-A).ῡAincomp  [454]. Yet while we only have the mean scores for 
the A ‘comp’ group, the bias in the scores for treatment group A is given by: 
BiasA  = ῡA - ῡAcomp 
 = A.ῡAcomp + (1-A).ῡAincomp - ῡAcomp 
 = (1-A).( ῡAincomp - ῡAcomp)                       [446] 
Thus, we cannot reduce the bias by increasing the study size; rather we should achieve this 
by reducing the proportion of those with incomplete questionnaires. While it is tempting to 
deal with the missing data using statistical methods, such as multiple imputation, these 
methods do not account for confounding. Statistical methods assume that those who have 
not completed the questionnaires are similar to those who did complete the questionnaires. 
However, where it is not possible to account for all variables associated with incomplete 
questionnaires this assumption will be erroneous.  Our study design did not account for 
reasons why patients did not respond to the baseline questionnaire; however this was a 
small proportion of patients, fewer than 15.0%. Furthermore, we failed to record factors 
which led to incomplete questionnaires over the course of 1 year follow-up. In order to 
ameliorate this we included a linear mixed model which led to the inclusion of over 97/106 
patients. By increasing the number of time points included, the mixed model improved the 
reliability of HRQOL parameters by reducing the standard error of the within-patient change 
in the HRQOL parameter estimates [455][456]. Despite this our study compares favourably 
with other studies where the missing questionnaires or non-responder rates were up to 
30.0% for a single time-point questionnaire [457].  
While we were able to demonstrate longitudinal trends for generic HRQOL measures, we 
did not include a disease specific QOL measure, such as an angina score. Disease specific 
measures assess the progression and modification by treatment of the organ specific 
pathology [458]. One such widely used measure is the Seattle Angina Questionnaire [459]. 
Disease specific QOL have disadvantages though, while the treatment may improve disease 
specific QOL measures it may lead to a decline in other QOL measures. Take for example a 
scenario where CABG improves the angina score but due to the severe trauma of the 
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surgery it leads to a worsening in musculoskeletal pain or limitation in mobility as a result. It 
is recommended to include both disease specific and generic HRQOL measures [460].  
Correlation between angina and repeat revascularisation has been demonstrated in trials 
comparing PCI to CABG [461, 462]. While it is known that CABG offers greater freedom from 
angina than PCI for multivessel disease [463], other studies have shown no difference in 
angina scores between these two treatments [377].   
There seems a large dispersion of baseline global MacNew scores which become more 
bunched up towards the 1 year follow-up period. Firstly, this indicates the large variability in 
baseline characteristics; secondly, it may indicate learning as patients become more 
accustomed to the questionnaires. Other confounding variables may account for the wide 
dispersion in baseline scores such as including patients presenting with both stable and 
acute coronary syndromes and timing of recruitment, e.g. soon after a CABG or STEMI 
versus an elective admission. In the case of clinical syndrome, baseline scores may be 
‘abnormally low’ amongst patients recruited immediately following PPCI for STEMI. 
Furthermore, where some patients were recruited in the first few days following their CABG, 
they too may have ‘abnormally low’ baseline scores. These ‘abnormally low’ baseline scores 
may thus result in a ‘significant’ increase over 1 year as it is the rate of change in scores over 
time which we describe with growth curves [377].  The acuity of presentation itself and 
indeed the trauma of the management is a confounding factor in these baseline scores. In 
order to negate this confounding, patients were asked to relate their baseline answers to 
the premorbid, 2 weeks prior to presentation, life. Moving forward it would be important to 
address when the baseline questionnaires were administered. In the SYNTAX trial this was 
prior to randomisation [377] . It may be prudent to exclude STEMI patients and those we are 
unable to recruit prior to surgery or PCI. 
 
 
 
 
 
6.7. Conclusions 
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Serial global and sub-domain QOL scores improve over 1 year for both revascularisation 
groups but not for medically managed patients, while CABG and not PCI is a predictor of 
significantly improved QOL outcomes. Medically managed patients did not have any 
improvement in QOL compared with those who had revascularisation, yet it should be 
noted that there may be a significant placebo effect. A recent study of revascularisation in 
less severe stable coronary disease has shown that revascularisation with PCI offers no 
symptomatic benefit over medical management when employing a sham procedure for 
randomisation [359].  While this study informs the risk benefit analysis of whether a limited 
or targeted revascularisation strategy may be appropriate in medically managed patients, it 
is not powered to draw any conclusions. The current study design limits the exploration of a 
causative model for all known predictors of poor QOL and does not exclude the significant 
confounding from the placebo effect. Ongoing recruitment would allow a meaningful insight 
into the medically managed cohort which has hitherto not been studied in published data. 
However, future studies should be designed as randomised controlled trials using sham 
procedures to study PCI versus medical management for symptom control in severe LMCA 
disease. 
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Chapter 7: Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.1 Retrospective study 
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Current recommendations for revascularisation of LMCA disease are based on randomised 
controlled trials comparing CABG and PCI for patients with LMCA disease [69, 299]. Patients 
randomised in these trials were considered appropriate for either CABG or PCI as the 
revascularisation strategy; indeed they have low surgical risk [464]. The SYNTAX trial was 
designed to investigate patients with extensive coronary disease, including LMCA disease 
and patients with three vessel coronary disease [47]. Thus, the left main cohort of all-
comers had a wide range of coronary disease severity which could be treated with either PCI 
or CABG [61]. The results indicated worse outcomes from PCI in patients with the greatest 
burden of atheroma, including patients with LMCA disease and extensive atheroma, SS >32 
[215], for these patients CABG offered superior results. Later studies were designed to focus 
on patients with less complex and less extensive coronary atheromatous disease [59, 60]. 
After a recent meta-analysis of these randomised studies, one can conclude that the study 
populations are more restricted by risk profile and extent of coronary disease [465, 466] 
than a large proportion of the actual population treated with LMCA PCI in the UK [154]. 
Indeed recent randomised trials have excluded just over half of all patients screened [59, 
465, 467]. 
Current revascularisation guidelines encourage weighing the risk of surgery and the clinical 
presentation, as in LMCA culprit acute STEMI, against the complexity of coronary disease 
using the SS and the anatomical location of LMCA disease when deciding on the optimal 
revascularisation strategy [468]. While for decades CABG has remained the accepted best 
practice for LMCA revascularisation, previous published national PCI registries have 
demonstrated that PCI was offered to patients considered high surgical risk [154]. It is 
amongst these high surgical risk patients for whom predictors of poor outcomes from LMCA 
PCI are unknown. While published registries provide large patient cohorts [154], they fail to 
provide the depth of data required to examine all anatomical and demographic factors 
which more recent studies have shown are predictors of poor outcomes in randomised 
samples [47, 82, 155]. In order to further examine the clinical and anatomical factors which 
are associated with poor outcomes following revascularisation with PCI, we chose to study a 
retrospective cohort of consecutive unselected patients presenting to a cardiac surgery unit 
and who had LMCA  revascularisation with PCI.  
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Notwithstanding these patients may be considered high surgical risk, they may also have 
coronary anatomy which would otherwise be considered unfavourable for PCI [299, 469]. 
Examples of unfavourable coronary anatomy include distal LMCA disease and SS>32. 
Outcomes from LMCA bifurcation PCI is associated with poor outcomes [271] and while 
there is evidence suggesting a provisional single stent for coronary bifurcation disease is the 
preferred option [82], there are no randomised studies of two versus single stent strategies 
for the treatment of LMCA bifurcation disease [106, 271]. Current published non-
randomised studies comparing single and two stent strategies for LMCA bifurcation PCI 
suffer from bias, with groups unmatched for atheroma burden at the LMCA bifurcation [77, 
113, 114]. Current evidence suggests a greater the burden of atheroma at the LMCA 
bifurcation predicts poor outcomes from PCI, particularly involvement of the side branch in 
‘True’ bifurcation disease [96, 113]. Indeed, current guidelines suggest a two stent strategy 
for ‘True’ left main bifurcation disease [119]. Thus, we assessed the factors associated with 
poor outcomes from revascularisation in a subgroup of patients with ‘True’ LMCA 
bifurcation disease. 
 
Furthermore, while a previous analysis of ULMCA PCI in a national registry revealed that 
age >80 years old is a predictor of poor outcomes [154], it is not known which factors are 
associated with these poor outcomes, nor if it is simply a consequence of a long lived 
patient group. However, this age group has seen a great increase in life expectancy over the 
last 10 years [470], with the proportion of octogenarians in the population expected to rise 
from 5% currently up to 20% by 2050 [134]). Coronary revascularisation offers greater 
absolute gains in survival in the elderly in comparison to the young [130, 142]. However, 
octogenarians are more likely to have more complex coronary lesion including multivessel 
disease and left main disease compared to younger patients [1, 126, 130, 141, 146, 152]. 
Indeed with greater complexity of coronary disease one finds incremental levels of 
incomplete revascularisation [47, 155], yet the merits of complete revascularisation has only 
been demonstrated in younger cohorts [155].  
While rSS has been shown to be a reliable quantification of residual coronary disease [155], 
there is conflict in the data assessing the association of rSS with poor outcomes in 
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octogenarians. A recent study of less than 100 patients suggested that residual coronary 
disease was associated with poor outcomes in octogenarians presenting with ACS [170]. 
However, a much larger retrospective study, including the largest ever analysis of 
angiograms calculating the SS and rSS, found no association between rSS and poor 
outcomes in the octogenarians [171]. Both of these studies included relatively small cohorts 
of patients with LMCA disease, with fewer than 10.0% of patients in the larger study and 
fewer than a third of patients in the smaller study with LMCA disease. Furthermore, while 
rSS was validated in patients with extensive coronary disease [155], in relatively low risk 
populations with a narrow delta SS, such as in the larger UK study, where the median SS was 
only 18.3 and the median rSS 10.1 [171], it may be less discriminative. 
 
Greater coronary artery lesion severity and complexity as well as the presence of multi-
morbidity may introduce challenges in achieving complete revascularisation in elderly 
patients with ULMCA disease. Indeed while it is known that incomplete revascularisation 
following CABG in the elderly leads to worse survival compared with complete 
revascularisation [169]; it is uncertain whether the residual coronary disease burden, as 
measured by the rSS, is associated with poor long term outcomes among octogenarians 
treated with ULMCA PCI. Given the sparsity of data for outcomes in octogenarians with 
LMCA disease, we sought to determine whether the residual coronary artery disease burden, 
as measured by the rSS, was associated with mortality in the elderly treated with ULMCA 
PCI. 
 
 
 
 
 
7.1.1 Principal findings 
 
   247 
 
Overall cohort 
In this retrospective study, 366 unselected patients with ULMCA disease were treated with 
PCI between March 2005 up to March 2013. Over a median (IQR) follow-up of 584 (1036) 
days,  cardiogenic shock on presentation contributed more than fivefold hazard to the risk 
of MACCE, [aHR 5.88, 95% CI 3.81-9.06, p<0.05], when compared to other significant 
covariates. Other independent covariates associated with MACCE include the burden of 
coronary disease, as measured with the SS [aHR 1.01, 95% CI 1.00-1.02, p<0.05], previous 
MI [aHR 1.94, 95% CI 1.37-2.75, p<0.05] and a history of diabetes [aHR 1.61, 95% CI 1.12-
2.31, p<0.05]. In view of up to a third missing LV function assessments, we conducted 
multiple imputation which confirmed the association of these covariates with MACCE. 
However, the multiple imputation datasets further identified that moderate to severe LV 
dysfunction was associated with poor outcomes. 
We identified cardiogenic shock on presentation as a predictor of early death, in patients 
presenting with cardiogenic shock, cardiac death accounted for 85.0% of all MACCE at 30 
days. By including patients presenting with cardiogenic shock, the regression analysis was 
less discriminatory of long term outcomes [180]. A separate analysis of patients who did not 
present with cardiogenic shock prior to the admission, found that the SS [aHR 1.02, 95% CI 
1.00-1.04, p<0.05], previous MI [aHR 1.89, 95% CI 1.28-2.80, p<0.05] , peripheral vascular 
disease [aHR 1.68, 95% CI 1.09-2.61, p<0.05] and renal impairment [aHR 1.89, 95% CI 1.05-
3.43, p<0.05] were significantly associated with MACCE.  
Furthermore, when one assesses the components of MACCE, we report a repeat 
revascularisation rate of only 2.8% in the first year. Death therefore makes up the largest 
component of MACCE.  Considering that all-cause death contributed over 80.0% of all the 
MACCE in this relatively long-lived cohort, median(IQR) age was 76.0(18.0) years old, we 
assessed the separate composite end-point of: cardiac death, MI, stroke and repeat 
revascularisation. For this composite end-point we found that SS [aHR 1.02, 95% CI 1.02-
1.04, p<0.05], previous MI [aHR 1.82, 95% CI 1.15-2.88, p<0.05] and diabetes [aHR 1.81, 95% 
CI 1.13-2.91, p<0.05] were associated with poor outcomes. 
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Bifurcation study 
We conducted a subgroup analysis of 262 patients with LMCA bifurcation disease with a 
median (IQR) follow-up of all patients of 642 (1069) days. Unadjusted Kaplan-Meier survival 
analysis showed a significantly worse outcome for patients with ‘True’ left main bifurcation 
disease compared with ‘Non-True’ LMCA bifurcation disease. After adjustment we found 
that ‘True’ left main bifurcation disease was associated with a two-fold increase in the risk 
of MACCE over long-term follow-up, [aHR 2.0; 95% CI, 1.1-3.6; p<0.05]. In addition we found 
that the presence of significant right coronary artery disease [aHR 1.8; 95% CI, 1.1-2.9; 
p<0.05], diabetes [aHR 1.7; 95% CI, 1.1-2.7; p<0.05] and peripheral vascular disease [aHR 1.7; 
95% CI, 1.0-2.8; p<0.05] were independently associated with MACCE. A separate analysis of 
162 patients with ‘True’ left main bifurcation disease identified peripheral vascular disease 
[aHR 1.9; 95% CI, 1.1-3.3; p<0.05] and diabetes [aHR 1.7; 95% CI, 1.0-2.9; p<0.05] as 
independently predictors of MACCE over long-term follow-up. Unadjusted survival analysis 
showed that there was no significant difference in outcomes when comparing patients 
treated with a single or two-stent strategy. 
 
Octogenarian study  
In this retrospective analysis of 139 octogenarians treated with ULMCA PCI, we found that 
patients with incremental levels of residual coronary disease after PCI, as calculated from 
the residual Syntax score (rSS), were at greater risk of mortality over long-term follow-up. 
Each 10 unit increase in rSS was associated with a 3% increase in all-cause mortality. Whilst 
one year survival amongst this aged population approached 90% and at about 2 years, was 
77%, we found that, in addition, the SS was significantly associated with poor long term 
outcomes. Furthermore, the presence of ‘True’ LMCA bifurcation disease was associated 
with a three-fold increase in risk of death after a median follow-up of 645 (IQR 1041) days. 
While ‘True’ LMCA bifurcation was independently associated with MACCE, no other 
covariates were associated with MACCE after adjustment. 
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7.1.2 Context of findings  
 
7.1.2.1 Overall cohort 
 
We identified an overall registry cohort with significantly higher surgical risk than published 
randomised trials examining outcomes from LMCA revascularisation [25, 45, 46, 59, 60, 211, 
215]. Indeed, the median age was close to 10 years greater than in other studies published 
on LMCA revascularisation[25, 30, 31, 33, 59-61, 209, 210], with nearly twice the proportion 
of octogenarians than that reported for LMCA PCI in the UK national PCI registry [147, 154]. 
In addition the study population had more comorbidity than these other published studies, 
with a greater prevalence of previous MI, CKD and peripheral vascular disease reported for 
the study population [25, 33, 210]. International guidelines on LMCA revascularisation draw 
on randomised trials to inform best practice. PCI is a Class IIb recommendation for patients 
at high surgical risk, where risk of mortality is >2%, and modest coronary complexity (SS<33, 
not distal LMCA disease), while it is a Class IIa recommendation for those with a mortality 
risk of >5% [69]. In our study the median (IQR)risk of mortality, estimated using EuroSCORE 
II (IQR), was 8.4% (13.7), with only 34 (9.3%) of patients with a EuroSCORE of less than 2% 
[211]. Of these 34 patients, 26 (7.1%) had a SS of under <32 while 22(6.0%), had distal LMCA 
disease. It could therefore be argued that at least 34 (9.3%) patients in this cohort should 
have had CABG. While we were unable to determine the reason for PCI in our patient cohort, 
this study represents the typical high surgical risk patients who have LMCA PCI in a tertiary 
UK centre. 
 
This unselected cohort includes over an eighth of patients with cardiogenic shock, yet 
cardiac death amongst these patients accounts for close to two-thirds of all MACCE at 30 
days. While it is known that patients presenting with cardiogenic shock have poor outcomes 
despite revascularisation [202, 203, 471], in our cohort the 30 day and one-year survival was 
worse still compared with the SHOCK trial and the SHOCK trial registry where less than a 
quarter of patients had a significant LMCA stenosis. This comparison taken together with 
other data seem to suggest that increasing severity of coronary disease results in worse 
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outcomes for patients presenting with cardiogenic shock [204]. Indeed, the mortality rate 
for patients with cardiogenic shock and LMCA disease was close to two thirds at 1 year, 
similar to nationally reported outcomes [154]. 
 
Despite a similar incidence of subsequent MI compared with other studies, we reported a 
considerably lower repeat revascularisation rate [18, 73, 205]. This may indicate a tendency 
to manage subsequent cardiac events more conservatively in this older cohort [18, 73, 170, 
206, 207]. All-cause death was another significant component of MACCE. While death may 
be the earlier event in this older population, it may not be a disease-specific or device-
specific measure of long term outcomes from LMCA revascularisation. It could be argued 
that all-cause death represents a better overall measure of outcomes in randomised 
samples, where we are comparing the overall treatment efficacy; while in a non-randomised 
sample, with no treatment comparator, the use of a more disease-specific measure may 
further illuminate our understanding of the disease process in long-lived individuals, in this 
case we are measuring the effectiveness of treatment [472]. Considering that all-cause 
death contributed over 80.0% of all the MACCE in this relatively long-lived cohort, we 
assessed the separate composite end-point of: cardiac death, MI, stroke and repeat 
revascularisation. For this composite end-point we found that SS, previous MI and diabetes 
were associated with worse outcomes. 
 
In agreement with other studies, for the overall cohort we found that the SS was 
significantly associated with MACCE [47, 63] such that for every 10 point increase in the SS 
there was a 2.0% increase in risk of MACCE. Similar to other studies, patients in the high SS 
tertile, SS>32, had the worst survival compared with the lower two tertiles [215]. The SS is 
predictive of death and MACCE following PCI in multivessel revascularisation [47, 212] as 
well as LM revascularisation [61-64, 213].  However, the interaction between SS and 
outcomes has not always been found to be consistent across studies and some may argue 
that the SS is not predictive of MACCE in more recent studies [59, 60]. These inconsistencies 
are mainly explained by the significant differences in median SS between studies which 
results in differing tertile cut points [62-64, 212]. In more selective study populations with a 
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narrower range of SS, it becomes less discriminatory, such as the recent randomised trial 
comparing PCI and CABG [59, 60]. What is evident is that event rates vary with the extent of 
coronary disease which represents an interplay between disease-specific and treatment-
specific end-points. Other factors which could account for an apparent lack of sensitivity of 
the SS include the different DES used to validate the SS in the SYNTAX trial, first generation 
DES, compared with second and third generation DES used in more recent studies [59, 60, 
473]. While in our cohort close to two thirds of patients received a second generation DES, 
over a quarter were treated with a BMS. 
 
Diabetic patients have an increased risk of cardiac death [217-219]. They have an earlier 
onset of more extensive coronary disease [220, 221], including LMCA disease [125]. 
However, there is some conflict in the published data on outcomes from ULMCA 
revascularisation in diabetic patients. While some observational studies have not shown an 
association between diabetic status and MACCE [18, 224], these studies were not designed 
to examine outcomes from LMCA revascularisation in diabetic patients. Larger non-
randomised studies of LMCA revascularisation have shown diabetes was a predictor of 
MACCE [36, 223, 225, 226], while diabetes is not a predictor of early mortality following PCI 
[24] or CABG [465]. Early results from the SYNTAX trial and left main subgroup identified 
diabetes as a predictor of worse outcomes [61, 227]; however in a later analysis at 4 years 
the association was no longer evident [228]. Indeed diabetes was not included in the 
SYNTAX II model of predictors of long term outcomes [43, 229]. Other randomised studies of 
left main revascularisation, comparing CABG and PCI, found no excess hazard with diabetes 
[62, 216]. These last two studies can be criticised for significant differences in the burden of 
coronary disease between diabetic and non-diabetic groups, and between the two 
treatment arms. Patients with the worst coronary disease burden were treated with CABG 
in both groups, so it seems that when accounting for coronary disease severity and 
adjusting treatment decisions accordingly, there is no excess effect from diabetes on 
outcomes.  
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 It is suggested that the end-organ consequences, rather than the presence of diabetes are 
strongly predictive of poor outcomes [229-231]. The burden of coronary disease can be 
viewed as an end-organ effect of diabetes. This is evident in the BARI registry where 
patients received physician-led choice of treatment strategy; they found no difference in 
outcome between CABG and PCI for diabetic patients [232]. As the majority of patients 
screened ended up in the registry, the choice of revascularisation strategies were based on 
the merits of treating the specific pattern of coronary disease burden. Similarly in the LMCA, 
where the choice of revascularisation strategy was based on the burden of disease, we find 
no interaction between diabetes and poor outcomes [216].  However, randomised studies 
of ULMCA revascularisation comparing groups with similar burdens of coronary disease 
have found significantly worse outcomes in diabetic patients [233].  While there is a lack of 
data for outcomes amongst diabetic patients with ULMCA disease, after correction for SS 
and other comorbidities, we found a significant association between diabetes and adverse 
outcomes. Our study indicates diabetes may be an important factor with respect to MACCE 
in ULMCA revascularisation independent of SS.  
 
Despite significant differences in comorbidity but a similar burden of coronary disease 
between deprivation groups, we did not demonstrate a statistically significant difference in 
survival after PCI between the quintiles of deprivation. Other studies have found worse 
outcomes amongst the more deprived following PCI; however they failed to quantify the 
coronary disease between groups [178, 240, 241]. In our study cohort the more deprived 
patients had more comorbidity, diabetes and renal impairment compared with the least 
deprived, which is consistent with other PCI study populations [178, 238]. There is an earlier 
onset of subclinical coronary disease amongst the more deprived [239], and while we found 
no difference in the burden of coronary disease amongst the quintiles of deprivation, 
measured with the SS, the more deprived patients were younger. This may reflect the 
earlier development of worse categories of coronary artery disease, such as left main 
coronary artery disease, amongst the more deprived [175, 239]. Hence the younger more 
deprived with severe disease.   
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We report a large number of complications, over 25.1%. While one may accept this high 
complication rate is due to the significantly older cohort of patients it is five times higher 
than the complication rate reported for elderly patients in other studies [133]. Over half of 
all our reported complications include coronary dissections. Untreated coronary dissections 
post-angioplasty may result in acute complications [244, 245], poor long term outcomes 
[242-244], additional stenting [246, 247]. Nevertheless, we did not demonstrate an 
association between poor long term outcomes and angiographic LMCA dissection during 
angioplasty. 
 
Access site complications were reported in 5.7% of all patients; over 90.0% of these 
complications were reported in patients where larger sheaths (7-8Fr) were used via femoral 
access. Over three quarters of these patients had LMCA bifurcation disease. Arterial sheaths 
greater than 7 Fr in size were used in almost 70.0% of our total cohort which is ten times the 
proportion reported in other studies [250, 251]. The combination of larger sheaths and a 
greater burden of PVD in our patients may account for the increased rate of access site 
complications compared with these studies [250, 251]. We report a large burden of LMCA 
bifurcation disease, and while this may require a two stent strategy to treat, it may account 
for the need to use larger sheaths and catheters. Further analysis is required to determine 
the mechanisms and decision making leading to the use of large catheters in a population 
with higher than reported rates of peripheral vascular disease. 
 
We report a definite and probable stent thrombosis ST rate of 1.9% in the first year, rising to 
2.2% over the course of the follow-up. While this is similar to that reported for other LMCA 
PCI cohorts [31, 252], it is twice the number reported in a large multi-centre registry of 
ULMCA PCI [253]. There could be a few of reasons for this increased ST rate in our study 
compared to this registry, including: 1) significantly longer median stent length used in our 
study [253]; 2) our patients have significantly more comorbidity [254]. While LMCA 
bifurcation requiring a two stent strategy may be a risk of ST [31, 77], we had a similar 
burden of distal LMCA disease and similar usage of the two stent approach compared to this 
registry [253]. Despite less DES use in our cohort compared to the multi-centre registry, we 
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reported very late ST (VLST), while they reported none. Unfortunately, we were unable to 
exclude premature cessation of DAPT in our patients. One other factor which may explain 
the significantly lower ST in this multi-centre registry is that the study authors may have 
under-reported ST in unexplained deaths [253] 
 
7.1.2.2 LMCA bifurcations 
 
In order to study long-term outcomes from ULMCA bifurcation disease, and given the 
known association of cardiogenic shock with early mortality [256-259], we did not include 
patients with cardiogenic shock in this analysis. This methodology is in keeping with the 
study design of prospective left main bifurcation studies and other bifurcation studies 
where they excluded patients with cardiogenic shock [106, 110]. We included all Medina 
classes of LMCA bifurcation disease, both ‘True’ and ‘Non-true’ [84, 104]. 
 
The MACCE rate in this study population was 13.1% at 30 days and 26.2% at 1 year, which is 
similar to that reported in registries of LMCA PCI with 1st generation DES [21], while it is 
almost twice the MACCE found in other LMCA PCI registries of 1st generation DES which 
include close to 80.0% distal LMCA disease [22, 23, 26, 77]. However, the burden of 
coronary disease may not be comparable as these studies do not specify the Medina class of 
LMCA bifurcation disease, nor do they use the SYNTAX score to quantify associated coronary 
involvement. Our MACCE rate seems to be comparable with the treatment of complex 
LMCA bifurcations [73].  
 
This is the first study reporting outcomes in ‘True’ versus ‘Non-true’ left main bifurcation 
disease, we found a significant association between ‘True’ left main bifurcation disease and 
MACCE. While significant distal LMCA disease and poor long-term outcomes [78] and ‘True’ 
coronary bifurcations have worse outcomes when compared to 'Non-true' [260], no study 
has demonstrated this within the LMCA bifurcation. While it is known that the greater the 
burden of atheroma at the bifurcation, the worse the long-term outcomes [78, 96], this is 
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the first study reporting outcomes in ‘True’ versus ‘Non-true’ left main bifurcation disease 
using the Medina classification of bifurcation disease [104, 107, 114]. 
 
Distal left main disease is associated with a greater burden of multivessel disease [62, 300-
302]  and indeed this is the case for ‘True’ left main bifurcation disease, more so than ‘Non-
true’ bifurcation disease. We report significantly more multivessel disease, LM +2VD and 
LM+3VD, amongst the ‘True’ bifurcation cohort compared with the ‘Non-true’ cohort. 
However, other studies of PCI for unselected distal LMCA disease have reported associated 
multivessel coronary disease in up to four-fifths of patients [113, 115], twice the proportion 
in our study. They show no difference in the burden of coronary disease between the 'True’ 
and 'Non-true' groups [72]. Despite this association with multivessel disease, after 
multivariate analysis including the SS, we can conclude that the association of 'True' LMCA 
bifurcation disease with poor outcomes were independent of the greater coronary disease 
burden. 
 
In the separate analysis of patients with ‘True’ left main bifurcations, we showed no 
statistically significant difference in outcomes for single and two stent strategies. There are 
no randomised trials comparing single to two stent strategies for ‘True’ LMCA bifurcation 
PCI and there is contradiction in the available data for the use of either a single or two stent 
strategies in the treatment of LMCA bifurcation disease.  While some studies report better 
outcomes from a single-stent strategy [90, 112, 115, 127], they have compared unmatched 
samples. Due to the nature of observational data the groups compared are unmatched with 
regards to ‘True’ vs ‘Non-true’ LMCA bifurcation disease [90, 112], and in other cases due to 
comorbidity [115].   Furthermore, there is often a lack of reporting atheroma burden in the 
left main bifurcation [115, 127]. Similarly, studies reporting no difference in outcomes 
between the single and two stent strategies for LMCA bifurcation PCI [113, 114, 261, 266] 
suffer from the inherent issues with observational data. These issues include a mismatch 
between the treatment groups with more ‘true’ bifurcation disease in the two stent group 
[113, 114, 266], while only a third of patients may have ‘true’ bifurcation disease [113, 114, 
266]. There may also be significant differences in accepted practice between the treatment 
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groups, such as significantly fewer final kissing inflations in the single stent group compared 
with the two stent group [114]. This is the first study reporting outcomes from a two stent 
versus single-stent strategy in ‘True’ left main bifurcation disease, while other studies have 
compared two stent strategies to one another [111, 267]. 
 
PCI of the distal LMCA carries a higher risk of ST compared with other LMCA lesions [127]. 
While we report a greater number of definite and probable ST in the ‘True’ bifurcation 
group compared with the ‘Non-true’ LMCA group, 3.1% vs 0.0, this was not statistically 
significant. The ST rate for ‘True’ left main bifurcation disease in our study was similar to 
that reported in other left main bifurcation PCI studies [114, 127].  However, while other 
studies report a greater risk of ST amongst patients treated with a two stent strategy 
compared with a single stent strategy [127, 261], we found no difference between the single 
and two stent treatment groups with respect to ST rates. Other studies confirm our findings 
that the ST rate is similar for single and two stent groups, however these studies include 
patients with both ‘True’ and ‘Non-true’ LMCA disease [113, 114].  
 
Side branch occlusion rates in our study were numerically higher amongst patients with 
‘True’ left main bifurcations; while amongst the patients with ‘True’ bifurcation disease 
those treated with a single stent suffered more SB occlusions than the two stent group, 5.4% 
vs. 1.1%. However, this was not statistically significant. Sixteen patients treated with 
rotational atherectomy and a single stent in the ‘True’ bifurcation disease group did not 
suffer side branch occlusions. While this was not statistically significant in our study, other 
studies confirm that debulking of bifurcation lesions results in less SB occlusion especially 
when employing a single stent procedure [274, 283]. SB occlusion is a recognised 
complication of bifurcation PCI and may occur in up to 8.0% of all cases [80, 291-293]. It is 
commonly due to carina shift after main across side branch stenting [103]. While some 
studies suggest that ‘True’ bifurcations are at risk of side branch occlusion [260, 291, 294], 
our study suggests that using a single-stent strategy in ‘True’ LMCA bifurcation disease 
increases this risk but not after rotational atherectomy. 
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7.1.2.3 Residual Coronary disease 
Our findings suggest that residual coronary disease, as measured with the rSS, may be 
predictive of poor outcomes in octogenarians with severe coronary disease. While other 
studies agree with these findings [155, 474, 475], we demonstrated these findings in a 
patient with limited life expectancy. There is some disagreement with the impact of rSS on 
PCI outcomes in octogenarians [171], however in this study there may a few reasons why 
the rSS was not associated with mortality. In this study, the largest study to assess SS and 
rSS in over 8000 angiograms, the cohort of patients had less severe baseline coronary 
disease, median SS of 18.7 compared with 32.0 in our study or 28.4 in the SYNTAX trial. 
While they included less than 10.0% of patients with LMCA disease the findings are 
therefore not comparable to our study. Furthermore, while we excluded patients with 
cardiogenic shock in their study over a fifth of all patients who died had cardiogenic shock. 
They report an 8 fold increase in hazard of death with cardiogenic shock, which may blunt 
the sensitivity of the multivariate analysis to determine factors associated with longer term 
outcomes.  
 
We reported almost twice the burden of residual coronary disease compared with other 
randomised studies [155, 167] but similar to other observational studies [474]. In our study 
rSS and SS were strongly correlated: we observed greater residual coronary disease in 
patients with higher baseline SS. Indeed patients with more complex coronary disease are at 
greater risk of residual coronary disease. While other studies report no correlation between 
rSS and SS [155, 474], they achieved complete revascularisation in over 49% of patients, 
whereas only 4.3% of our patients had complete revascularisation. Accordingly, the median 
delta SS did not differ across the rSS tertiles confirming a tendency for selective rather than 
complete revascularisation in our cohort and this explains the significant collinearity of the 
SS with other measures of coronary disease, such as the rSS and distal LMCA involvement. 
There can be a number of reasons for selective revascularisation, which we will explore. 
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While the elderly are more likely to present with complex, multivessel coronary disease [304, 
309, 310] including distal LMCA disease and multivessel disease [39, 146, 307], we report a 
significantly higher median baseline SS than that reported in other randomised trials of 
LMCA PCI [47, 61]. In agreement with other observational studies, we found that LMCA 
bifurcation disease was associated with poor outcomes [78], indeed using the Medina 
classification, we can report worse outcomes for ‘True’ LMCA bifurcation disease amongst 
octogenarians receiving PCI. Compared with younger patients our patients with ‘True’ LMCA 
bifurcation disease tended to have a provisional single stent rather than complex two stent 
strategy [31, 61]. It is not certain if the provisional single stent is inferior to the two stent 
strategies for treatment of the LMCA bifurcation disease [77, 113, 115].  
 
Our analysis was limited to octogenarians, yet other all-comer studies of residual coronary 
disease found that incremental levels of rSS were correlated with increasing age of the 
patients [155, 474].  Selective revascularisation in the elderly has been reported in other 
studies [170, 206].  Over two thirds of our patients presented with an ACS compared with 
only 50-55% in other registries of octogenarians with ULMCA PCI [143, 144, 308] , while it is 
similar to UK national revascularisation trends [476]. Elderly patients are less likely to have 
access to revascularisation compared with younger patients [206, 207]. Octogenarians are 
more likely to receive treatment for unstable syndromes than stable angina when compared 
with younger patients [126, 130, 133, 146], indicating a possible preference to manage 
stable symptoms conservatively for this age group. While haemodynamic compromise has 
been implicated in poor outcomes from revascularisation of ACS in the elderly [131] we 
excluded patients presenting with cardiogenic shock. Less extensive revascularisation and 
increasing rSS following the treatment of ACS in octogenarians has been associated with 
poor outcomes [170]. Nevertheless, ACS on presentation was not associated with poor 
outcomes. 
 
The presence of a chronic total coronary occlusion is a major factor in failing to achieve 
complete revascularisation by PCI [312]. CTOs were more prevalent and tended to be left 
untreated in our patients when compared with a younger LMCA study cohort [61]. However, 
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we were unable to assess whether CTO revascularisation was appropriately deferred due to 
lack of myocardial viability or ischaemia testing.  
 
Octogenarians suffer more complex coronary disease than younger patients, including more 
bifurcation disease [477] and more calcified lesions [278-280, 321]. Calcified lesions are 
identified as a major factor leading to selective revascularisation [322], and are markers of 
poor prognosis following revascularisation [323]. Rotational atherectomy was required to 
treat the LMCA in almost a fifth of our patients, while it is used in less than half the 
proportion of younger patients with LMCA disease [32, 43]. In this context octogenarians 
are more likely to suffer complications following PCI [1, 133], making clinicians less likely to 
consider complex revascularisation strategies [206].  
 
This study cohort had a large burden of peripheral vascular disease, similar to the levels 
reported in other observational studies of coronary revascularisation in the elderly [39, 126, 
141] and more than twice the prevalence in younger patients [126, 129, 133, 141, 142, 332]. 
While the presence of peripheral vascular disease indicates widespread macrovascular 
disease, it has implications for the management of coronary disease in the elderly due to 
and increased risk of access site complications [133]. 
 
Our study population had a similar prevalence of comorbidities and burden of coronary 
disease compared with other reported registries of octogenarians treated with ULMCA PCI 
[126, 141, 143, 144, 308]. While the elderly undergoing revascularisation have a large 
burden of distal LMCA disease [39, 146, 307], poor outcomes from LMCA bifurcation 
revascularisation are driven by repeat revascularisation [115, 117]. Yet only 5.8% of our 
patients suffered repeat revascularisation compared with over 10.0% in other LMCA PCI 
studies [29, 60, 61, 464]. The 1 year mortality of 11.5% made up almost two thirds of all 
MACCE, rising to over 30.9% or four fifths of all MACCE for the median follow-up. However 
we reported a repeat revascularisation rate of only 2.8% at 1 year and 5.8% over the median 
   260 
 
follow-up. When compared with other observational studies of DES revascularisation in 
octogenarians, our repeat revascularisation rate is similar or slightly higher [39, 303, 340].  
 
In this older cohort, with more baseline and residual coronary disease compared with the 
SYNTAX trial patients [155], we did not observe a difference in the risk of repeat 
revascularisation across the rSS groups. It should be noted that in our cohort all repeat 
revascularisation was performed in the context of subsequent acute coronary events rather 
than stable angina. The younger cohorts studied in randomised trials seem to be at greater 
risk of repeat revascularisation [47, 59, 60].  This greater risk may in part be due to the 
difference in the pathology of the atheroma. Despite a greater burden of coronary disease 
in older age, the plaque morphology is more stable than in younger patients [321], and thus 
the older patient is less likely to present with further acute coronary events. In this way, 
while it is known that coronary revascularisation offers greater gains in survival for the 
elderly than the young [130], revascularisation also seems to offer a more robust form of 
treatment for the elderly. However, a more plausible explanation may be the greater 
likelihood of these patients suffering death prior to further coronary events. 
 
7.1.3 Study implications 
 
Firstly, the results of this observational study reflect the outcomes from LMCA PCI within 
the high surgical risk population treated in most cardiac centres in the UK [154]. We have 
demonstrated that this population differs considerably from those typically included in 
randomised trials in terms of baseline characteristics and outcomes. While our study 
findings are not generalizable due to the non-randomised nature of the data, it provides 
insight into the factors affecting outcomes from LMCA PCI in high surgical risk populations. 
This population of patients now represent a large proportion of those who are treated with 
LMCA PCI in the UK [154].   
We have demonstrated that, due to specific characteristics of this study population, current 
accepted end-point measures may not allow meaningful interpretation of study outcomes. 
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Meta-analyses of randomised LMCA revascularisation studies show that while mortality is 
similar for CABG and PCI, differences are driven by MI and repeat revascularisation [57, 58, 
478] even amongst older patient cohorts [479]. However, in our relatively high risk and long 
lived study population, mortality was the main contributor to MACCE where the 1 year 
mortality was nearly three times higher compared with these selected study populations. 
Amongst our study population the repeat revascularisation rate was only 2.8%, which is 
significantly less than reported in these randomised studies, even compared with older 
randomised cohorts [479].  While the high mortality rate is a reflection of the greater 
comorbidity in our population, after adjusting for covariates, SS remained a significant 
predictor of outcomes. Recent studies have demonstrated that amongst patients with low 
to intermediate burden of coronary disease the risk of repeat revascularisation is similar for 
PCI and CABG [59, 215, 478, 480]. CABG is the preferred option for those with more 
extensive burdens of coronary disease. So while it is relevant that further studies examine 
PCI outcomes in this high surgical risk population with large atheromatous burden, we 
should explore the possible reasons for this low repeat revascularisation rate.  
 
This study cohort is older and has more extensive coronary disease than patients recruited 
to published studies from which the LMCA bifurcation PCI guidelines have been drawn [119]. 
Our study is the first to show that ‘True’ LMCA bifurcation disease, using the Medina 
classification, is associated with worse outcomes following PCI. While we demonstrated 
equal survival from two and single stent strategies for LMCA bifurcation PCI, this was 
unadjusted survival. While our data support the notion that a single or two-stent strategy is 
acceptable for the treatment of ‘True’ LMCA bifurcation disease, given the lack of lesion-
level outcomes, including TLR, this is hypothesis generating rather than conclusive. Even 
now, the EBC is working to address this issue by recruiting to the EBC MAIN study, where 
they aim to exclude patients with extensive coronary three vessel disease [106].  
 
Diabetes is associated with a two-fold increase in the risk of poor outcomes in patients with 
LMCA bifurcation disease, albeit patient-level rather than lesion-level outcomes. Our study 
sample is representative of current clinical practice, which include high risk patients with 
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complex coronary lesions. These data highlight the challenges facing both clinicians and 
researchers. Future research to assess single vs. two stent strategies for ‘True’ LMCA 
bifurcation disease should include a more specific outcome measure and the selection of 
patients with limited associated coronary disease to minimise confounding. The challenge, 
therefore, would be to design a study which can answer the narrow question of how to 
treat the LMCA bifurcation while acknowledging that the typical patient presenting with 
LMCA bifurcation disease would usually have extensive coronary disease and may well be 
older with more comorbidity. These patients, therefore, may not be appropriately managed 
with CABG.  While we await the results of the EBC MAIN study, our findings seem consistent 
with the EBC recommendations for treating LMCA bifurcations. 
 
While several recently published studies have attempted to identify a cohort of patients 
with LMCA disease who could appropriately be treated with PCI, the proportion of 
octogenarians included in these studies is low. Nevertheless, we have demonstrated that 
amongst a high surgical risk cohort of octogenarians with LMCA disease, survival can be 
similar if not better than other reported studies of revascularisation in octogenarians [307].  
 
Baseline coronary disease burden, measured by the SS, is associated with poor outcomes in 
octogenarians with ULMCA disease. While octogenarians suffer from selective 
revascularisation, octogenarians in our real-world series had levels of residual disease more 
than twice those reported in randomised studies of ULMCA revascularisation [155, 167]. 
Incremental residual coronary disease among octogenarians who received ULMCA PCI was 
significantly associated with mortality. Currently, we are unable accurately determine the 
benefit octogenarians would receive from more complete revascularisation, however 
further studies designed to quantify this are warranted. While we have applied an 
anatomical quantification of incomplete revascularisation, future studies should be 
designed with functional classification of completeness of revascularisation.  
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Furthermore, while repeat revascularisation remains a significant factor limiting the use of 
PCI for LMCA disease, we have found a very low repeat revascularisation rate amongst 
elderly patients despite the large burden of residual disease; this is probably related to the 
more stable nature of plaque disease in the elderly [321]. The main discriminator of 
outcomes in our study is mortality, rather than repeat revascularisation as we find in the 
younger trial populations. Thus in future consideration needs to be given to assessing 
outcomes including measures of quality of life given the high burden of comorbidity in this 
population. 
 
While this study indicates improvement in prognosis with increasing levels of 
revascularisation in octogenarians, the obvious selection bias would indicate that clinicians 
applied clinical judgement in assessing individuals. Thus a risk-benefit analysis, balancing the 
increased risks of revascularisation against prognostic gains and quality of life gains, should 
be analysed in future studies. Quality of life is an important outcome measure in the success 
of revascularisation in patients with limited life spans [358].  
 
7.1.4 Strengths 
 
Non-randomised data retains the strength of describing a population which remains 
clinically relevant to current practice. While randomised studies have allowed us to describe 
a narrower spectrum of patients for whom PCI is equal to CABG, those with less complex 
coronary disease, there is a lack of data describing the outcomes in patients for whom PCI is 
the only alternative. This makes our study relevant to current practice, as these patients 
represent a majority, when one considers the large numbers of patients excluded from 
recent randomised LMCA studies [59, 60].  
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7.1.5 Limitations 
 
Selection bias was inherent in this retrospective study of a group of individuals for whom 
one can only presume CABG was not an option. Whether it is due to the acuteness of their 
presentation or high surgical risk, this heterogeneous study population would not be 
included in a randomised trial of ULMCA revascularisation. Considering the mode of 
presentation, this alone would bias the results in favour of those presenting free of 
cardiogenic shock. This is reflected in the significant differences between patients with and 
without cardiogenic shock. Therefore it was appropriate to consider these two groups 
separately for further analysis.  
 
Limited access to patient data due to patients, as in the case of STEMI, being treated at one 
hospital and then repatriated to another with no access to their subsequent data at the 
district general hospital. We did attempt to negate this by applying to each hospital for data, 
however there was difficulty due to missing data at district hospital as this was retrospective 
data collection. In some cases physical files were no longer available and no electronic 
records existed. All this led to a large number of missing data points. 
Missing data present a specific confounding on the analysis of outcomes, in particular when 
considering that poor LV function is accepted as a significant factor predicting poor 
outcomes from revascularisation. While accepting this was unavoidable given the 
retrospective nature of the study, missing LV function has been observed in nationally 
audited coronary interventional datasets [154]. Furthermore, other randomised trials report 
similarly high missing LV functions, up to a quarter in some instances [110]. Our sensitivity 
analysis seems to suggest that the data may be missing not at random, however taking into 
account plausible predictor variables, we performed multiple imputation. While this 
imputed data cannot be used to provide conclusions, we were able to confirm the findings 
from the initial analysis. The regression model for the imputed datasets was in agreement 
with the findings of our incomplete dataset. While these findings may confirm the model as 
predictive of poor outcomes, there may indeed be significant bias due to the missing data. 
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In addition to clinically relevant data, we were unable to locate relevant multidisciplinary 
discussions prior to the decision to revascularise these patients. While we may infer based 
on EuroSCORE and clinical presentation that over 90.0% of patients had PCI due to high 
surgical risk, there are 34 (9.3%) patients who one may reasonably argue could have had 
CABG. While this probably does not impact on the outcomes of the study, it does represent 
a potential governance issue. This does not imply a serious ethical issue with our study, but 
allows us the chance to design a future prospective registry with the appropriate checks and 
balances. 
 
While we report a large amount of complications, these complications represent a 
combination of operator-reported complications, recorded on Cardiobase® at the time of 
the procedure, and those identified at the time of angiographic review for this analysis. The 
interventionalist who reviewed the angiograms was blinded to the procedural notes; 
complications were imported directly into the database and were not allocated separately 
by the reviewer or operator. Due to this method of data collection and coding, we were 
unable to discriminate those reported by the operator from those reported at the time of 
angiographic review. Complications are divided into procedural or access site related 
complications. Due to the way in which our data was collected, on a bespoke database, we 
were unable to elucidate whether the reported coronary dissections were edge dissections 
post-stenting and whether these resulted in unplanned additional stenting. In addition there 
was lack of information concerning the angiographic grades of dissection being reported. 
 
There may be significant inaccuracy with respect to the outcomes employed to analyse the 
bifurcation dataset. Given that all cause death makes up three quarters of the MACCE, age 
may be considered a confounder as patients treated with a two stent strategy were 
significantly older than those treated with a single stent strategy. However, older patients 
treated with a single stent have been shown to do better than a younger patients treated 
with a two stent approach, where MACE was driven by TLR [115]. While we report MACCE, 
including death, MI, repeat revascularisation and stroke, we did not report on TLR due to a 
lack of lesion-level outcome data. TLR in the stented left main bifurcation is reported in up 
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to a fifth of patients over long term follow-up [127]. So, while it is considered an important 
determinant of outcomes, restenosis can be asymptomatic and is often diagnosed after 
routine angiographic follow-up [190]. Only a small number of our patients suffered repeat 
revascularisation, while MACCE was mainly driven by death. In this older cohort it could be 
suggested that a lack of access to revascularisation procedures may have led to an 
underreporting of TLR [207].  The choice of composite outcomes may therefore lack 
specificity, due to the lack of reported TLR. This could indicate a certain amount of 
inaccuracy in the outcome data. The inaccuracy relates to the clinical follow-up, as the data 
was collected retrospectively and a proportion of the patients were followed up at district 
hospitals. However, every effort was made, to ameliorate this by confirming patient 
reported events with information gathered from each hospital using PAS and GP summary 
care records.  
 
Furthermore, the lack of specificity in the outcome data may be related to selection bias, e.g. 
measuring all cause death in older patients doesn’t examine the long term treatment effect 
of revascularisation. There are two solutions to this problem, while the outcomes may be 
less specific by including more variables in the regression model, in particular unmeasured 
confounders, for example a frailty and dementia. The most glaring omission is the missing 
LV function. Due to the nature of this retrospective sample, we are unable to include these 
variables in our model. While for this older cohort, we used cardiac death in our composite 
end-points, which we argue would improve the disease-specific outcome measures. 
Unmeasured confounders could be addressed by constructing a prospective registry 
including known predictors of death in the elderly. This would be essential, given the 
context of current guidelines for LMCA PCI, it seems probable that any future prospective 
registry would continue to recruit a predominantly long-lived population.  
 
While, we found ‘True’ LMCA bifurcation disease was associated with greater MACCE, this 
may reflect considerable confounding from the total burden of atheroma, we found 
significant collinearity with the SS. While we demonstrated equal survival from two and 
single stent strategies for LMCA bifurcation PCI, this was unadjusted survival. In the analysis 
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of ‘True’ bifurcation disease, patients treated with a single stent had a significantly greater 
median SS compared with patients in the two stent group. The greater SS is mainly 
accounted for by the associated coronary vessel disease, LM+2VD and LM+3VD, where half 
of patients in the single stent group had associated coronary disease as opposed to only a 
third of those in the two stent group. In contemporary registries up to 80% of patients with 
LMCA bifurcation disease are reported to have LM+2VD and LM+3VD [112, 113]. Other 
studies have failed to account for this confounding when demonstrating worse outcomes 
from a two stent strategy compared to a single stent, despite significantly more mulitvessel 
disease in the two stent group [112].  
Patients with a greater SYNTAX score generally do worse [55]. The higher SYNTAX score for 
patients with ‘True’ bifurcation disease in our study is not accounted for alone by the 
burden of atheroma around the LMCA bifurcation. A ‘True’ left main bifurcation stenosis 
contributes only 2 points to the SYNTAX score when compared with a 'Non-true' lesion [35, 
299]. When treatment groups are matched for SS, outcomes seem to be comparable; 
however these patients have SS in the low-intermediate tertile range compared to the high 
median SS in our study population [114]. After adjustment, SS was not an independent 
predictor of poor outcomes, yet there may be significant confounding from the coronary 
disease burden. Future studies examining the PCI strategy for distal LMCA disease should be 
designed to reduce the confounding created by this associated multivessel disease. Indeed 
the EBC MAIN study excludes patients with a SS of greater than 32 [106]. However, bearing 
in mind that we treated significantly older patients with more extensive coronary disease, 
the data from this study should be applied cautiously to the ‘real world’ patient cohorts. 
 
Prospective trials, such as the BBC ONE and Nordic trials, include clear study treatment 
protocols which allow the identification of treatment crossover due to an unsuccessful stent 
strategy [83]. In this respect, while our retrospective study reports equal outcomes from a 
two stent vs single stent treatment for the LMCA, for those patients treated with ‘T-
stent’/’Culotte’/’TAP’ strategies, there may have been considerable crossover from a 
provisional single stent to a T-stent strategy. In the EBC II trial the crossover was up to 16% 
[110]. Other confounders of an ‘intention-to-treat’ analysis would include the lack of QCA 
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data to confirm the size of the SB, while the viability of the subtended myocardial bed was 
unknown for a number of patients. 
 
While our data support the notion that a single or two-stent strategy is acceptable for the 
treatment of ‘True’ LMCA bifurcation disease, given the lack of lesion-level outcomes, 
including TLR, this is hypothesis generating rather than conclusive. As this was a 
retrospective study we were unable to determine the revascularisation strategy on a per-
patient level. This creates significant confounding when considering the reasons for failure 
to achieve complete revascularisation in our patients. While the elderly patients are at 
greater risk of selective revascularisation [171], our data lacks functional lesion assessment. 
While the rSS is an anatomical assessment of untreated coronary disease and does not 
necessarily imply functionally incomplete revascularisation Clinicians are more inclined to 
demonstrate lesion ischaemia, using fractional flow reserve (FFR), to assess appropriate 
revascularisation in multivessel disease [352, 353]. Functional lesion classification could 
change the SS for up to a third of patients and thus lead to a change in management 
decisions, from CABG to PCI and vice versa [354]. While this would result in a change in SS 
and rSS, no study has demonstrated an advantage of functional complete revascularisation 
over anatomical complete revascularisation in multivessel disease [355].  Indeed, while we 
await the results of the SYNTAX II and FAME 3 studies which will assess the FFR guided 
revascularisation of multivessel disease, these studies will not include patients with left 
main disease [356, 357]. Similarly, as information on myocardial viability was unavailable we 
are unable to exclude the possibility that stenoses in vessels subtending non-viable 
myocardial segments may have been appropriately left untreated. Chronic total occlusions 
were present in 15.0% of all octogenarians, while these significantly contribute to the SS and 
rSS, it is not certain if these lesions would have met the criteria for revascularisation with 
PCI due to a lack of data on viability and ischaemia assessments. 
 
More so amongst elderly patients, selection bias may play a huge impact on outcomes from 
observational studies of revascularisation [206]. The elderly patients who eventually have 
revascularisation represent those most likely to benefit from the procedure. Indeed, there 
   269 
 
are also a number of unmeasured confounders which were not accounted for in our analysis, 
such as dementia and frailty.  
Overall the study size is small and thus with a modest number of MACCE events, it could be 
argued that we are unable to draw conclusions due to an underpowered study. Furthermore, 
while this is a long lived sample in which death predominates the MACCE, the associations 
could be considered confounded while they may even be inaccurate for the analysis of 
LMCA revascularisation. 
 
 
7.2 Prospective Quality of life study 
 
Recent analysis of LMCA revascularisation has revealed that TVR is the main discriminator 
between PCI and CABG. Yet it is suggested that the lesser impact of TVR events on quality of 
life compared with other MACCE events would result in equipoise [481]. It seems 
reasonable therefore to assume that these effects can be measured through quality of life 
assessments.  
Physician-oriented measures of revascularisation include traditional outcomes, such as 
MACCE and mortality, describe the natural history of the pathophysiological processes as 
well as treatment effects [180]. These outcome measures inform treatment decisions of 
perceived prognostic benefit [69, 299]. Mortality correlates well with prognostic 
improvement; however the composite outcome, MACCE, does not. Due to binary 
censorship of MACCE, one may ascribe a minor MI as an equal outcome to a disabling stroke. 
In this way, for the treatment of LMCA disease, while PCI may be considered non-inferior to 
CABG on the basis of mortality [59, 60], for more extensive coronary disease, PCI is 
considered inferior to CABG on the basis of excess repeat revascularisations despite a higher 
risk of stroke with CABG [47, 215]. Of note, there is only one recently published study which 
found a greater risk of stroke with PCI compared to CABG for the treatment of LMCA disease 
[60]. These outcome measures inform the risk-benefit analysis for each patient when 
deciding between either PCI or CABG [47, 229]. In the case of high risk patients, where 
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revascularisation may offer no prognostic benefit, these outcome measures do not inform 
us of symptomatic benefit to the patient. 
 
Increasing proportions of patients are having PCI rather than CABG for coronary disease 
[360], including those considered high surgical risk, such as the elderly [360, 361] and others 
with more complex coronary disease [362], such as LMCA disease [2]. Revascularisation 
decisions are therefore not solely based on improving traditional outcome measures, such 
as mortality, but rather symptomatic improvement. There is a need for data which informs 
this management approach.  
 
Patient-oriented outcome measure or quality of life outcome measures may nuance the 
risk-benefit analysis. Quality of life outcomes amongst patients with coronary disease are 
predictive of poor outcomes, such as death [363, 364], repeat revascularisation [365, 366] 
and hospitalisation [367]. Poor quality of life outcomes within the first year predicts 
mortality up to a decade following revascularisation [368], including the long lived [369-371]. 
Several studies have compared quality of life outcomes in patients treated with coronary 
revascularisation using PCI or CABG [372-385], however the results are conflicting with 
some reporting no difference [377, 383, 386, 387], while other studies report greater 
benefit from CABG [376, 380-385, 388]. While these observational studies compare patients 
with varying degrees of severity of coronary disease only the SYNTAX trial and EXCEL trial 
compared large cohorts with LMCA disease [388, 391].  
 
While it is known that CABG improves angina compared to medical management in patients 
with LMCA disease [389], the data from this study may be considered outdated given the 
changes that have occurred in treatments offered. A previous study comparing QOL 
outcomes from CABG or PCI in patients with LMCA disease failed to assess the known 
longitudinal changes in QOL by using only a single time point measure [390]. HRQOL 
outcomes in patients with LMCA disease has never been described over a 1 year 
longitudinal study in patients with left main coronary artery disease comparing patients who 
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are medically managed to those undergoing revascularisation with CABG or PCI [377, 388, 
390, 391]. While other studies are designed to investigate prognostic outcomes in patients 
considered appropriate for prognostic improvement, our study will include those 
revascularised as well as those conservatively managed.  
 
7.2.1 Principal findings 
 
We undertook the analysis of the first 103 patients were recruited into the prospective 
Leeds left main stem registry, they had all completed 1 year clinical follow-up in May 2015. 
Whilst the aim was to follow-up all patients for 1 year completing 4 time point HRQOL 
questionnaires, we achieved a completion rate of 45% for all time points. The conventional 
general linear model therefore included data from only 45 patients and indicated serial 
improvements in quality of life from baseline up to 6 months, maintained up to 1 year, for 
the revascularisation treatment groups. The medically managed cohort did not show an 
improvement in quality of life scores over the course of 1 year.  Independent predictors of 
poor quality of life at 1 year were a history of cardiac surgery, previous CVA and 
presentation with a STEMI, while predictors of good quality of life at 1 year included elective 
procedures, previous MI, good baseline quality of life scores and CABG. The best fitting 
linear growth model, 98 patients were included, indicated that quality of life improves 
significantly with time from baseline in patients treated with CABG. PCI was not identified as 
a predictor of improvement in QOL when compared with CABG. Recent MI, within 90 days, 
was identified as a significant predictor of improvement in QOL over 1 year. 
For HRQOL domain scores, derived from MacNEW questionnaire, the overall cohort showed 
improvement in emotional, physical and social domain scores. Both revascularisation groups 
showed an increase in emotional and social domain scores, while medically managed 
patients did not experience an increase over 1 year. All treatment groups showed an 
increase in the physical domain scores. 
Over 1 year follow-up there was a total of 6 acute coronary syndromes, 3 patients required 
further revascularisation. The 1 year mortality rate for the entire cohort was 5.8%, including 
3 deaths within the medically managed group, 2 patients treated with PCI and 1 patient who 
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had CABG.  MACCE identified as a predictor variable in the best fitting growth model for 
global mean MacNew scores.   
Follow-up continued for the entire cohort until completion of all 1 year questionnaires for 
all patients, the median follow-up was 502 (286) days (table 6.9). MACCE recorded for this 
period include 1 further ACS within the PCI patient cohort, 1 patient treated with PCI initially 
suffered a repeat revascularisation, while 1 patient failed medically management and 
converted to a revascularisation strategy. There was 1 additional CVA within the CABG 
managed group and no further deaths were recorded. 
 
In summary, while there is no significant difference in HRQOL outcomes between CABG and 
PCI for LMCA revascularisation, there was a trend for a quantitatively larger improvement in 
QOL with CABG than with PCI. PCI however achieves an earlier improvement in QOL than 
CABG. Medical management showed no improvement in HRQOL outcomes. 
 
7.2.2 Context of findings 
 
These are the first published data on repeated measures quality of life data for patients with 
LMCA disease which includes medically managed patients as a comparator [388, 390, 391]. 
The SYNTAX study compared QOL outcomes in patients with multivessel disease treated 
with PCI or CABG using the linear growth model; however only 39.2% of study patients had 
LMCA disease and they did not include a medically managed cohort [377]. We did not show 
a significant difference in HRQOL outcomes between PCI and CABG, which is consistent with 
other studies comparing HRQOL outcomes for CABG and PCI used to revascularise LMCA 
disease [388, 390]. However, as we used the linear growth model, as opposed to a single 
time-point measure, we found there was a non-significant trend for better outcomes from 
CABG over 1 year follow-up.  
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7.2.3 Strengths 
 
Published data indicate that mixed model analysis using the linear growth models provides a 
better fitting model due: (a) to the inclusion of a larger number of cases, where missing data 
are estimated with maximum likelihood, and (b) by allowing the construction of a growth 
curve using data collected at unequal time points [416, 425]. These are the first published 
data on repeated measures quality of life data for patients with LMCA disease which include 
medically managed patients as a comparator [388, 390, 391]. 
While the study design allows us to assess outcomes in medically managed patients, if this 
study were suitably powered we could assess if medically managed patients could benefit 
from limited low risk revascularisation with PCI.  
 
 
7.2.4 Limitations 
 
This is not a randomised cohort, so outcomes may not be comparative between the three 
treatment groups. In this way there is probable confounding of the QOL outcomes. This 
exists due to the study design and limitations which exist in the inherent inclusion of a 
medically managed group. Nevertheless, while we cannot draw conclusions from the sample 
due to the size of the sample we can accept that the medically managed group, however 
small, did not have any improvement in QOL outcomes whatever the severity of their 
disease. So the confounding of disease severity will mainly affect our comparison of CABG 
and PCI samples.  
The most obvious and glaring limitation in this study was the omission of an angina score. 
While other studies have reported angina scores, we did not measure this. However, while 
angina is a principle symptom of patients with coronary disease, due to placebo effect 
associated with coronary revascularisation [359], it may be beneficial to use a cumulative 
muti-modal measure of symptom improvement such as the MacNew. Nevertheless, future 
studies should always include an angina score in addition to other validated QOL scores, 
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while recent studies suggest an objective measure of exercise tolerance may also be 
required [359].  
 
While the placebo effect may over-estimate the benefit from revascularisation, in a similar 
way medically managed patients, who may be aware of the severity of their condition, may 
interpret their HRQOL as being worse off, due to the awareness of a ‘lack of treatment’. This 
is acknowledged as the mechanism in the way patients education may alter HRQOL 
outcomes [482]. This could be reflected in BIP consequence scores, however this was not 
included in the best fitting final model and medically managed patients seemed to have an 
observable improvement in BIP consequence over time. 
 
Due to slow recruitment of the medically managed cohort, we cannot draw conclusions 
from the analysis of this sample. The principle reason for poor recruitment was down to 
where patients received their ultimate management. While stable and semi-urgent patients 
for revascularisation would be referred to the recruiting centre, medically managed patients 
would be managed in the periphery soon after diagnosis. In order to overcome this issue we 
designed the study with the capability of multicentre recruitment. However, due to poor 
regional uptake, in part due to the lack of a study co-ordinator for a large duration of the 
study, we  did not have any uptake from other centres. Another reason for the poor 
recruitment of medically managed patients was the poor utilisation of clinicians of the 
‘heart team’. Indeed the MDT at the LGI was probably under-utilised for the purposes of 
decision making for patients with LMCA disease despite the recommendations by the ESC 
[299]. 
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7.3 Study implications  
 
Prognostic outcomes are similar from PCI or CABG for LMCA disease for patients with 
intermediate severity of coronary disease [59, 60, 215]. In these patients HRQOL outcomes 
may be an important factor in deciding between the two strategies as this will inform not 
only physicians but patients during the decision-making process [426]. Serial global and sub-
domain QOL scores improve over 1 year for both revascularisation groups but not for 
medically managed patients, while CABG and not PCI is a predictor of significantly improved 
QOL outcomes.  Furthermore, we found no improvement in HRQOL scores for those who 
had medical management, which is consistent with previous studies [389]. This study 
informs the risk benefit analysis, while revascularisation may not be considered appropriate 
on prognostic grounds, for these patients who would normally be considered for 
conservative management, it may be reasonable to consider a limited or targeted 
revascularisation strategy to improve QOL [426].  
 
7.4 Future considerations  
 
While selection bias is unavoidable for an all-comer registry type of study, by dividing the 
patients into subgroups, e.g. excluding cardiogenic shocked patients; it is possible to explore 
some research questions. A prospective registry may include exclusion and inclusion criteria, 
which would allow more conclusive outcomes research. Yet, given the context of current 
guidelines for LMCA PCI [299], it seems probable that any future prospective LMCA PCI 
registry would continue to recruit a predominantly long-lived population. So while exclusion 
criteria would usually provide a study population which allows the analysis of long term 
outcomes the nature of this population would continue to limit the applicability of the data. 
Current data suggest patients with limited atheromatous burden have equal outcomes from 
PCI and CABG for LMCA revascularisation. While recent randomised trials have sought to 
examine these restricted population samples [60], for the majority of patients treated with 
LMCA PCI in the UK, CABG may not be an option [154]. Due to comorbidity these patients 
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would not usually be included in randomised trials, however no study thus far has examined 
outcomes from this high surgical risk patient cohort who suffer from extensive atheroma.  
While the current study design limits the exploration of a causative model for all known 
predictors of poor QOL, ongoing recruitment would allow a meaningful insight into the 
medically managed cohort which has hitherto not been studied in published data. This 
would allow the study of interventions which could improve patient illness beliefs which we 
have demonstrated are correlated with QOL outcomes. 
 
7.5 Thesis conclusions  
 
For patients who may be considered high surgical risk, this study indicates that the burden 
of coronary disease is associated with poor outcomes, even amongst a long-lived sample. 
While there appears to be an association with residual coronary disease and poor outcomes 
for octogenarians, we cannot predict the benefit from more complete revascularisation to 
this population. ‘True’ left main bifurcation disease is associated with poor outcomes, yet 
there is no obvious benefit from a two strategy, however this conclusion is significantly 
biased by the lack of ‘intention-to-treat’ analysis.  
 
Patients managed conservatively for LMCA disease have no improvement in HRQOL scores 
over 1 year follow-up. While patients who have received any revascularisation had 
improvement in HRQOL scores, only CABG was included in the final model as a predictor of 
improvement in HRQOL scores over 1 year.
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Appendices 
 
Appendix 1: Patient information sheet 
 
Version 1.6 23 16/12/2013 Leeds Central REC number 12/YH/0484  
 
Left Main Stem Study  
Patient Information Sheet  
Title: Prospective study of outcomes following revascularisation for left main 
stem coronary artery disease  
We would like to invite you to take part in a research study. Before you decide, you 
need to understand why the research is being done and what it would involve for 
you. Please take time to read the following information carefully. One of our team will 
go through the information sheet with you and answer any questions you have. We‘d 
suggest this should take about 5 minutes. Talk to others about the study if you wish.  
Part 1 tells you the purpose of this study and what will happen to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study.  
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
Part 1 of the information sheet  
What is the purpose of the study?  
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The main artery to the heart is called the left main stem, and this artery can be 
affected by cholesterol plaque narrowing. The two main treatment options for this 
condition are surgery and the insertion of stents. We are undertaking this study to 
see if we can determine which option provides the best and safest treatment for the 
patient.  
Why have I been invited?  
You have been invited to take part because you have a narrowing in the left main 
stem artery which may require treatment.  
Do I have to take part?  
It is up to you to decide. We will describe the study and go through this information 
sheet, which we will then give to you. We will then ask you to sign a consent form to 
show you have agreed to take part. You are free to withdraw at any time, without 
giving a reason. This would not affect the standard of care you receive, the decision 
about which treatment option you would receive will not be affected.  
1 
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What will happen to me if I take part?  
We will look through your medical records and identify data that may include results 
from routine tests and personal information from hospital appointments. We will 
follow up this data for up to 20 years. We will register your data with the Office of 
National Statistics so that we can track your progress over the study time period.  
If you presented as an emergency, the decision about the best treatment will be 
made by your treating physician. If you have already received treatment (either a 
stent or surgery) we would still like to include you in our study as we would like to 
follow-up all patients with this condition.  
If you are not referred as an emergency, the physician looking after you has referred 
you for a review in a multi-disciplinary (MDT) meeting involving cardiologists and 
surgeons. At the MDT we discuss the options of treatment which would include, 
either placing a stent in the artery or surgery to bypass the narrowing or in some 
cases just medical treatment.  
Some patients are deemed only suitable for surgery and others only suitable for 
stents. However there are patients who could have both treatment options. These 
patients will have the opportunity of discussing these options in a clinic or on the 
ward with the surgeon and cardiologist who will perform the relevant treatments.  
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If you have a stent fitted you will return for this as a day procedure. Subsequent clinic 
follow up will be arranged at the discretion of your physician. If required a repeat day 
case angiogram in about 6 months to 1 year may be performed to ensure the stent is 
still working.  
If you have surgery, this will be arranged for you. Further follow up will be arranged 
at the discretion of your physician.  
You will be given questionnaires to complete relating to your care and monitoring 
your progress. These will be given to you at these time points: prior to your 
scheduled procedure and then posted to you at 1 month, 6 months and then 1 year 
after the procedure.  
A member of the research team will contact you by telephone/letter/e-mail at 6 
months and then yearly for up to 10 years, in order to determine the status of 
your health. You can choose how you would prefer to be followed up if you prefer 
(by letter, online, or by telephone). Your data will be identifiable to us.  
You will not need to attend the hospital any more (or less) frequently than would 
normally be requested by your specialist.  
We will store your contact details on a secure database. This is so that we can 
contact you to see if you would like to participate in future research studies.  
The data that we collect on you may be enhanced through linkage with other clinical 
and administrative databases.  
Version 1.6 23 16/12/2013 Leeds Central REC number 12/YH/0484  
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Expenses and payments  
There are no expenses available for this study.  
What will I have to do?  
You will need to sign the consent form. You will be asked to choose your preferred 
method of questionnaire follow-up which will occur at 1 month, 6months and 1 year 
after the procedure, either sent to you in the post, provided online, or telephone.  
What is the drug, device or procedure that is being tested?  
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We are looking at whether a different approach, by implementing international 
guidelines, relating to planning treatment for patients improves outcomes. 
Specifically, the way we decide on treatment, by increasing patient involvement 
through a multi-disciplinary clinic with the cardiologist and surgeons in attendance. 
Your participation in the study will not affect the decision about your treatment as all 
cases will be decided upon in this way.  
What are the possible disadvantages and risks of taking part?  
There is no risk to your health from this study as it is an observational study looking 
at recognised treatment strategies for narrowing in the heart arteries. The data that 
we collect will be stored securely on our computers.  
What are the possible benefits of taking part?  
We cannot promise the study will help you but the information we get from this study 
will help improve the treatment of people with a left main stem artery narrowing in the 
future.  
What happens when the research study stops?  
Your access to healthcare and the treatment you receive will be no different during 
or after the study.  
What if there is a problem?  
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this is 
given in Part 2.  
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2.  
This completes part I. If the information in Part 1 has interested you and you are 
considering participation, please read the additional information in Part 2 before 
making any decision.  
Version 1.6 23 16/12/2013 Leeds Central REC number 12/YH/0484  
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Part 2 of the information sheet  
What will happen if I don’t want to carry on with the study?  
You can withdraw from the study if you wish, but we will need to use the data 
collected up to your withdrawal.  
What if there is a problem?  
Complaints and harm  
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. If you remain unhappy 
and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from the hospital.  
NHS based research  
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for a legal 
action for compensation against the Trust but you may have to pay your legal costs. 
The normal National Health Service complaints mechanisms will still be available to 
you (if appropriate).  
Will my taking part in this study be kept confidential?  
Any personal data that is stored on anything other than the research database will be 
linked anonymised and will not contain any primary identifiers. Only those in the 
research team, employed by the cardiovascular research department working within 
the Leeds TH trusts data protection policies, will have access to the data. Your data 
will be managed within the confines of the trusts policies. We will forward identifiable 
data to the Office of National Statistics.  
What will happen to any samples I give?  
The samples that you give will have been requested by your specialist as part of 
your standard care. We will have access to results from previous samples that have 
been taken as part of your routine care. Data from blood tests and heart scans are 
normally stored on computers and will we access these computers to look at your 
results. Samples will not be transferred outside the UK.  
Involvement of the General Practitioner  
We will inform your General Practitioner of your participation in this study, if you 
consent to this.  
Version 1.6 23 16/12/2013 Leeds Central REC number 12/YH/0484  
4  
   308 
 
 
 
What will happen to the results of the research study?  
The results of the study will be presented at local and international cardiology 
meetings, and published in medical journals. The results will also be made available 
to local Cardiologists and to Nurses who routinely work with patients with artery 
narrowing’s in the heart. You will not be identified in any report/publication.  
Who is organising and funding the research?  
There are a number of funders of this research including:  
1) The Take Heart charity 
2) Abbott Vascular Ltd.  
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study has been reviewed and given favourable opinion by Yorkshire and Humber 
Research Ethics Committee.  
Further information and contact details  
If you require further information about the study, then please contact Professor UM 
Sivananthan, Leeds General Infirmary, LS1 3EX, telephone number 0113 3925735. 
Alternatively, Research Nurse Rebecca Dickinson, Cardiology Research, Leeds 
General Infirmary, LS1 3EX, telephone number 0113 3925393.  
Version 1.6 23 16/12/2013 Leeds Central REC number 12/YH/0484  
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Appendix 2: Consent form 
 
 
REC number: 12/YH/0484      Chief investigator: 
Centre Number: LGI      Prof. UM Sivananthan 
Study Number:  1      University of Leeds 
Patient study ID: ____________      Version 1.2; 04 November 2013 
 
CONSENT FORM 
 
Title of Project:  Left Main Stem Revascularisation Study 
Prospective study of outcomes following revascularisation of the left main stem coronary 
artery 
 
Name of Researcher:  Dr C Maart  
 
 
1. I confirm that I have read and understand the information sheet (Version 1.5) for the above study. I have 
had the opportunity to consider the information, ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time without giving 
any reason, without my medical care or legal rights being affected.    
             
3. I understand that relevant sections of my medical notes and data collected during the study may be looked 
at by regulatory authorities or from the NHS Trust, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to my records.   
             
4. I understand that my details will be registered with the Office of National Statistics  
 
5. I understand that information held by the NHS and records maintained by the NHS Information Centre, the 
NHS Central Register and by my General Practitioner may be used to help contact me and provide 
information about my health status. I give permission for this information to be obtained from the NHS 
Information Centre, the NHS Central Register and/or my GP if necessary. 
 
6. I understand that my clinical data may be linked with other clinical or administrative databases.   
            
7. I understand that my data may be used in future research studies and that appropriate researchers from 
other research and academic groups may have access to my data after my personal details have been 
 
 
 
 
 
 
Please initial box 
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removed, upon application and at the discretion of the Chief Investigator. 
 
8. I understand that my GP will be informed of my participation in this study and that you may contact my 
GP, if required, to confirm any medical data relevant to the study. 
 
9. I consent to having my name and contact details stored so that I may be contacted in the future regarding 
other research projects  
 
10. I agree to take part in the above study.          
   
_______________    ________________  ________________     
Name of Patient    Date    Signature  
 
_________________   ________________  ________________   
Name of Person    Date    Signature  
taking consent 
When completed, 1 for patient; 1 for researcher site file; 1 to be kept in medical notes 
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Appendix 3: Health related quality of life questionnaires 
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Appendix 4: West Yorkshire Cardiac Patient and Public Involvement Group consultation 
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Appendix 5: Ethics approvals 
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